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Abstract 
Myostatin, a TGF-β superfamily member, is a key negative regulator of 
embryonic and postnatal muscle growth. In order to further elucidate the role of 
myostatin during postnatal growth, several lines of investigation were undertaken 
in mice. Analysis of myostatin downstream target genes identified several known 
and unknown genes. From these, the regulation of an androgen receptor binding 
co-factor, ARA70, was selected for further investigation. Reverse Northern 
analysis on the differentially expressed cDNA library indicated an increased 
expression of ARA70 in myostatin-null muscles, which was later confirmed by 
Northern blot and semi-quantitative PCR analysis. In corroboration, treatment of 
myoblast cultures with exogenous myostatin resulted in the down-regulation of 
ARA70, confirming that myostatin is a negative regulator of ARA70 gene 
expression. The role of myostatin during sarcopenia, a progressive age-related 
loss of skeletal muscle mass and strength, was also investigated. The atrophy 
associated with sarcopenia is frequently correlated with insufficient muscle 
regeneration, resulting from an impaired propensity of satellite cells to activate 
and a subsequent decline in myogenesis. Myostatin is a known inhibitor of 
postnatal satellite cell activation and muscle regeneration, thus muscle mass and 
regeneration, and satellite cell behaviour were examined in young and aged 
myostatin-null mice. Myostatin-null mice had increased individual muscle 
weights, as a consequence of massive fibre hypertrophy and hyperplasia, and an 
increased proportion of type IIB fibres. Aging induced oxidative fibre type 
changes and atrophy in the wild-type muscle while no fibre type switching was 
observed in the myostatin-null muscle and atrophy was minimal. No decrease in 
satellite cell numbers was observed with aging in both genotypes; though a 
gradual decline in the number of activated satellite cells was noted during aging. 
However, both young and aged myostatin-null mice displayed increased satellite 
cells and activation compared to wild-type mice, suggesting a greater myogenic 
potential in the myostatin-null satellite cells. Consistent with this, aged myostatin-
null myoblasts proliferated faster and displayed a higher fusion index during 
differentiation than the aged wild-type myoblasts, confirming that the reduced 
sarcopenia in the myostatin-null mice was due to a preserved increase in the 
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myoblast myogenic activity. An increase in a Pax7-only myoblast population 
from myostatin-null muscle indicated an enhanced satellite cell self-renewal 
process, consistent with the increased satellite cell number observed on the 
myostatin-null muscle fibres. Additionally, muscle regeneration of aged 
myostatin-null muscle following notexin injury was accelerated, and fibre 
hypertrophy and type were recovered with regeneration, unlike the aged wild-type 
muscle. Testing the therapeutic value of a myostatin antagonist, Mstn-ant1, 
indicated that a short term blockade of myostatin by the antagonist significantly 
enhanced muscle regeneration in aged mice after injury and during sarcopenia. 
Antagonism of myostatin led to satellite cell activation, increased Pax7 and MyoD 
protein levels, and greater myoblast and macrophage cell migration culminating in 
enhanced muscle regeneration in the aged mice.  
In conclusion, the hypertrophic phenotype associated with myostatin-null 
mice may in part result from increased androgen receptor (AR) activity due to the 
up-regulation of ARA70, given that increased expression of the AR leads to 
hypertrophy. Additionally, the increased muscle mass in myostatin-null mice is 
likely to result from an augmented myogenic potential and self-renewal process. 
Overall, a prolonged absence of myostatin reduced sarcopenia and the associated 
loss of muscle regenerative capacity. Furthermore, the antagonism of myostatin 
displayed significant therapeutic potential in the alleviation of sarcopenia, through 
the restoration of the myogenic and inflammatory responses in the aged 
environment. Thus, the research work clearly demonstrates the role of myostatin 
in sarcopenia, and documents for the first time a valid therapeutic for alleviating 
sarcopenia.  
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Chapter One 
Review of Literature 
In this thesis, the role of myostatin during postnatal growth and sarcopenia 
was examined. Thus, to provide background for the work, this Chapter reviews 
the current literature on skeletal muscle structure, and prenatal and postnatal 
myogenesis. Sarcopenia is then discussed, focussing on the phenotype of 
sarcopenic muscle and the causes behind the condition. Later, the structure and 
function of myostatin is addressed with particular emphasis on the regulation of 
postnatal myogenesis and muscle wasting. Finally, the aims of this thesis are 
reviewed. 
1.1 The structure of skeletal muscle  
Vertebrate skeletal muscle is composed of numerous individual contractile 
cells (myocytes) commonly referred to as muscle fibres (Figure 1.1). Each muscle 
contains, or is surrounded by, connective tissue sheaths; endo-, peri- and 
epimysium (Borg and Caulfield 1980). While the whole muscle is surrounded by 
the epimysium, the perimysium groups tens to several hundred myofibres into 
fascicles. Each myofibre contains of a large number of contractile myofibrils, and 
possesses an extracellular basal lamina (Timpl and Dziadek 1986). It is also 
individually surrounded by the endomysium. Microscopic studies on myofibrils 
have identified alternating light (I-bands) and dark (A-bands) areas, as well as a 
band transversally bisecting the I-band (the Z-line). The pattern of bands between 
one Z-line and the next is referred to as a sarcomere. Myofibrils display this 
specific banding pattern due to the arrangement of two types of protein filaments; 
thick filaments, mainly consisting of myosin, and thin filaments, largely 
containing actin. The thin filament consists of two strings of actin units and a 
strand of nebulin arranged in a double helical formation and is associated with 
tropomyosin and troponin, both of which are involved in the regulation of muscle 
contraction (Ebashi et al., 1969). Each myofibre is connected with a single motor 
neuron, which can innervate over one thousand myofibres, allowing them to 
respond to impulses conducted by motor neurons of the spinal cord or brain stem.  
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Figure 1.1 The structure of skeletal muscle 
A skeletal muscle consists of fascicles enclosed by the epimysium. The bundles 
are separated by the perimysium, and within each fascicle, the muscle fibres are 
surrounded by the endomysium. Each myofibre contains numerous myofibrils, 
consisting of repeating sarcomeres along the myofibril length. Adapted from 
Martini (1998). 
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The junction between the muscle and the terminal branches of the axon is referred 
to as the motor end plate or neuromuscular junction, and is responsible for the 
transduction of neural signals to the muscle fibre. Myofibers also express specific 
proteins for contractile function and metabolic enzymes. Individual muscles are 
composed of a mixture of fibres types and thus have different physiological 
properties, depending on what proteins each myofiber expresses (discussed further 
in Section 1.4.1). As muscle fibres are the basic contractile units of skeletal 
muscles, the proportion of each fibre type within a muscle determines its overall 
contractile property. 
1.2 Skeletal muscle function  
During muscle contraction the sarcomere length decreases. However, only 
the I-band shortens, while the A-band length remains the same. A theory for these 
phenomena was first proposed in 1954, which described the shortening of the 
sarcomere as a result of the thick and thin filaments sliding past one another 
(Huxley and Niedergerke 1954; Huxley and Hanson 1954). Examination of rigor 
muscle provided the initial evidence of the thick and thin filaments being linked 
by projections (myosin heads), to form cross-bridges with the actin molecules 
(Huxley 1953; Huxley 1957). These cross-bridges were proposed to cause the 
relative motion of the filaments. The sliding filament theory later detailed the 
steps involved in muscle contraction, and includes the following. Prior to 
contraction, the myosin heads are tightly bound to the actin filament. The binding 
of an ATP molecule induces the release of the myosin head from actin, while ATP 
hydrolysis alters the myosin head angle. Calcium then binds to troponin, which 
shifts the tropomyosin, leading to the exposure of the myosin-binding sites on the 
actin filament. This allows the myosin heads to re-bind to the actin filament. The 
subsequent release of the products of ATP hydrolysis induces a conformational 
change in the myosin head back to its initial state, pulling the thin filaments 
inward, resulting in sarcomere shortening, and thus contraction. The initiation of 
this muscle contraction process is via nervous impulses, which alter the electrical 
state of the muscle fibre membrane. An interconnective system of transverse 
tubules (t-tubules) transfers this change into the fibre interior causing the release 
of calcium from the sarcoplasmic reticulum surrounding each myofibril (Huxley 
1967). This change in calcium concentration produces an alteration in the thin 
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filament structure allowing the cross-bridges to form and the muscle to contract. 
Connective tissue within the muscle combines with the contractile myofibres 
creating a functional unit. Myofibre contraction is then transformed into 
movement via myotendinous junctions at each end of the myofibre, which attach 
the muscle to the skeleton via tendons.   
1.3 Prenatal myogenesis  
1.3.1 Prenatal muscle development 
In vertebrates, skeletal muscle is derived from the somites, which are 
segmental blocks of paraxial mesoderm that develop on each side of the neural 
tube (reviewed by Christ and Ordahl (1995) and Cossu et al. (1996)). Somites 
differentiate dorsally into dorsal cells of the dermomyotome (Figure 1.2), and 
ventrally into the sclerotome. While the sclerotome gives rise to cells that form 
the ribs and vertebrae, emanating from the dermomyotome are the muscle 
precursor cells (myoblasts) as well as cells that contribute to other tissues. 
Dermomyotomal cells migrate dorsally to give rise to the epaxial myotome 
(source of trunk and back muscles) and ventrally to give rise to the hypaxial 
myotome (source of limb muscle). Three categories of myoblasts exist; 
embryonic, foetal and adult (or satellite cells). All of these cell types originate 
from the hypaxial region of the somite in the early embryo (White et al., 1975; 
Feldman and Stockdale 1992; Smith and Miller 1992). Following migration to the 
limb bud, embryonic myoblasts begin to fuse into primary fibres. After a period of 
time, the primary myoblast population is replaced by foetal myoblasts, which are 
subsequently replaced by a population of myoblasts that have adult or satellite 
cell-like features (Miller and Stockdale 1986a; Miller and Stockdale 1986b). 
Satellite cells first emerge during late foetal development coinciding with the 
formation of the basal lamina, and are the last myoblast population to appear 
during muscle development (Ontell and Kozeka 1984; Feldman and Stockdale 
1991; Feldman and Stockdale 1992; Hartley et al., 1992). In contrast to this 
sequential appearance of the different classes of myoblasts, a human skeletal 
muscle study has demonstrated that all the human myoblast populations 
concurrently exist as soon as the first primary myotubes are formed (Edom-
Vovard et al., 1999). Furthermore, the authors suggested that it is the proportion  
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Figure 1.2 Prenatal myogenesis  
(A) During the early stages of myogenesis, cells delaminate from the edges of the 
epithelial dermomyotome, initially mainly from the epaxial lip and then from the 
other edges. Cells from the hypaxial lip are a major source of myogenic cells. 
They express Myf5 and Mrf4, and form the skeletal muscle of the early myotome. 
(B) At certain axial levels, Pax-positive cells delaminate and migrate from the 
hypaxial dermomyotome to found muscle masses elsewhere. Some of these cells 
retain their Pax-positive progenitor cell status, contributing to later muscle 
growth. (C) At later stages, the central region of the dermomyotome loses its 
epithelial structure and Pax-positive cells enter into the muscle mass of the 
myotome. These provide progenitor cells for all subsequent muscle growth in the 
muscle masses of the trunk. Modified from Buckingham et al. (2006) 
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of the myoblast populations that differs during development, rather than their 
sequential appearance. Various studies support the hypothesis that muscle 
precursor cells, including the myogenic satellite cell population, emanate from the 
multipotential mesodermal cells of the somite (Schultz and McCormick 1994; 
Ordahl et al., 2000). This concept has been challenged by studies suggesting that 
precursors of the satellite cell may be multipotential cells of nonsomitic origin (De 
Angelis et al., 1999; Ordahl 1999). In one of these studies, cells isolated from the 
embryonic dorsal aorta were shown to possess a similar morphological 
appearance and gene expression profile to that of satellite cells (De Angelis et al., 
1999). However, agreement on the precise origin of muscle precursor cells 
remains unresolved. 
1.3.2 Fibre formation  
Muscle mass is increased by three mechanisms: muscle precursor cell 
proliferation; formation of muscle fibres (both prominent during embryonic 
development); and fibre hypertrophy, which begins during foetal development and 
dominates postnatally. Several waves of fibre formation occur during early 
development (reviewed by Stockdale (1997)). The primary wave occurs during 
embryonic development and produces primary fibres. These are formed from the 
first population of myoblasts and act as a scaffold for future fibres. This process 
involves myoblasts, from differing populations, fusing together to produce 
myofibres (Stockdale and Holtzer 1961). The second myogenic wave is initiated 
during late embryonic/early foetal development and forms the secondary fibres 
responsible for much of the muscle mass. This muscle growth is due to the rapid 
increase in fibre number, nucleation, and fibre diameter, occurring on the surface 
of the primary fibres (reviewed by Patel et al. (2002)).   
1.3.3 Myogenic regulatory factor signalling 
Basic helix-loop-helix (bHLH) proteins are a large family that function 
primarily as transcriptional activators. Two distinct domains characterise this 
group of proteins: the helix-loop-helix (HLH) domain (which facilitates 
dimerisation) and the basic region (containing positively charged amino acids that 
mediate binding to DNA). Myogenic regulatory factors (MRFs) are a subgroup of 
this family, as they share a region of homology with the two functionally 
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significant domains. It is generally accepted that MRFs play a vital regulatory role 
in the development of skeletal muscle (Buckingham 1992). This family of 
transcription factors is exclusively expressed in skeletal muscle, and includes 
MyoD (Tapscott et al., 1988; Sassoon et al., 1989; Weintraub 1993), myogenin 
(Braun et al., 1989a; Edmondson and Olson 1989; Wright et al., 1989), Myf5 
(Braun et al., 1989b) and MRF4, (also called herculin and Myf6) (Rhodes and 
Konieczny 1989; Miner and Wold 1990). All of the MRF family members are 
expressed in somites as well as developing muscle during embryogenesis, and 
function by forming heterodimeric DNA-binding complexes with other bHLH 
transcription factors to regulate gene expression (Weintraub et al., 1989; Lassar et 
al., 1991; Martin et al., 1992). Over the years, the essential role of the MRF 
family during myogenesis has been established, particularly through the practice 
of gene disruption technologies (Braun et al., 1992; Rudnicki et al., 1992; Hasty 
et al., 1993; Nabeshima et al., 1993; Patapoutian et al., 1995; Zhang et al., 1995). 
For example, Kassar-Duchossoy et al. (2004) demonstrated, using triple-mutant 
mice, that MyoD, Myf5, and MRF4 are all essential for the specification of the 
skeletal muscle lineage. In addition, inactivation of myogenin has been shown to 
result in perturbed muscle differentiation and neonatal lethality (Hasty et al., 
1993; Nabeshima et al., 1993). Various studies indicate that these transcription 
factors are activated sequentially (which appears to be species specific) during the 
skeletal muscle developmental program. For example, in mice, Myf5 mRNA is 
first detected in the day 8 somite and is later reduced after day 14 (Ott et al., 
1991). On day 8.5, myogenin mRNA appears and is continually expressed 
throughout foetal development (Sassoon et al., 1989). MRF4 mRNA is transiently 
expressed on days 10 and 11, then again from day 16 and continues to be until 
after birth (Bober et al., 1991), whereas MyoD mRNA is expressed throughout 
development after appearing around day 10.5 (Sassoon et al., 1989).  
1.3.4 Regulation of myogenesis by paired-box transcription factors 
Other key regulators of myogenesis are the paired-box (Pax) transcription 
factors, which include Pax3 and Pax7. During the maturation of the somite, Pax3 
and Pax7 have been used to identify cells of the dermomyotome and within the 
muscle mass of the myotome (Jostes et al., 1990; Goulding et al., 1991). Both 
Pax3 and Pax7 have been shown to be expressed in a population of muscle 
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precursor cells that are maintained throughout embryonic development in an 
uncommitted state (Kassar-Duchossoy et al., 2005; Relaix et al., 2005). Pax3 
expression marks the early stages of myogenic specification as well as playing a 
crucial role in the specification and/or migration of limb myogenic precursors 
(Bober et al., 1994; Goulding et al., 1994; Williams and Ordahl 1994). 
Differential modulation of Pax3 delineates the medial dermomyotome containing 
precursors of axial (back) muscle, and the lateral dermomyotome containing 
precursors of the limb muscle (appendicular muscle) (Williams and Ordahl 1994). 
In addition, Pax3-null mice (Splotch mice) have been shown to result in major 
disruptions in the early limb muscle development, suggesting Pax3 is necessary 
for the formation of limb muscles (Franz et al., 1993; Goulding et al., 1994). This 
is possibly through the generation of myogenic precursors or through the 
migration of cells to the limb buds. A number of studies indicate that muscle 
precursor cells from the lateral portion of the dermomyotome migrate into the 
limb bud where they differentiate and fuse to form the primary myotubes of the 
limb muscles (Chevallier et al., 1977; Christ et al., 1977). For this to proceed, 
Pax3 is repressed as dermomyotome-derived cells activate the MRF family of 
transcriptional activators, which control a later step(s) in myogenic specification 
and the terminal differentiation of muscle (Williams and Ordahl 1994).  
1.4 Postnatal myogenesis 
1.4.1 Fibre types 
Mammalian skeletal muscle is composed of various fibre types which 
differ in their contractile rate as well as their structural and metabolic properties. 
This allows the fibres, and thus the muscle as a whole, to perform various 
functional capabilities. Identification of the different fibre types has been 
performed using a number of histochemical staining techniques. A number of 
studies have utilised the pH lability of myofibrillar adenosine triphosphatase 
(mATPase) (Guth and Samaha 1969; Brooke and Kaiser 1970), as the myosin of 
slow muscle was found to be more alkali-labile than that of fast muscle (Sreter et 
al., 1966). Other methods such as immunohistochemistry and electrophoretic 
analysis have also been performed to identify the various fibre types within a 
muscle. Perhaps more commonly, fibre types are often classified on the myosin 
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heavy chain (MHC) isoform(s) they express. Four major fibre types have been 
identified in the adult skeletal muscles of small mammals using the MHC 
classification system, though approximately eleven isoforms have been identified 
in total (Pette and Staron 2000). These four main fibre types are; slow type I, 
which are suggested to originate from the primary fibres (Crow and Stockdale 
1984), and fast type IIA, B and D(X) (for reviews see Pette and Staron (2001) or 
Schiaffino and Reggiani (1996)). Functionally, these MHC isoforms have been 
correlated with shortening velocity. Studies indicate that type IIB fibres are the 
fastest contracting fibres, followed by IID, IIA and I being the slowest (Bottinelli 
et al., 1991; Bottinelli et al., 1994; Galler et al., 1994).  
Embryonic, foetal and adult cell populations contain myoblasts that have 
the capacity to form various fibre types. Clonal in vitro cultures of embryonic 
chick myoblasts have demonstrated the ability to form single parental myoblasts 
of three different fibre types (Rutz and Hauschka 1982; Miller and Stockdale 
1986a). This suggests that myoblasts are committed to a specific fibre type and 
this commitment is retained in the progeny cells. However, in contrast, mouse or 
rat embryonic myoblast cultures reportedly only express a slow MHC isoform, 
while foetal myoblasts will only express fast MHC isoforms (Vivarelli et al., 
1988; Pin and Merrifield 1993). Thus, it is unclear whether myoblasts have a 
predetermined fibre type fate, or whether it is species-specific.  
In addition to fibres expressing a single MHC isoform, fibres can also co-
express two or more MHC isoforms, thus creating intermediate fibres (Pette and 
Staron 1990; Schiaffino and Reggiani 1996). These fibres are classified according 
to the isoforms they express. For example, co-expression of MHCI and MHCIIA is 
referred to as type I/IIA. This co-expression may be brought about by the 
functional pressures upon the muscle, or an indication of fibre type transitions 
initiated by various conditions. Along with transitions in the expression of MHC 
isoforms, skeletal muscle also demonstrates a high degree of adaptive potential in 
its metabolic properties, as specific exercise programs have shown to induce shifts 
from anaerobic to aerobic metabolism (via alterations in enzyme levels and 
activities) (Gollnick et al., 1973; Holloszy and Booth 1976; Green et al., 1983). 
Overall, muscle fibres demonstrate a significant degree of plasticity, and are 
capable of changing their phenotype in response to various conditions such as 
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neuromuscular or hormonal alterations, mechanical loading/unloading, as well as 
aging (discussed in detail in Section 1.5.1.2). 
1.4.1.1 Neuromuscular innervation 
Innervation has been shown to be a crucial factor in the establishment and 
maintenance of the muscle fibre properties (reviewed by Pette and Vrbová 
(1985)). Only during the earliest stage of embryonic muscle formation are there 
no influences from motor neurons (Christ and Ordahl 1995). However, during the 
later stages of muscle development, it has been identified that the site of 
innervation on the primary myotubes is crucial to the placement of new secondary 
myotubes, as secondary myotubes centre on these innervation sites (Duxson 
1992). Through cross-innervation experiments, the role of innervation during the 
establishment of muscle types has been demonstrated (Buller et al., 1960). With 
cross-innervation, slow muscles become fast when innervated with a fast nerve 
(and vice versa). This induced change is reportedly brought about through the 
neural impulse patterns, which are specific for each nerve type. Furthermore, the 
phenotype of a muscle can be altered with defined electrical simulation. Applying 
chronic low frequency stimulation (CLFS) to a fast muscle mimics the tonic low 
frequency impulse pattern typically delivered to a slow twitch muscle (Salmons 
and Vrbova 1969), thus inducing the expression of slow MHC isoforms. When 
CLFS has been performed in rabbit m. tibialis anterior (TA) muscles, MHC type 
IID isoforms are sequentially changed with MHC type IIA, which are later 
changed for MHC type Iβ (Leeuw and Pette 1993; Hamalainen and Pette 1997; 
Peuker et al., 1998).  
1.4.1.2 Hormones 
Two types of hormones that can heavily influence the muscle fibre type 
composition are testosterone and thyroid hormones. While testosterone-induced 
changes have been observed in the sexually dimorphic temporalis muscle of the 
guinea pig (Lyons et al., 1986), thyroid hormones generally have the greatest 
impact on fibre type compositions. Hypothyroidism is known to induce fast to 
slow fibre type transitions while the converse transitions are observed with 
hyperthyroidism (Nwoye and Mommaerts 1981; Caiozzo et al., 1992; Larsson et 
al., 1994; Canepari et al., 1998). Furthermore, thyroid hormones are important 
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during muscle development and maturation, as low or high levels respectively 
result in the delay or acceleration of the transition from developmental to adult 
MHC isoforms (Gambke et al., 1983; Butler-Browne et al., 1987; Mahdavi et al., 
1987). 
1.4.1.3 Mechanical loading/unloading 
Increased neuromuscular activity produced through exercise has been 
shown to induce similar alterations in muscle as CLFS. However, the extent of 
change which occurs as a result of exercise is significantly reduced. Endurance 
exercise training is well known to increase enzymatic activities of aerobic-
oxidative energy supply, and induce fast to slow MHC transitions (Holloszy and 
Booth 1976; Green et al., 1983). Furthermore, mechanical loading also induces 
fast to slow MHC transitions. Several studies indicate that overload to a muscle in 
a stretched position can also cause the repression of fast-type genes, and induce 
the activation of slow-type genes (Loughna et al., 1990; Goldspink et al., 1991). 
Conversely, unloading through hind-limb and spaceflight has been shown to result 
in deceases in MHCI with a concomitant increase in MHCII. 
1.4.2 Fibre number 
It is generally believed that the number of fibres that form during foetal 
muscle development defines the fibre number in adult muscle, as little to no new 
fibre formation occurs after birth (Ontell and Kozeka 1984; Ross et al., 1987; 
Ontell et al., 1988). Thus, foetal muscle proliferation and fusion is a pivotal 
determining factor in regards to fibre number. One mechanism for the control of 
myoblast proliferation and thus fibre number is through innervation. Ross et al. 
(1987) demonstrated that innervation has been directly correlated with the 
regulation of secondary myotubes, as nerve terminals on the primary fibres 
regulate mitosis of myoblasts to promote secondary fibre formation. A second 
mechanism which may regulate myoblast numbers is through insulin-like growth 
factors (IGFs) and transforming growth factor-beta (TGF-β) family members 
(Olson et al., 1986; Bischoff 1994; Cusella-De Angelis et al., 1994; Thomas et 
al., 2000) (discussed further in Section 1.6.4).  
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1.4.3 Fibre hypertrophy 
The augmentation of muscle mass from the neonatal stage is largely due to 
increases occurring in the existing muscle fibres. Muscle hypertrophy is an 
increase in muscle size, which relates to the cross-sectional area of each muscle 
cell. Any change in fibre volume reflects alterations in the number of nuclei per 
unit fibre length and/or the volume of cytoplasm per nucleus. While one reflects 
nuclear turnover (nuclear addition or loss) the other reflects turnover of cell 
constituents (e.g. protein synthesis or degradation). Numerous studies indicate that 
muscle fibre hypertrophy is correlated with an increase in myonuclear number 
(Cabric and James 1983; Winchester and Gonyea 1992; Allen et al., 1995; McCall 
et al., 1998), and is reliant on the proliferation and contribution of satellite cells 
(Rosenblatt et al., 1994; Adams and Haddad 1996).  
Conversely, a stretch-overload study using avian muscle demonstrated that 
hypertrophy can also occur without satellite cell proliferation (Lowe and Alway 
1999). In addition, Dupont-Versteegden et al. (1999) have suggested that 
increases in myofibre size can be obtained without addition of nuclei and that a 
considerable plasticity in the nuclear domain of myofibres exists.  
1.4.4 Satellite cells  
1.4.4.1 Satellite cell location and origin  
Satellite cells were first described in 1961 through studies using frog 
muscle fibres (Katz 1961; Mauro 1961). Using electron microscopic studies, 
Mauro (1961) described the position of satellite cells on the muscle fibre as being 
wedged between the plasma membrane and the basement membrane (basal 
lamina). It is generally believed that satellite cells are derived from the somites 
(Armand et al., 1983), and are responsible for the majority of postnatal 
myogenesis. However, recent studies have challenged this theory by suggesting 
that additional muscle progenitors may exist, including bone marrow-derived cells 
or cells of haematopoietic origin. Green fluorescent protein- (GFP) labelled bone 
marrow-derived cells have been shown to contribute to muscle myofibres and 
express satellite cell markers when transplanted into irradiation-induced damaged 
muscle (LaBarge and Blau 2002). In other studies, bone marrow-derived cells 
injected directly or intravenously into injured muscle have demonstrated that these 
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cells were capable of contributing to the myofibres (Ferrari et al., 1998; Gussoni 
et al., 1999; Ferrari et al., 2001; Fukada et al., 2002). However, Sherwood et al. 
(2004) recently compared the myogenic properties of endogenous satellite cells 
with those of bone marrow-derived, haematopoietic stem cell-derived, and 
circulating cells engrafting the skeletal muscle. The findings from this study 
indicated that there were significant differences in the myogenic properties within 
the different cell populations. Although each cell population was able to localise 
the same anatomic compartment as the myogenic satellite cells, they did not 
display any intrinsic myogenicity (Sherwood et al., 2004).  
Lastly, muscle-derived side population cells (basis on Hoechst dye 
exclusion) (Asakura et al., 2002) injected intramuscularly (McKinney-Freeman et 
al., 2002), or when co-cultured with myoblasts (Asakura et al., 2002), have also 
been shown to contribute to myofibres. In accordance with these findings, muscle-
resident CD45+Sca1+ cells (referred to as stem cells) have also been shown to 
generate myogenic cells in co-culture and in vivo after muscle injury or activation 
(Polesskaya et al., 2003). These findings suggest a further muscle progenitor cell 
population.  
1.4.4.2 Role of satellite cells 
In addition to providing the location of satellite cells, Mauro (1961) also 
hypothesized that these satellite cells were remnants from embryonic development 
which remain dormant until repair of an existing fibre was required. Satellite cells 
are now defined as mitotically quiescent mononuclear cells that, in response to 
regenerative cues, are capable of proliferating to form myoblasts, which can 
terminally differentiate and fuse into multinucleated myotubes (Beauchamp et al., 
1999; Beauchamp et al., 2000). During development, satellite cells proliferate and 
later become mitotically quiescent in the mature muscle (Schultz et al., 1978). 
Rodent studies indicate that cessation of proliferation in postnatal muscle occurs 
within weeks after birth (Moss and Leblond 1971; Snow 1979). Furthermore, the 
percentage of satellite cells has been shown to decline from 30% of muscle nuclei 
in neonatal muscle to only 5% in adult mouse muscles (Bischoff 1994). In relation 
to the postnatal function of satellite cells, various studies indicate that they have a 
crucial role in muscle maintenance and repair (discussed in Sections 1.4.5.2 and 
1.5.2). Techniques involving the isolation of single muscle fibres, along with their 
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resident satellite cells, via the enzymatic digestion of a muscle have provided 
significant insight into the mechanism for this maintenance and repair process. In 
vitro studies using isolated fibres have confirmed that satellite cells give rise to 
myoblasts and differentiating myotubes (Bischoff 1975; Konigsberg et al., 1975; 
Yablonka-Reuveni and Rivera 1994; Rosenblatt et al., 1995; Beauchamp et al., 
2000). Furthermore, it was recently shown through individually grafting 
myofibres into radiation-ablated muscles of dystrophic mdx-nude mice that 
satellite cells associated with the myofibre give rise to progeny competent to 
generate thousands of myonuclei and were capable of extensive self-renewal 
(Collins et al., 2005).  
Although satellite cells have traditionally been considered to be unipotent, 
more recently, studies have suggested that they are in fact multipotent cells.  In 
vitro studies have demonstrated that satellite cells are also capable of 
differentiating into osteogenic and adipogenic lineages (Asakura et al., 2001; 
Wada et al., 2002; Shefer et al., 2004). It remains unclear however, whether these 
alternative pathways are brought about through transdifferentiation of the satellite 
cells, are representations of differing cell types within the satellite cell niche, or 
simply a reflection of gene stimulation within the context of the myogenic 
progeny. Furthermore, it is also unknown if satellite cells possess the ability to 
alter their differentiation program in vivo. 
1.4.4.3 Markers of satellite cells 
The availability of molecular markers in recent times has allowed accurate 
identification of satellite cells at a light microscope level. An array of markers has 
been shown to detect satellite cells. These include Pax7 (Seale et al., 2000), M-
cadherin (Irintchev et al., 1994), CD34 (Beauchamp et al., 2000), c-Met 
(Cornelison and Wold 1997), lysenin (Nagata et al., 2006), caveolin 1 (Galbiati et 
al., 2001), along with others (see reviews (Hawke and Garry 2001; Charge and 
Rudnicki 2004)). Numerous studies utilising satellite cell markers have detailed 
the expression profile of satellite cells during various stages of myogenesis 
(Figure 1.3). For example, once quiescent satellite cells become activated, they 
begin to express MyoD while co-expressing Pax7 and Myf5 (Cooper et al., 1999; 
Zammit et al., 2004), as well as genes associated with cell cycling such as the 
proliferating cell nuclear antigen (PCNA) (Johnson and Allen 1993). With the  
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Figure 1.3 Schematic of satellite cell myogenesis and markers  
Satellite cells are quiescent in normal adult muscle and can be activated upon 
stimulation. Once activated, satellite cells divide to produce satellite cell-derived 
myoblasts that further proliferate, before committing to differentiation and fusing 
to form myotubes, which then mature into myofibers (for clarity, satellite cell self-
renewal is not included). CD34, Pax7, and Myf5/β-gal are expressed in quiescent 
satellite cells. Satellite cell activation is marked by the rapid onset of MyoD 
expression, whereas myogenin later marks the commitment to differentiation. 
Myf5/β-gal denotes the fusion protein product of the targeted allele of the 
Myf5nlacZ/1 mouse (Tajbakhsh et al., 1997). Adapted from Miller et al. (Miller 
et al., 1999) and Zammit et al. (2006) 
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onset of myogenic differentiation, myogenin is expressed coinciding with a 
decline in MyoD and PCNA (Yablonka-Reuveni and Rivera 1994). 
1.4.4.4 Satellite cell self-renewal 
A replenishment of the satellite cell pool is required, as it is estimated that 
a 1-2% myonuclear turnover occurs per week (Schmalbruch and Lewis 2000). In 
addition, it is thought that in vivo, satellite cells undergo only one or two divisions 
prior to differentiation (Grounds and McGeachie 1987). A mechanism for satellite 
cell self-renewal first proposed in 1971, suggested either a stochastic event, or an 
asymmetrical cell division resulting in one daughter cell being committed to 
myogenic differentiation while the second proliferated and returned to a 
quiescent-like state (Moss and Leblond 1971). In vitro studies using myoblast 
cultures, have demonstrated that upon serum withdrawal, a population of cells, 
referred to as "reserve cells”, stop cycling and down-regulate MyoD, a 
characteristic mimicking quiescence cells (Kitzmann et al., 1998; Yoshida et al., 
1998). After isolating these reserve cells and returning them to growth conditions, 
they again began to proliferate and express MyoD (Yoshida et al., 1998). Using 
single fibre cultures, a similar behaviour has been observed in the associated 
satellite cells. As previously described, proliferating satellite cells can suppress 
Pax7 expression while maintaining MyoD and differentiate, or alternately, down-
regulate MyoD, maintain Pax7, and enter a quiescent-like state (Zammit et al., 
2004). This clearly suggests a mechanism for maintaining the satellite cell pool 
via a self-renewal process. However, it remains unconfirmed whether the satellite 
cell population is self-sufficient in restoring the satellite cell pool through self-
renewal, or whether it relies on a non-satellite progenitor cell. These putative non-
satellite progenitor cells are suggested to be multipotent stem cells residing 
outside of the satellite cell niche (Figure 1.4). Proposed candidates include 
interstitial cells (Tamaki et al., 2002; Polesskaya et al., 2003; Kuang et al., 2006), 
endothelial-associated cells (De Angelis et al., 1999) and side population cells 
(Asakura et al., 2002). To date, it remains unclear how crucial these cell types are 
to the replenishment of the satellite cell pool.   
In addition, it is currently unresolved whether Pax7 is critical for satellite 
cell self-renewal. Seale et al. (2000) first reported that a complete absence of 
satellite cells in Pax7-null skeletal muscle, suggesting that an induction of Pax7  
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Figure 1.4 Proposed mechanisms for satellite cell self-renewal  
Satellite cells generate proliferative myoblasts, which subsequently commit to 
differentiation, differentiate and fuse to repair or replace damaged myofibres. 
Satellite cell self-renewal could result from asymmetric division and/or by the 
cycling myoblasts returning to quiescence. Non-satellite cell phenotypes derived 
from the muscle interstitium and circulation may also give rise to small numbers 
of myonuclei and cells in the satellite cell position. Reproduced from Collins 
(2006) 
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induces satellite cell specification. However, other studies have demonstrated the 
presence of satellite cells in Pax7-null mice, though the mice display a rapid 
depletion of satellite cells during early postnatal growth (Seale et al., 2000; 
Oustanina et al., 2004). Asymmetrical division has also been correlated with 
divergent fates of daughter cells. Numb, a Notch antagonist has been found to be 
localised asymmetrically in dividing myogenic cells in Drosophila embryos (Ruiz 
Gomez and Bate 1997; Carmena et al., 1998; Park et al., 1998) and in murine 
cells (Conboy and Rando 2002). This asymmetric segregation of Numb appears to 
determine the fate of daughter myoblasts during terminal divisions (Numb+ cells 
differentiate, while Numb- proliferate and possibly return to a quiescent state), 
thus providing another mechanism for satellite cell self-renewal.  
1.4.5 Skeletal muscle regeneration 
Skeletal muscle is a highly regenerative tissue that is second only to bone 
marrow with regards to its regenerative capacity. This extensive regenerative 
capacity has been demonstrated through repetitive injury studies (Sadeh et al., 
1985; Luz et al., 2002). Various injury models such as crush, freeze, and chemical 
injuries have previously been performed to examine the regenerative mechanisms 
discussed here.  
1.4.5.1 Muscle injury and the degenerative phase 
Muscle regeneration is characterised by an initial degenerative phase, 
which is later integrated with a regenerative phase. The degenerative phase is 
generally initiated by necrosis of the muscle fibres elicited by a disruption of the 
myofibre sarcolemma. Any disruption of this kind would induce an increase in the 
permeability of the myofibre, resulting in a cascade of molecular and cellular 
events. It is likely that the increased calcium influx after membrane damage 
results in a calcium-dependent proteolysis, driving tissue degeneration via the 
action of calpains. These are calcium-activated proteases which cleave 
myofibrillar and cytoskeletal proteins (Bodensteiner and Engel 1978; Belcastro et 
al., 1994; Spencer et al., 1995; Williams et al., 1999). An initial stage of muscle 
recovery is the influx of mononucleated cells, predominantly consisting of 
inflammatory cells. This process is believed to be initiated by factors released 
within the injured muscle, which activate resident inflammatory cells. Activation 
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of these cells causes them to release chemotactic signals attracting circulating 
inflammatory cells to the injury site (reviewed by Tidball (1995)). The first 
inflammatory cells to rapidly migrate to the site of injury are neutrophils, which 
release trophic factors to activate satellite cells within 2 hr of injury (Goetsch et 
al., 2003). The infiltrating neutrophils may be phagocytic, however, they are also 
capable of releasing proteases that can participate in the degradation of cellular 
debris resulting from the muscle damage. The second inflammatory cell type to 
migrate into the damaged area is macrophages (Orimo et al., 1991). Macrophages 
are antigen-presenting cells that play an important role in the regulation of cellular 
immune responses in injured muscle. Studies using rat skeletal muscle have 
demonstrated that macrophages which migrate to the injury site are phagocytic, 
and are at highest concentrations where the tissue is most damaged (Honda et al., 
1990; McLennan 1993). Various other roles macrophages may play during muscle 
repair and remodelling have also been proposed. For example, muscle 
regeneration using transplanted myogenic cells can be severely impaired when the 
host monocyte-macrophages are completely depleted (Lescaudron et al., 1999). 
Interestingly, conditioned media from peritoneal macrophage cultures or 
macrophage cell lines have been shown to increase the proliferation rate and the 
number of MyoD expressing cells in myoblasts cultures (Cantini and Carraro 
1995; Massimino et al., 1997; Merly et al., 1999). Furthermore, intensive physical 
exercise studies have demonstrated the stimulation of peritoneal macrophages 
(Fehr et al., 1988; Lotzerich et al., 1990). This suggests that a systemic factor is 
released following muscle damage, which can elicit an inflammatory response 
throughout the body. However, currently the identity of the macrophage-derived 
factor(s) that induce these changes is unknown.  
Various techniques have been employed to measure muscle injury. For 
example, increased serum levels of muscle proteins, such as creatine kinase, have 
been measured to observe the extent of muscle damage due to muscle 
degenerative diseases, such as muscular dystrophies (Percy et al., 1979). Uptake 
of low-molecular-weight dyes, such as Evans blue or procion orange, by the 
myofibre have also been shown to be reliable indicators of sarcolemmal damage 
(Matsuda et al., 1995; Straub et al., 1997). 
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1.4.5.2 Muscle regenerative phase 
Following the degenerative and inflammatory responses to muscle injury 
is the process of muscle repair and regeneration. The ability of adult skeletal 
muscle to regenerate, even after total disruption (Studitsky 1964; Carlson 1986), 
has largely been attributed to satellite cells (Partridge 2002). Mammalian 
myonuclei within a muscle fibre are terminally differentiated, and therefore 
cannot replace themselves. After injury, regeneration occurs via the activation and 
proliferation of satellite cells (Figure 1.5A). These cells later differentiate and fuse 
to provide the myonuclei required to repair or replace the damaged myofibres 
(Moss and Leblond 1971; Snow 1978; Bischoff 1994). Numerous nuclear 
radiolabelling experiments have demonstrated the contribution of dividing 
myogenic cells (emanating from the resident satellite cells) to regenerating 
myofibres, thus providing clear evidence that satellite cells indeed function as 
myogenic precursors (Snow 1977b; Snow 1978; Trupin et al., 1982; Schultz et al., 
1985; Darr and Schultz 1987). Furthermore, it has been demonstrated that 
following a chemical injury, the normally quiescent satellite cells become 
activated, re-enter the cell cycle and exhibit a significant proliferative capacity 
between 2 and 3 days following injury (Goetsch et al., 2003). This proliferation is 
vital for muscle regeneration, as demonstrated by the impaired regenerative 
capacity after exposure to colchicine (an inhibitor of mitotic division) or after 
irradiation (prevents satellite cell proliferation) (Pietsch 1961; Quinlan et al., 
1995). Satellite cell proliferation is generally followed by a differentiation 
process, where myoblasts withdraw from the cell cycle and form small basophilic 
(reflecting high protein synthesis) centronucleated myotubes (Goetsch et al., 
2003) (Figure 1.5B). The initial phase of myogenic cell expansion is essential for 
this latter phase as muscle repair is reliant on the number of myoblasts available 
for fibre formation and repair. Newly formed myofibres often initially express 
embryonic or developmental forms of MHC (Whalen et al., 1990), and contain 
centrally located myonuclei. These nuclei can be located in discrete portions or 
along the entire regenerating new fibre, suggesting cell fusion is focal to the site 
of injury (Blaveri et al., 1999). After fusion of the myogenic cells has concluded, 
the myofibres further increase in size through cytoplasmic expansion, while the 
myonuclei move to the fibre periphery (Figure 1.5C). Thus the newly regenerated  
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Figure 1.5 Muscle repair is dependent on myogenesis 
(A) Illustration of the regenerative stages after injury including: satellite cell 
activation (within 2 hr of injury); satellite cell proliferative stage (peaking at days 
2-3); differentiation (characterised by centrally located nuclei within the 
regenerating myofibers); and maturation. (B) Following cardiotoxin injury, 
regeneration results in the formation of small myofibres containing centrally 
located nuclei (indicated by arrowhead). (C) With further regeneration, these 
nuclei move to the myofibre periphery. Reproduced from Shi and Garry (2006). 
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fibres morphologically and functionally resemble the undamaged fibres within the 
muscle. During this regenerative period, numerous genes associated with 
myogenesis are systematically expressed. For example, studies indicate that 
MyoD is induced within 2-6 hr after injury correlating to the activation of satellite 
cells (Grounds et al., 1992; Megeney et al., 1996), while Myf5 and myogenin 
display a delayed expression peaking within 5 days of injury (Goetsch et al., 
2003). In addition, various components of the Notch/Numb pathway (which plays 
a role in the activation of satellite cells), as well as transcriptional regulators 
(including Pax3 and Pax7, Forkhead, and Sox family members) are up-regulated 
during the repair and regenerative period (Goetsch et al., 2003; Turk et al., 2005).  
Collectively, the various studies described herein, indicate that the 
regenerative process after injury shares a high degree of similarity with prenatal 
and neonatal myogenesis.   
1.4.5.3 Collagen formation 
Myofibres and connective tissue have an imperative association essential 
for effective muscle function, normal transmission of force, and maintenance of 
the tensile strength of a muscle. Following an injury, the functional continuity of 
the tendon-myofibre-tendon unit is often disrupted (Grounds 1991; Hurme et al., 
1991). Therefore, successful repair of the damaged muscle is reliant on a balance 
between the regeneration of muscle fibres and connective tissue synthesis. These 
are two simultaneous processes which are supportive of, but also competitive 
with, each other.  
Normally collagen forms a sheath around the fusing myoblasts during 
myotube formation (Allbrook 1973; Bailey et al., 1979). However, excessive 
proliferation of fibroblasts, and thus synthesis of connective tissue, can lead to 
excessive scarring and fibrosis. This may lead to the formation of a dense 
mechanical barrier that can impede myofibre regeneration (McMinn 1967; 
Allbrook 1973; Burry 1975). 
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1.5 Sarcopenia 
1.5.1 Phenotype of the aged muscle 
A significant characteristic of the aging process in mammals is the 
profound loss of skeletal muscle mass and strength, commonly referred to as 
sarcopenia. Imaging techniques have confirmed an age-related loss of muscle 
mass within specific muscle groups (Coggan et al., 1993; Frontera et al., 2000). In 
humans, much of the observed muscle loss disproportionately occurs in the lower 
body (Janssen et al., 2000). The rate of muscle loss after 50-years of age appears 
fairly constant at approximately 1-2% annually (Sehl and Yates 2001; Hughes et 
al., 2002). 
A number of studies have indicated that the functional decrease in muscle 
strength associated with aging is proportionally greater than the reduction in 
muscle mass (Overend et al., 1992; Welle et al., 1996b; Lynch et al., 1999; 
Martin et al., 2000). Contrary to this, others dispute that the decline in muscle 
mass is sufficient to account for the decreases in strength (Young et al., 1984; 
Alway et al., 1996; Frontera et al., 2000). Irrespective of these inconsistencies, a 
decrease in muscle efficiency is largely responsible for the age-related decline in 
muscle strength and is most likely due to the loss of and/or alteration in the 
contractile properties of the muscle motor units (Faulkner et al., 1995; Kadhiresan 
et al., 1996). With advancing age, a decrease in muscle protein synthesis is known 
to occur (Welle et al., 1993; Welle et al., 1996a; Balagopal et al., 1997). This loss 
is particularly prominent in the resident mitochondria, possibly due to the age-
related mutations and deletions that occur in mitochondrial DNA (Barazzoni et 
al., 2000). In addition, the decrease in mitochondrial protein synthesis has also 
been correlated with a decline in mitochondrial oxidative enzymes and VO2max 
(the highest rate of oxygen consumption attainable during maximal or exhaustive 
exercise) that occurs with age (Rooyackers et al., 1996).  
Various physiological characteristics associated with the age-related loss 
of muscle mass and strength include decreases in muscle fibre numbers or specific 
fibre types, atrophy of existing fibres, loss of motor innervation, defective muscle 
regeneration, altered vasculature, and increased fibrosis. 
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1.5.1.1 Muscle fibre loss 
Whether a loss of fibres occurs with age is somewhat contentious, and is 
most likely species-specific (Caccia et al., 1979; Hooper 1981; Sato et al., 1984; 
Eddinger et al., 1985; Larsson and Edstrom 1986; Alnaqeeb and Goldspink 1987; 
Brown 1987; Daw et al., 1988; Lexell et al., 1988; Timson and Dudenhoeffer 
1990). Likewise, it is credible that muscle type is important for the analysis of 
fibre number, as the degree of age-related atrophy appears to be muscle-specific 
(as muscles vary in their fibre type composition). In saying this, human studies 
which have described a fibre loss, showed no discrimination between the fibre 
types (Sato et al., 1984; Lexell et al., 1988). The inconsistencies as to whether a 
loss of fibres occurs may also be due to the occurrence of fibre splitting, which 
complicates the analysis of the overall fibre number (Alnaqeeb and Goldspink 
1987). Fibre splitting or branching has been associated with muscle regeneration 
and is possibly related to incomplete fusion of fibres regenerating within the same 
basal lamina (Bourke and Ontell 1984; Blaivas and Carlson 1991; Blaveri et al., 
1999). A number of studies report that fibre splitting is a common characteristic 
observed in aging mouse muscles, and has been suggested to correlate with its 
abnormal regenerative capacity (Bockhold et al., 1998; Charge et al., 2002). In 
the muscles of aged rats, the increased fibrosis observed within the regenerating 
muscle has provided an explanation for the observed myofibre branching (Sadeh 
1988; Blaivas and Carlson 1991). One major cause of fibre loss that has been 
clearly identified is the process of denervation, which is known to occur with 
aging (refer to Section 1.5.1.4 for further discussion).  
1.5.1.2 Muscle fibre type changes 
Aging has been suggested to cause fast to slow fibre type transitions. 
Various studies indicate fibre type shifts within the MHCII isoforms or to an 
MHCI isoform (Kugelberg 1976; Alnaqeeb and Goldspink 1987; Larsson et al., 
1993; Musaro et al., 1995). In addition, aging has been associated with a relative 
increase in muscle fibres co-expressing two or more MHC isoforms, signifying 
that there is less distinction between the slow and fast fibre types with age 
(Andersen et al., 1999).  
It has been difficult to determine however, the exact cause of these 
transitions, as aging is a multifactorial condition, and it is unknown whether fibre 
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type changes represent primary or secondary events. Two factors implicated in the 
age-related fibre type transitions are denervation via a selective loss of fast α-
motor neurons (Hashizume et al., 1988; Ansved and Larsson 1990) (discussed 
further in Section 1.5.1.4), and alterations in the level of thyroid hormones, which 
can modulate MHC gene expression and the protein composition of muscles 
(Sieck et al., 1996).   
1.5.1.3 Muscle fibre atrophy 
As previously discussed, muscle fibre size is dependent on any alterations 
in the number of nuclei per unit fibre length, as well as the volume of cytoplasm. 
By using a number of muscle atrophy models, it has been shown that the fibre 
cross-sectional area and the myonuclear number are both consistently decreased 
with age (Allen et al., 1995; Allen et al., 1996; Kasper and Xun 1996b; Kasper 
and Xun 1996a; Allen et al., 1997). However, it is unclear how the myonuclear 
domain (nucleo-cytoplasmic ratio) changes during age-related atrophy. For 
example, Vassilopoulos et al. (1977) demonstrated that the myonuclear domain 
remained unchanged with age, while Manta et al. (1987) showed a decrease. 
Interestingly, one study showed that human males who maintained physical 
activity into their eighties demonstrated compensatory hypertrophy of muscle 
fibres to compensate for a decrease in fibre number (Aniansson et al., 1992). 
However, this observation appears to be uncommon among other aging studies. 
The observed fibre atrophy is generally associated with type II fibres 
(Lexell et al., 1988; Coggan et al., 1992; Lexell 1995), which functionally would 
weaken the muscle due to the greater power that these fibres generate compared to 
type I fibres. Little is known about the control of fibre size in normal adult muscle 
fibres, and it is unclear why fibre size declines with age. One possibility is that a 
deficiency in satellite cell function results in a reduction in the number of nuclei 
within a muscle fibre. Alternatively, modifications intrinsic to the fibres could 
reduce the recruitment of satellite cells into the fibre during re-modelling, as well 
as reduce the production of muscle fibre-specific proteins. A number of studies 
have demonstrated that the synthesis of muscle protein declines by approximately 
30% with aging (Welle et al., 1993; Welle et al., 1996a; Balagopal et al., 1997). 
Of note, a selective reduction of muscle protein synthesis appears to occur, 
resulting in a decrease in the rate of MHC synthesis, while the synthesis of 
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sarcoplasmic protein is either maintained or increased with age (Balagopal et al., 
1997). More specifically, mRNA levels of both MHC IIA and IID isoforms are 
significantly reduced with age (Balagopal et al., 2001). However, it is unclear 
whether this is related to transcriptional or pre-transcriptional defects, or mRNA 
instability. Since the ability of a muscle to synthesize MHC has been highly 
correlated with muscle strength (Balagopal et al., 1997), this decline in MHC 
production is particularly relevant to the fibre atrophy observed during aging. And 
finally, extrinsic factors such as innervation or systemic factors are highly likely 
to be of major importance to fibre atrophy. There is no doubt that a loss of motor 
neurones occurs during aging (Ansved and Larsson 1990). This is highly pertinent 
to fibre size as denervation causes rapid atrophy of the fibres through loss of 
cytoplasmic volume and myonuclei (Viguie et al., 1997), and can possibly result 
in the loss of the fibre. 
1.5.1.4 Innervation 
As previously described, innervation appears to be vital in fibre 
development, and also during maintenance of fibre size and type. In fact, 
following denervation, muscle mass can decline by over 50% within 1 month 
(Gutmann 1962). The denervation reported to occur with age  is related to motor 
neuron cell death or neuromuscular junction remodelling (Pettigrew and Gardiner 
1987; Hashizume et al., 1988; Ansved and Larsson 1990), and has been directly 
linked with the progressive loss of muscle mass (Viguie et al., 1997). In humans, 
a 50% loss of motor neurons can occur in individuals over 60-years of age 
(Tomlinson and Irving 1977). Numerous studies have shown not only a reduced 
number of motor units (consisting of a motor neuron and all of the fibres it 
innervates) with age (Campbell et al., 1973; Doherty and Brown 1993; Luff 
1998), but also an increase in the motor unit size (Sica et al., 1976). This would 
indicate that if a fibre has lost contact with its motor neuron, it becomes 
reinnervated by another neuron by axonal branching. A selective loss of specific 
motor neuron types has been correlated with both fibre type grouping and fibre 
atrophy grouping, resulting in a reduction in the mosaic composition of a muscle 
(Grimby et al., 1982; Larsson et al., 1991). In addition, neuromuscular junction 
(Lexell 1997; Luff 1998) and axon myelination (Grover-Johnson and Spencer 
1981; Kazui and Fujisawa 1988; Knox et al., 1989) abnormalities, which would 
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impede stimulations for muscle contractions, have also been observed in aged 
rodents and humans. These observations are highly suggestive of neural 
degeneration occurring with age. Interestingly, innervation studies using rats have 
reported conflicting results as to whether aging is associated with an impaired 
ability to reinnervate muscle fibres (Kanda and Hashizume 1991; Carlson and 
Faulkner 1996; Carlson and Faulkner 1998), possibly indicating other influencing 
factors.  
1.5.1.5 Regeneration 
Various studies indicate that the efficacy of old muscle to regenerate is 
reduced due to a decreased rate of regeneration, as well as a reduced amount of 
muscle replaced (Carlson and Faulkner 1988; Sadeh 1988; Carlson and Faulkner 
1989). Successful regeneration of the muscle is believed to be heavily reliant on 
an adequate satellite cell population and effective innervation (Grounds and 
Yablonka-Reuveni 1993). As previously discussed, satellite cells have a crucial 
role in muscle regeneration (Schultz and Jaryszak 1985), with their activation and 
proliferation being intimately linked to the regeneration capabilities of the muscle. 
However, it is generally accepted that this process is reduced or retarded with age 
(discussed further in Section 1.5.2). In addition, the participation of satellite cells 
during regeneration is significantly dependent on the inflammatory response. Of 
note, macrophage infiltration has been shown to be retarded after injury in old rats 
compared to young rats (Sadeh 1988). As macrophages are required for the 
removal of necrotic tissue and the promotion of satellite cell activation, any 
impediment in macrophage infiltration would result in delayed myofibre 
regeneration. This has been confirmed in a study demonstrating that an age-
related decline in macrophage activity contributed to slower wound healing in 
aged mice (Danon et al., 1989). Circulating leukocytes, hormones and cytokines 
(as well as the efficacy of cells responding to them) have also been suggested as 
potential candidates responsible for the altered macrophage activity (Grounds 
1987; Cannon 1995; Rall et al., 1996). 
1.5.1.6 Vasculature 
A number of studies have indicated changes in regards to vasculature 
within skeletal muscle. Reduced blood supply (McCully and Posner 1995), 
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decreased capillary density (Coggan et al., 1992) and alterations in the vascular 
pathology (Cooper et al., 1994) have all been reported to occur with age. 
Decreases in vascularity would have serious negative effects on muscle 
regeneration due to subsequent reductions in the inflammatory cell infiltration.  
1.5.1.7 Fibrosis 
With age, an increase in interstitial fibrotic connective tissue is frequently 
observed. In mice, endomysial collagen is reported to double between 3- and 26-
weeks of age (Marshall et al., 1989). Increased fibrosis is also reported to occur in 
regenerating muscles of aged animals (Carlson and Faulkner 1989; Ullman et al., 
1990). Furthermore, increases in the external lamina encircling the satellite cells 
has also been reported to occur with age (Snow 1977a), thus impacting their 
activation and proliferative capabilities. All of these fibrotic alterations would 
substantially reduce the myogenic capacity of a muscle.   
1.5.2 Satellite cell activation 
Aged muscle appears to have impaired satellite cell function. This would 
significantly contribute to the age-related loss and weakening of a muscle, as well 
as reduce the regenerative capacity. To date, it is unclear whether satellite cell 
numbers decline with age, although much of the confusion may arise through 
variations in muscle types and animal species (Gibson and Schultz 1983; Nnodim 
2000; Conboy et al., 2003; Schafer et al., 2005; Shefer et al., 2006). The ability of 
satellite cells to become activated as well as their proliferative capacity has also 
been shown to decrease with age (Schultz and Lipton 1982; Dodson and Allen 
1987; Johnson and Allen 1993; Barani et al., 2003; Conboy et al., 2003; Machida 
and Booth 2004). Furthermore, satellite cells from aged muscle show an extended 
latent period between an activation stimulus and proliferation (Tatsumi et al., 
1998; Yablonka-Reuveni et al., 1999). For example, an autoradiographic study 
performed on crush injured muscles has shown that myoblast proliferation is 
retarded in aged mice compared to young mice (McGeachie and Grounds 1995). 
In humans a decrease in the satellite cell pool and proliferative ability has been 
observed from early childhood years. Renault et al. (2000) showed that satellite 
cells from human neonatal and infant muscle were capable of 60 and 45 
replications respectively. In comparison, 9-year-old and 60-year-old cells were 
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only capable of 20-30 replications. Additionally, with increasing age, satellite 
cells fused to form thinner, more fragile myotubes.  
A mechanism for the impaired regenerative capacity associated with age-
related myopathies such as sarcopenia has been suggested to result from both the 
macro- and microenvironment (Carlson and Faulkner 1989; Coggan et al., 1992; 
Carlson and Faulkner 1996; Chakravarthy et al., 2000). Surgical procedures have 
eloquently demonstrated that introduction of old muscle to a young environment 
rejuvenates the capacity of the satellite cells to contribute to the muscle 
regeneration (Carlson and Faulkner 1989; Conboy et al., 2005). This clearly 
indicates that the aged environment is a major component in the decline of 
satellite cells participating during muscle regeneration. Interestingly, cross-
transplantation of m. extensor digitorum longus (EDL) muscles between young 
and old rats demonstrated that the mature skeletal muscle was equally capable as 
young skeletal muscle in recovering from the transplantation (Carlson and 
Faulkner 1989). However, young nerve-muscle autografts functioned significantly 
better than old nerve-muscle autografts, suggesting that a deficiency in re-
innervation with increasing age accounts for the poorer muscle regeneration in the 
aged muscle (Carlson and Faulkner 1996).  
One molecular mechanism shown to be directly linked with the impaired 
proliferative capacity of aged satellite cells is the Notch signalling pathway, as 
induced expression of activated Notch restores the regeneration capacity of aged 
muscle (Conboy et al., 2003; Luo et al., 2005). Furthermore, parabiosis studies, 
whereby young and old mice were surgically joined to establish a shared 
circulatory system, have shown that as yet unknown circulating factors in the 
young mice restored both Notch signalling and the muscle regeneration capacity 
in the aged mice (Conboy et al., 2005). 
Various other factors have been suggested to affect the efficiency of 
skeletal muscle regeneration within the aged environment. These include 
thickening of the basal lamina (Snow 1977a), accumulation of collagen within the 
muscle (Marshall et al., 1989), and reduced capillary density (Coggan et al., 
1992). In addition, aging has been shown to result in a decrease in inflammatory 
factors and macrophages essential for the normal satellite cell response to injury 
(Danon et al., 1989). Reduced serum levels of growth factors such as IGF-I, 
which acts as a potent mitogen for satellite cells in culture (Allen and Boxhorn 
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1989; Doumit et al., 1993), have also been reported in both aged rats and humans 
(Ullman et al., 1990; Reeves et al., 2000). 
1.5.3 Hormonal and growth factor regulation 
Several hormones and growth factors which have multifactorial roles, 
including the regulation of muscle fibres, satellite cells and motor neurons, are 
thought to alter with age. The age-related decline of both testosterone and IGF-I 
have been suggested to be the most significant of the endocrine changes 
associated with sarcopenia. Studies in human males have shown that free 
testosterone declines by approximately 40% between 25- and 75-years of age, 
correlating with a decrease in muscle strength (Nankin and Calkins 1986; 
Vermeulen et al., 1996; van den Beld et al., 2000). In addition, the decline in free 
testosterone, and to a lesser extent IGF-1, has been linked with a reduction in the 
rate of MHC synthesis (Balagopal et al., 1997). Circulatory levels of IGF-I are 
also known to decline with age. For example, in a human study, a 25% decrease in 
the level of IGF-I was observed in aged muscles compared with adult muscles 
(Welle et al., 2002). IGF-I normally exerts several anabolic effects in muscle 
including increased protein synthesis, myoblast proliferation and differentiation, 
as well as enhanced re-innervation of the muscle fibres (Bischoff 1994; Caroni et 
al., 1994; Butterfield et al., 1997). Thus it is likely that decreases in testosterone 
and IGF-I levels in both animals and humans play a significant role in the decline 
of skeletal muscle mass.  
1.5.4 MRF expression 
As the expression of MRFs relate to the level of myogenesis occurring 
within a muscle, their periodic detection can indicate the myogenic state of a 
muscle. For example, during the neonatal stage, MyoD and myogenin are 
expressed at relatively high levels, however, the expression of both MRFs decline 
in adult muscles to a barely detectable level (Eftimie et al., 1991; Witzemann and 
Sakmann 1991; Musaro et al., 1995). With further aging the expression of MyoD 
and myogenin mRNA again increases (Musaro et al., 1995; Marsh et al., 1997; 
Gomes and Booth 1998; Kostrominova et al., 2000; Alway et al., 2001). Various 
studies have indicated that these changes in MyoD and myogenin expression in 
both adult and senescent muscle may be elicited either by denervation (Eftimie et 
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al., 1991; Voytik et al., 1993; Weis 1994; Kostrominova et al., 2000) or by 
regeneration (Fuchtbauer and Westphal 1992; Grounds et al., 1992; Kami et al., 
1995; Koishi et al., 1995; Marsh et al., 1997; Cooper et al., 1999; Launay et al., 
2001). In a study which analysed MyoD and myogenin protein levels in skeletal 
muscles of senile rats, Dedkov et al. (2003) demonstrated that the higher level of 
MyoD and myogenin protein was associated with their accumulation in the nuclei 
of both muscle fibres and satellite cells. Furthermore, these authors speculated 
that the up-regulation of the MyoD and myogenin protein in the muscle fibre 
nuclei was associated with a loss of innervation, whereas in the satellite cell nuclei 
it was an indication of their participation in the regenerative process relating to the 
denervation and/or re-innervation of the fibres.  
Overall these studies demonstrate that while aged muscle is able to 
respond to myogenic-inducing stimuli, it does not exhibit a high level of 
myogenic efficacy during this response, due to numerous factors.  
1.5.5 Treatment 
1.5.5.1 Testosterone replacement  
An overview of the numerous studies of testosterone replacement in 
elderly humans (recently reviewed by Gruenewald and Matsumoto (2003)) has 
provided a highly variable conclusion. Some authors report a modest increase in 
lean mass, muscle strength and protein synthesis (Urban et al., 1995; Sih et al., 
1997; Snyder et al., 1999; Kenny et al., 2001) or increased grip strength (Sih et 
al., 1997), while others observed no change (Clague et al., 1999; Snyder et al., 
1999). Furthermore, a number of studies have addressed whether testosterone 
replacement positively alters lower body strength (Sih et al., 1997; Clague et al., 
1999; Snyder et al., 1999; Kenny et al., 2001; Brill et al., 2002; Ferrando et al., 
2002), however, only a small number reported an increase. Although testosterone 
treatment appears to have minimal effectiveness in increasing in lean muscle 
mass, these studies do not necessarily indicate aged males are non-responsive (or 
have a low response) to testosterone, as aspects such as dosage could factor into 
the treatment response. 
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1.5.5.2 IGF-I 
Studies involving the over-expression of IGF-I in transgenic mice have 
demonstrated increased satellite cell proliferation, mobilisation of non-muscle 
stem cells, and improved response to injury and regeneration in skeletal muscle of 
aged mice (Musaro et al., 2001; Musaro et al., 2004; Mourkioti and Rosenthal 
2005). In addition, viral-mediated expression of IGF-I in mice has been shown to 
block age-related muscle atrophy (Barton-Davis et al., 1998). Barton-Davis et al. 
(1998) hypothesized that this was achieved by enhancing muscle regeneration 
through resident satellite cell activation. Other studies adopting an IGF-I infusion 
procedure have demonstrated that IGF-I treatment results in muscle hypertrophy 
(Adams and McCue 1998), by increasing the proliferation potential of skeletal 
muscle satellite cells (Chakravarthy et al., 2000). In addition, the hypertrophy 
observed following IGF-I treatment has also been suggested to be due to an 
enhancement of protein synthesis (Bark et al., 1998) or increased nerve sprouting 
(Vergani et al., 1997). 
1.5.5.3 Exercise 
Depending on the type of exercise training programme, increases in 
strength can be achieved. For example, resistance training, such as weightlifting, 
is a more powerful stimulus of muscle hypertrophy than endurance-type exercise 
regimes such as swimming (Klitgaard et al., 1990). Another resistance training 
study reported significant muscle strength and size gains even in frail elderly 
people (Fiatarone et al., 1990). Functionally, exercise programs have 
demonstrated increases in the size of both type I and type II muscle fibres, as well 
as muscle protein synthesis (Larsson 1982; Welle et al., 1995; Yarasheski et al., 
1999; Hasten et al., 2000; Balagopal et al., 2001). 
Although some clinicians have shown reluctance in regards to 
recommending high-intensity resistance training for elderly subjects, most studies 
have indicated that resistance training can be safely undertaken (Campbell et al., 
1994; Campbell et al., 1999).  
1.6 Myostatin 
One group of growth factors which play a number of vital roles in the 
regulation of both prenatal and postnatal myogenesis is the TGF-β superfamily. 
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This superfamily consists of a large number of growth and differentiation factors. 
A prominent member of this superfamily is myostatin, also referred to as growth 
and differentiation factor 8 (GDF8). First identified in mice, myostatin has been 
shown to be expressed in both embryonic and adult skeletal muscle, where it 
elicited its effect through an autocrine fashion to inhibit muscle development 
(McPherron et al., 1997).  
1.6.1 Expression of myostatin 
Myostatin can be detected in mice as early as 9.5 days postcoitum in 
approximately one third of the somites, and by 10.5 days it is expressed in almost 
every somite (McPherron et al., 1997). With further development, myostatin can 
be detected in a large proportion of the developing muscles. Expression continues 
in the adult where it is almost exclusively expressed in the muscle tissue at 
varying amounts (McPherron et al., 1997; Carlson et al., 1999; Wehling et al., 
2000). This muscle-specific expression has been strongly associated with the fast 
fibre types (Carlson et al., 1999). In addition, other studies using different animal 
species have also detected low levels of myostatin mRNA or protein in the 
porcine lactating mammary gland (Ji et al., 1998), purkinje fibres and 
cardiomyocytes of the sheep heart (Sharma et al., 1999), murine adipose tissue 
(McPherron et al., 1997), serum in humans (Gonzalez-Cadavid et al., 1998), 
several tissues of tilapia (Rodgers et al., 2001), Atlantic salmon (Ostbye et al., 
2001), and rainbow trout (Rescan et al., 2001), and in the brain and ovary of 
brook trout (Roberts and Goetz 2001). 
1.6.2 Structure of myostatin 
Myostatin was first discovered in 1997 through a degenerate polymerase 
chain reaction (PCR) on murine DNA, using oligonucleotides corresponding to 
highly conserved regions within the TGF-β family members (McPherron et al., 
1997). By screening a murine skeletal muscle library, a full length cDNA 
sequence containing a single open reading frame, encoding a 376 amino acid 
protein, was obtained. The predicted sequence contained distinct properties shared 
by TGF-β superfamily members; a secretion signal sequence, a proteolytic 
processing site, an amino-terminal propeptide domain and a carboxyl-terminal 
domain consisting of the active ligand (McPherron et al., 1997) (Figure 1.6). 
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Figure 1.6 The structure and processing of myostatin protein  
(A) The myostatin precursor molecule undergoes two proteolytic processing 
events: one which removes the amino-terminal signal sequence, and a second that 
generates the mature carboxyl-terminal fragment by cleaving at a RSRR site. (B) 
Following proteolytic processing, the LAP and the disulfide-linked mature dimer 
remain noncovalently bound in a latent complex. (C) Activation of latent 
myostatin occurs through proteolytic cleavage of the LAP. (D) This causes the 
dissociation of the latent complex, allowing receptor binding. Adapted from Lee 
(2004) 
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This carboxyl-terminal domain has been shown to contain the conserved pattern 
of nine cysteine residues, which allow the formation of the cysteine knot and 
homodimerisation essential for TGF-β activity (McPherron et al., 1997). 
Myostatin undergoes post-translational modification whereby it is cleaved 
between the propeptide domain and the carboxyl-terminal domain, at an RSRR 
cleavage site, to form the amino-terminal latency associated protein (LAP) and the 
active carboxyl-terminal mature processed peptide (McPherron et al., 1997).  
1.6.3 Myostatin receptors 
Like the other TGF-β family members, both the unprocessed and mature 
myostatin are capable of forming disulfide-linked dimers (Daopin et al., 1992; 
Daopin et al., 1993; McPherron et al., 1997; Lee and McPherron 2001). Lee and 
McPherron (2001) have demonstrated that the carboxyl-terminal dimer is capable 
of binding to activin type II receptors, Act RIIB, and to a lesser extent, Act RIIA. 
Lee and McPherron also proposed that following proteolytic processing, the 
myostatin carboxyl-terminal dimer remains in a latent complex with its 
propeptide. Analogous to other TGF-β family members, the LAP molecule has 
been shown to bind mature myostatin and confer latency (Lee and McPherron 
2001; Thies et al., 2001). Follistatin, which can bind to Activins and bone 
morphogenetic proteins (BMPs) to inhibit their activity (de Winter et al., 1996; 
Iemura et al., 1998), has also been reported to bind myostatin and compete for 
receptor binding (Lee and McPherron 2001). Upon release from the latent 
complex, the carboxyl-terminal dimer signals through the activin type II receptor, 
possibly resulting in the activation of a type I receptor and the Smad proteins (Lee 
and McPherron 2001). 
1.6.4 Function of myostatin 
1.6.4.1 Identifying the effect of myostatin on muscle mass 
Various experimental approaches have been adopted in order to establish 
the biological function of myostatin, primarily through knocking out the myostatin 
gene, or through its inhibition. McPherron et al. (1997) was the first to 
demonstrate that 3-6-month-old homozygous myostatin-null mice were 
significantly larger than their wild-type counterparts (Figure 1.7A).  
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Figure 1.7 The myostatin-null phenotype is characterised by heavy muscling 
(A) Increased skeletal muscle is observed in myostatin-null mice (ii) compared to 
wild-type littermates (i). Reproduced from McPherron et al. (1997). (B) A full 
blood Belgian Blue bull showing the double muscling phenotype. Adapted from 
McPherron and Lee (1997). (C) Heavy muscling can be observed in a human 
child at six-days-old (left) and at seven-months-old (right). The child possesses a 
myostatin mutation resulting in an inactive myostatin protein. Adapted from 
Schuelke et al. (2004).  
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This significant increase was reportedly due to a two to three-fold increase in 
muscle mass throughout the body, resulting from both muscle cell hyperplasia and 
hypertrophy (McPherron et al., 1997). These results clearly indicated that 
myostatin was acting as a powerful negative regulator of muscle growth.  
The heavy muscling observed in the myostatin-null mice is also known to 
occur in several bovine breeds, the most obvious being Belgian blue and 
Piedmontese, commonly referred to as double-muscled cattle (Figure 1.7B). 
Mapping of the bovine myostatin gene placed it at the same interval as the 
muscular hypertrophy locus that causes the double-muscle phenotype (Charlier et 
al., 1995; Smith et al., 1997). It was later discovered that the Belgian blue 
myostatin gene contained an 11 base pair (bp) deletion in the third exon, which 
resulted in a frame shift and subsequent early stop codon. This was found to 
produce an inactive truncated myostatin peptide (Grobet et al., 1997; Kambadur et 
al., 1997; McPherron and Lee 1997). Similarly, the Piedmontese myostatin gene 
was found to contain a mutation in exon three, leading to a cysteine to tyrosine 
substitution in the mature region of the protein, thus disrupting the formation of 
the cysteine knot (Kambadur et al., 1997; Berry et al., 2002).  
Transgenic mice expressing a mutant form of myostatin lacking the normal 
cleavage site (thus preventing dimerisation and cleavage), have also been reported 
to have increased skeletal muscle mass resulting from muscle hypertrophy (Zhu et 
al., 2000). In addition, Lee and McPherron (2001) investigated possible myostatin 
inhibitors which could promote muscle growth. These authors reported that by 
over-expressing follistatin or the myostatin propeptide though a skeletal muscle-
specific promoter (the myosin light chain promoter MLC1), the binding of 
myostatin to Act RIIB could be inhibited, resulting in significant increases in 
muscle mass. Lee and McPherron (2001) further suggested that these or other 
molecules which act to block myostatin signalling may be potential therapeutic 
agents for enhancing muscle growth. More recently, the inhibition of myostatin 
through the administration of a myostatin inhibitory antibody to adult mice has 
shown significant increases in muscle size and grip strength, due to muscle fibre 
hypertrophy (Whittemore et al., 2003). Interestingly, apart from the increase in 
fibre size, the muscle appeared histologically normal, no effect on organ size and 
histology was observed, and normal serum parameters were maintained, 
suggesting a high degree of specificity. More recently, a naturally occurring 
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myostatin mutation, consisting of a G to A bp transition in intron 1, has been 
identified in a human child (Schuelke et al., 2004) (Figure 1.7C). The mutation 
has caused the production of a misspliced mRNA. This is predicted to give rise to 
a severely truncated protein, due to the 108 bp insertion adding a single lysine 
residue, followed by a premature termination codon. Phenotypic observations of 
the child appear very similar to those observed in myostatin-null mice, and consist 
of a large increase in skeletal muscle mass and decreased fat accumulation.  
1.6.4.2 The mechanism of myostatin during cell proliferation 
Recent studies have indicated that myostatin regulates early myogenesis 
by controlling myoblast proliferation and differentiation. Cell cycle analyses have 
revealed that myostatin causes myoblasts to accumulate in the G0/G1 and G2 
phases of the cell cycle, resulting in a decrease of cells in the S phase (Thomas et 
al., 2000; Joulia et al., 2003). Progression of cells through the cell cycle phases is 
predominantly controlled by cyclin-dependent kinases (CDKs), their associated 
cyclins and CDK inhibitors (CKIs). Thomas et al. (2000) reported that myostatin 
arrests cell cycle progression through the up-regulation of p21 (previously shown 
to be involved in cell cycle arrest in the G1 and G2/M phases (Dulic et al., 1998)), 
whilst down-regulating Cdk2. This regulation effectively results in reduced Cdk2 
activity which normally, along with its associated cyclin, cyclin-E, acts by 
phosphorylating the retinoblastoma-susceptible gene product, Rb. Rb normally 
acts by binding to and repressing the activity of specific transcription factors. 
Upon phosphorylation by CDKs, Rb releases the bound transcription factor, thus 
allowing transcription of specific S phase genes (La Thangue 1996). Thus, by 
myostatin up-regulating p21 and down-regulating Cdk2, a reduction in the 
transcription of S phase-specific genes occurs. This in turn causes the cells to 
arrest at the G0/G1 phase and stop growing (Thomas et al., 2000; Langley et al., 
2002; Joulia et al., 2003). Conversely, inhibition of endogenous myostatin 
synthesis in C2C12 myoblasts, through the expression of an antisense myostatin 
mRNA, leads to decreased levels of p21 gene expression and increased cell 
proliferation (Joulia et al., 2003).  
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1.6.4.3 The mechanism of myostatin during cell differentiation 
Numerous studies have also shown myostatin negatively regulating 
myoblast differentiation. Culturing C2C12 myoblasts in low serum media 
containing increasing concentrations of recombinant mature myostatin has been 
shown to reversibly block the differentiation of myoblasts (Langley et al., 2002). 
Molecular analysis has indicated that this inhibition by myostatin results from the 
repression of MyoD, Myf5, myogenin, and p21 expression, leading to the 
suppression of myogenic differentiation. 
In corroboration, others have reported that myostatin over-expressing 
myoblasts have also been associated with the suppression of multinucleated 
myotube formation (Rios et al., 2002; Joulia et al., 2003). This suppression 
related to decreases in both MyoD and myogenin protein levels. A prerequisite for 
the initiation of myoblast differentiation is the arrest of the cell cycle in the G0/G1 
phase (Gu et al., 1993). This process involves the up-regulation of p21, which is 
enhanced by MyoD (Halevy et al., 1995). Furthermore, MyoD may also induce 
cell cycle arrest by binding to Rb, thereby enhancing its expression (Martelli et 
al., 1994) and inhibiting its phosphorylation (Gu et al., 1993; Zhang et al., 1999). 
This in turn would lead to a decline in S phase gene expression. Thus, myostatin-
induced decreases in myogenin and MyoD expression, and subsequent decreases 
in p21, may account for the poor cell cycle exiting and the decline in myogenic 
differentiation observed in the myoblast cultures. 
1.6.4.4 Effect on muscle fibres 
Numerous studies have been undertaken to determine whether the 
increases in muscle mass associated with the interference of myostatin, results 
from muscle fibre hyperplasia and/or hypertrophy. It appears that the increases in 
muscle mass are largely dependent on the mode of treatment (i.e. transgenically 
mutated or through inhibition) and perhaps is also species-specific. Histological 
analysis of mouse tibialis cranialis muscle has indicated that the myostatin-null 
phenotype is associated with significant hyperplasia, as total cell number was 86% 
higher than their wild-type counterparts (McPherron et al., 1997). In accordance 
with this, the amount of extracted DNA from pooled myostatin-null muscle was 
approximately 50% more than from wild-type muscle. This confirmed that 
hyperplasia accounted for a large proportion of the observed increased muscle 
 40
mass. Furthermore, analysis of individual cross-sectional fibre areas in the m. 
gastrocnemius (Gas) muscle showed an increase of up to 49% in the myostatin-
null muscle. Consistent with this was an increase in the protein to DNA ratio 
(w/w) in the myostatin-null muscles compared to the wild-type muscles. 
In agreement with these findings, over-expression of myostatin propeptide 
in mice has also been shown to cause both muscle fibre hyperplasia and 
hypertrophy (Lee and McPherron 2001). However, hyperplasia did not 
significantly contribute to the increased muscle mass observed in either the 
dominant negative mice, or in mice over-expressing the myostatin prodomain 
(Zhu et al., 2000; Yang et al., 2001). In these two cases, fibre hypertrophy, which 
occurred in both fast glycolytic fibres and fast oxidative glycolytic fibres, 
produced the observed muscle mass increases. Therefore, these studies suggest 
that total myostatin suppression is required to produce both muscle fibre 
hyperplasia and hypertrophy, while low or moderate inhibition of myostatin is 
more likely to result in fibre hypertrophy. 
Surprisingly, the increase in muscle mass seen in double-muscled cattle 
reportedly results from muscle fibre hyperplasia only (Wegner et al., 2000). 
Whether the differences between the two animal species relates to the inbreeding 
of double-muscled cattle, which inadvertently selects additional genes influencing 
muscle hypertrophy, remains unclear. Another explanation for this species 
discrepancy is a differential expression pattern of myostatin during 
embryogenesis. Myostatin is observed in bovine foetuses at a stage which can 
influence myoblast proliferation, however, unlike in murine muscle, its expression 
declines significantly during muscle differentiation (Kambadur et al., 1997; 
Deveaux et al., 2003). These observations are supported by in vitro evidence 
using bovine myoblasts, which indicates that myostatin expression peaks at the 
onset of fusion, decreases during terminal differentiation, and is later undetected 
in the myotubes (Deveaux et al., 2003).  
In addition to influencing muscle fibre size and number, myostatin can 
also affect the fibre type composition of a muscle. Wegner et al. (2000) reported 
that the number of type I fibres was unaffected in the Belgian Blue cattle, 
suggesting that the additional fibres were type IIB and IIA. Since myostatin is 
preferentially expressed in fast fibre types (Carlson et al., 1999; Deveaux et al., 
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2003), it is logical that fast fibre hyperplasia is associated with myostatin deficient 
animals.  
In mice, myostatin appears to significantly influence the overall fibre type 
composition of the muscle. Comparison between myostatin-null and wild-type 
adult muscles has indicated that loss of myostatin results in a larger proportion of 
fast fibres with a concurrent reduction of slow fibres in soleus and EDL muscles 
(Girgenrath et al., 2005). The effect of this alteration in fibre type composition 
would functionally result in an overall faster and more glycolytic muscle 
phenotype. Of note, Girgenrath et al. (2005) reported no change in the distribution 
of fibre types in EDL muscles from adult animals treated with a myostatin 
antibody. This would suggest that the fibre type alteration observed in myostatin-
null mice is a consequence of the early developmental processes. 
1.6.4.5 Myostatin and satellite cells 
In addition to regulating muscle during embryogenesis, myostatin also 
appears to be a major factor during postnatal muscle growth and repair. While 
myostatin regulates early myogenesis by influencing proliferation and 
differentiation, it has been suggested that myostatin regulates postnatal 
myogenesis through satellite cell activation. Of note, myostatin expression has 
been detected in satellite cells (McCroskery et al., 2003), indicating that myostatin 
may act by inhibiting satellite cell activation and proliferation. In support of this, 
not only do myostatin-null mice reportedly possess a greater number of satellite 
cells per muscle fibre, they also display an increased number of activated satellite 
cells in comparison to wild-type mice (McCroskery et al., 2003). These results 
suggest a direct link between myostatin and the activity and recruitment of 
satellite cells during postnatal myogenesis, correlating with the muscle 
hyperplasia and hypertrophy observed in the myostatin-null phenotype. It is also 
interesting that type IIB muscle fibres express the highest amounts of myostatin 
(Carlson et al., 1999) while containing the lowest numbers of satellite cells 
(Gibson and Schultz 1982). As previously discussed, satellite cells are a major 
component of muscle regeneration following injury or age-related muscle 
wasting. More recent studies have proposed a role for myostatin during the 
muscle repair process. A notexin-induced muscle regeneration study using young 
wild-type and myostatin-null mice has described accelerated migration and 
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enhanced accretion of myogenic cells and macrophages, as well as improved 
muscle regeneration and reduced fibrosis in the myostatin-null mice (McCroskery 
et al., 2005). Ex vivo assays corroborated these findings, as reduced satellite cell 
activation and chemotactic movements of both myoblasts and macrophages were 
observed with the addition of recombinant myostatin (McCroskery et al., 2005). 
Similarly, the muscles of aged myostatin-null mice reportedly regenerate more 
robustly after cardiotoxin injury, and attain larger diameter myofibres than their 
wild-type counterparts (Wagner et al., 2005). Wagner et al. (2005) reported that 
the initial markers of regeneration were also enhanced in the absence of 
myostatin. Furthermore, satellite cells isolated from myostatin-null muscle also 
demonstrated a greater capacity for activation and faster proliferation and 
differentiation than wild-type cells, suggesting myostatin functions to inhibit these 
processes (McCroskery et al., 2003; Wagner et al., 2005). Cell cycle analysis of 
the myostatin-null and wild-type satellite cells indicated that myostatin was up-
regulating p21, while decreasing the level and activity of Cdk2 protein 
(McCroskery et al., 2003). Thus myostatin was negatively regulating the G1 to S 
progression to maintain satellite cell quiescence.  
Collectively, these results indicate that myostatin can negatively regulate 
muscle regeneration by controlling satellite cell activation, proliferation and 
differentiation, whilst also regulating myoblast and macrophage migration to the 
site of injury. Furthermore, inhibition of myostatin expression and signalling, 
through gene inactivation or myostatin inhibiting antibodies, have shown to result 
in significantly reduced amounts of fibrosis and fat infiltration following muscle 
regeneration (Bogdanovich et al., 2002; Wagner et al., 2002; McCroskery et al., 
2005; Wagner et al., 2005) 
1.6.5 Muscle wasting 
The role of myostatin in muscle wasting has been investigated using a 
number of wasting models and human diseases. Immobilisation studies using 
rodents, have demonstrated significant increases in myostatin expression in 
association with the induced muscle atrophy (Carlson et al., 1999; Wehling et al., 
2000). The observed increases may relate to myostatin inhibiting satellite cell 
proliferation, as the peak of myostatin expression reportedly occurs at the same 
time as satellite cell proliferation decreases during hind-limb unloading (Darr and 
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Schultz 1989; Schultz et al., 1994). Interestingly, the increase in expression 
appears to vary according to the muscle observed and is strongly associated with 
the MHC IIB isoform (Carlson et al., 1999). In humans, a clinical study has been 
performed to establish the relationship between myostatin levels and the muscle 
atrophy associated with human immunodeficiency virus (HIV) infection. 
Measurements of serum and intramuscular concentrations of myostatin protein 
were shown to increase in the HIV-infected patients with weight loss, compared 
to the healthy subjects (Gonzalez-Cadavid et al., 1998). The increase in myostatin 
protein was also inversely correlated with the fat-free mass index. These results 
strongly suggest that increased myostatin levels contribute to HIV-associated 
muscle wasting, and raise the question whether myostatin is involved in the 
muscle loss associated with other pathologies.  
A number of human and rodent studies have also been performed in order 
to determine if there is a correlation between myostatin and age-related muscle 
wastage. A study involving the comparison of serum myostatin-immunoreactive 
protein levels, fat-free mass and muscle mass in young, middle-aged, and 
physically frail old humans indicated that serum myostatin-immunoreactive 
protein levels increased with age (Yarasheski et al., 2002). Furthermore, both fat-
free mass and muscle mass were inversely correlated with serum myostatin-
immunoreactive protein concentrations, suggesting that myostatin was acting as a 
negative regulator of muscle growth during aging. However, in a murine study, 
Kawada et al. (2001) reported that the content of myostatin protein in Gas and 
plantaris muscles was initially low and increased until their wet weight/body 
weight ratio reached a peak. The level of myostatin then remained unchanged with 
further aging, despite the occurrence of muscle atrophy. In contrast, a study 
examining the levels of myostatin mRNA and protein in rats during aging reported 
that while the level of myostatin mRNA in the Gas decreased with age, myostatin 
protein increased progressively (Baumann et al., 2003). Although the results from 
these studies are somewhat conflicting, it appears that myostatin protein levels 
rather than mRNA may increase with age. 
The phenotype observed in animals lacking functional myostatin (either 
through transgenic manipulation or myostatin inhibiting treatments), starkly 
contrasts the phenotype associated with myostatin over-expression. Transgenic 
mice over-expressing myostatin protein reportedly demonstrate an 18–24% 
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decrease in lower hind- and forelimb muscle mass (Reisz-Porszasz et al., 2003). 
This reduced muscle mass was associated with an 18% decrease in fibre cross-
sectional area and myonuclear number in the m. quadriceps (Quad) and Gas 
muscles. Furthermore, systemic over-expression of myostatin in adult mice has 
been shown to induce significant muscle and fat loss equivalent to that observed 
in human cachexia syndromes (Zimmers et al., 2002). This again raises the 
question as to whether myostatin expression is involved in human cachetic-type 
conditions as well as other pathologies. 
1.6.6 Adipogenesis 
While the effect of myostatin on skeletal muscle is reasonably well 
characterised, its influence on adipogenesis and adipose tissue, remains 
reasonably unclear. A number of murine studies have reported significant 
decreases in adipose tissue in association with loss of myostatin function. For 
example, Lin et al. (2002) described decreases in fat pad weights and total lipid 
content by 12-weeks of age in myostatin-null mice in comparison to wild-type 
mice. In agreement, McPherron and Lee (2002) reported wild-type mice fat pads 
weighing approximately 2-4 times those of myostatin-null mice at 5- to 6-months 
of age. With advancing age, wild-type fat pad weights continued to increase in 
size while the myostatin-null did not. Moreover, mean total body fat was reduced 
by 70% in myostatin-null mice, and serum leptin levels were also significantly 
lower. Despite having a normal food intake, body temperature and a reduced 
metabolic rate, the myostatin-null gonadal fat pad had approximately 25% fewer 
cells, as well as a reduced fat cell size, compared to the wild-type fat pad. These 
results suggest that loss of functional myostatin not only affects muscle mass, but 
also adipose tissue mass.  
In addition, myostatin prodomain transgenic mice have demonstrated a 
significant decrease in epididymal fat pad weight (Yang et al., 2001). However, 
Whittemore et al. (2003) reported no change in the fat pad mass when myostatin 
was inhibited with a blocking antibody. In accordance with these studies, over-
expression of myostatin in myostatin-transgenic male mice reportedly have 
significantly higher mean epididymal fat pad weights compared with wild-type 
controls (Reisz-Porszasz et al., 2003).  
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Only a small number of in vitro studies have been performed to determine 
the role of myostatin during adipogenesis. Contradictory to in vivo data, 
Rebbapragada et al. (2003) first reported that myostatin blocks BMP7-induced 
adipogenesis in both pluripotent mesenchymal precursor cells (C3H 10T1/2 cells) 
and preadipocytes (3T3-L1 cells) by competing for binding of the ActRIIB 
receptor. However, a more recent study has demonstrated that recombinant 
myostatin treatment of C3H10T1/2 cells, which were first differentiated using 
azacytidine, induced early and late markers of adipogenesis, while myogenic 
markers were inhibited (Artaza et al., 2005). Thus, this later study is in agreement 
with the observations of reduced fat accumulation associated with the myostatin-
null phenotype.  
1.6.7 The actions of androgens and their relationship to myostatin 
Androgens are steroidal hormones generally believed to elicit positive 
growth effects in muscle, increasing both muscle size and strength. Belonging to 
this group of hormones is testosterone, which is secreted by testicular Leydig cells 
and is considered the primary circulating androgen (reviewed Mooradian et al. 
(1987)). While testosterone is converted to 5α-dihydrotestosterone (DHT) in 
reproductive tissues by the cytoplasmic enzyme 5α-reductase, in skeletal muscle, 
testosterone remains in its unconverted form due to the low levels of 5α -reductase 
(Bartsch et al., 1980). Numerous clinical studies demonstrate that testosterone can 
augment muscle strength and increase muscle size (Brodsky et al., 1996; Mauras 
et al., 1998; Bhasin et al., 2001; Sinha-Hikim et al., 2002). Testosterone is a 
ligand of the androgen receptor (AR), a ligand-dependent transcription factor 
belonging to the steroid hormone receptor superfamily (Chang et al., 1988b; 
Chang et al., 1988a). Binding to the AR results in the formation of complexes, 
and forces conformational changes, which lead to dimerisation, nuclear 
localisation and DNA binding. This allows the AR to interact with androgen 
response elements (AREs) in various androgen target genes (reviewed by Chang 
et al. (1995)).  
Investigations into the effects of concentric and eccentric loading on 
skeletal muscle in human subjects have indicated that AR mRNA concentration 
increases during both types of loading (Bamman et al., 2001). Conversely, 
blockade of the AR during electrical stimulation in rats reportedly suppresses 
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muscle mass increases normally associated with the hypertrophy model (Inoue et 
al., 1994). Clinical trials in humans have indicated that administration of 
testosterone can result in increased muscle mass in hypogonadal men (Bhasin et 
al., 1997), HIV-infected men (Bhasin et al., 2000) and healthy men (Bhasin et al., 
1996; Bhasin et al., 2001).  
As both myonuclei (Dorlochter et al., 1994) and satellite cells (Doumit et 
al., 1996) express AR, it is believed that they are direct targets of androgens. A 
number of studies have demonstrated that the administration of testosterone can 
increase satellite cell numbers. Joubert et al. (1994) reported that administration 
of testosterone to rats before puberty resulted in a transient increase in satellite 
cells. Furthermore, this observed increase in cell proliferation led to an increase in 
myonuclei number and the activation of quiescent satellite cells (Joubert and 
Tobin 1989; Joubert and Tobin 1995). A human study involving weight-lifters 
also reported muscle fibre hypertrophy as well as an increased number of fibres 
with centrally located nuclei in steroid-using athletes compared to nonsteroid-
using athletes (Kadi et al., 1999). The authors suggested that these observations 
were brought about through the process of satellite cell activation which had been 
enhanced by the steroid use. Indeed, increases in satellite cell number, and 
subsequent fusion with muscle fibres, have been shown following testosterone 
treatment (Sinha-Hikim et al., 2003). However, in vitro studies have provided 
conflicting results in relation to satellite cell behaviour following testosterone 
treatment. While some report a modest effect of testosterone on primary myoblast 
proliferation (Powers and Florini 1975), others do not observe any change 
(Doumit et al., 1996).  
Since myostatin has been shown to negatively regulate myogenesis in a 
robust manor, the question of an interaction between myostatin and testosterone 
has been raised. Of note, the human myostatin promoter contains AREs in the 5'-
regulatory region (Ma et al., 2001), suggesting myostatin may be a direct target of 
the AR. However, a human study using healthy aged males failed to show any 
correlation between myostatin and AR mRNAs in muscle or with circulating 
testosterone levels (Marcell et al., 2001). Furthermore, a strength training program 
conducted with young men indicated that suppression of endogenous testosterone, 
by the gonadotropin-releasing hormone analogue, goserelin, resulted in similar 
MyoD, myogenin, myostatin, and AR mRNA levels as observed in the placebo 
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group. Therefore, these studies suggest little interaction between testosterone and 
myostatin with respect to the androgen hormone suppressing myostatin expression 
or action. However, the effect of myostatin on testosterone and AR expression 
and/or activity has received minimal attention, and thus requires further study to 
investigate their potential relationship. 
1.7 Aims of this thesis 
A considerable number of studies have addressed the structure of skeletal 
muscle and the nature of myogenesis. With the aid of technological advancements 
in the molecular and microscopic fields, significant insights into muscle biology 
have been made possible. Many regulators of muscle growth, as well as 
myogenic-related genes and markers have now been identified. The discovery of 
myostatin, a negative regulator of muscle growth, has also increased the 
understanding of myogenesis and muscle development. Previous studies have 
provided insights into the structure and function of myostatin as well as its 
signalling and the mechanism through which it regulates myogenesis. However, 
despite the current level of understanding of myostatin and its regulation of 
myogenesis, many questions remain. In particular, how myostatin influences 
postnatal myogenesis, and whether it is involved in the muscle wasting commonly 
associated with aging. The degree and efficacy of postnatal myogenesis is of 
significant relevance to human health and quality of life. Currently, treatments for 
various myopathies are limited, and their possible side effects are frequently 
questioned. The overall aim of the work detailed in this thesis was to further 
elucidate the role of myostatin during postnatal myogenesis and sarcopenia. The 
following aims were formulated then addressed using in vitro and in vivo 
experiments.  
 
1. Determine potential myostatin downstream targets to further elucidate how 
myostatin regulates postnatal myogenesis.  
 
2. Examine the physiological effect of aging in wild-type and myostatin-null 
murine muscle, and investigate variations between the two genotypes to 
determine the role of myostatin during sarcopenia.  
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3. Determine how aging and a prolonged absence of myostatin affects the 
behaviour of satellite cells/primary myoblasts and the overall myogenic 
process.  
 
4. Test the efficacy of a truncated myostatin protein to antagonise myostatin 
signalling and determine the effect of a short term blockade of myostatin 
during postnatal myogenesis.  
 
These investigations enabled the rigorous testing of the hypothesis that myostatin 
profoundly regulates myogenesis during postnatal growth and sarcopenia, and that 
its inhibition will permit increased myogenesis and muscle regeneration.  
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Chapter Two 
Materials and Methods 
2.1 Materials 
Common laboratory chemicals and reagents were obtained from BDH, 
Roche, Sigma and Invitrogen. Cell culture medium components were from 
Invitrogen (Dulbecco's Modified Eagle's Medium (DMEM), horse serum (HS) 
and foetal bovine serum (FBS)) and Sigma (Phenol red, collagenase). Antibiotics 
(penicillin, streptomycin, ampicillin), and carrageen lambda (cλ), were obtained 
from Sigma. Radiolabelled nucleotides were obtained from Amersham. 
Specialised equipment and commercially available kits described in this thesis are 
referred to in the relevant Methods Sections. 
2.1.1 Animals and ethical approval 
Myostatin-null mice (C57BL/10 background) were obtained from S.-J. Lee 
(The Johns Hopkins University, Baltimore, MD). These mice have a disrupted 
myostatin gene by homologous targeting (McPherron et al., 1997), involving the 
deletion of the mature carboxyl-terminal region, which was replaced with a neo 
cassette (resulting in a non-functional myostatin). Genotypic analysis allowed the 
selection of homozygous mutant pups. Periodically, mice were randomly chosen 
to perform genotypic analysis in order to maintain the integrity of the 
homozygous mutant mouse line. 
The wild-type mouse strain C57BL/10 was bred at the Ruakura Small 
Animal Colony. All animals were handled in accordance with the guidelines of 
the Ruakura Animal Ethics Committee (AgResearch, Hamilton, New Zealand). 
Specific experimental procedures were approved by the University of Waikato 
and Ruakura Animal Ethics Committees. The approved ethics application 
numbers for work described in Chapters 3-6 are as follows.  
Chapter 3 - ethics #630 (University of Waikato) and #10311 (Ruakura) 
Chapter 4 - ethics #630 (University of Waikato) and #10157/10311 (Ruakura)  
Chapter 5 - ethics #630 (University of Waikato) and #10311 (Ruakura) 
Chapter 6 - ethics #643 (University of Waikato) and #10637 (Ruakura)  
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2.1.2 Common solutions 
Common solutions were prepared as described in Sambrook et al. (1989) 
unless stated otherwise. The recipes for the common solutions are listed below: 
 
Church and Gilbert hybridisation buffer 
0.5 M Na2HPO4.H2O  
7% sodium dodecyl sulphate (SDS) 
1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0) 
0.35% H3PO4 
Made in diethyl pyrocarbonate (DEPC)-treated milli Q (MQ) H2O 
 
MOPS (3-(N-morpholine)-propane-sulfonic acid) (10X) 
200 mM MOPS (pH 7.0) 
100 mM NaOAc 
10 mM EDTA (pH 8.0) 
Made in DEPC-treated MQ H2O 
 
Phosphate buffer saline (PBS) 
1 PBS tablet (Oxoid) 
100 ml H2O 
 
PBS-T 
100 ml PBS 
0.2 ml Tween 20  
 
Protein lysis buffer 
0.5 ml 1 M 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris; pH 7.5) 
0.5 ml 5 M NaCl 
0.1 ml 0.5 M EDTA 
10 µl NP-40 
8.89 ml dH2O 
½ Protease inhibitor tablet (Complete; Roche) 
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Red blood cell lysis buffer 
9 parts 0.83% NH4Cl with 1 part 2.06% Tris (pH 7.65) 
Adjust to pH 7.2 if required and filter with a 0.22 µm Millex-GP filter unit 
(Millipore) 
 
Saline sodium citrate (SSC) (20X) 
3 M NaCl 
0.3 M sodium citrate (pH 7.0) 
 
Scotts tap water 
166 mM MgSO4 
36 mM NaHCO3 
 
1X SDS running buffer  
50 ml 20X NuPAGE™ MES SDS Running Buffer (Invitrogen) 
950 ml dH2O 
 
Tris acetate EDTA (TAE) solution 
40 mM Tris-acetate 
2 mM EDTA (pH 8.0) 
 
Tris buffered saline (TBS) 
50 mM Tris (pH 7.5) 
150 mM NaCl 
 
TBS-Tween (TBS-T) 
50 mM Tris (pH 7.5) 
150 mM NaCl 
0.2% Tween 20 
 
Tris-EDTA (TE) 
10 mM Tris-Cl (at desired pH) 
1 mM EDTA (pH 8.0) 
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Transfer buffer (pH 8) 
25 mM Tris 
190 mM glycine 
20% methanol 
 
10X Trypsin 
2.5% trypsin in PBS 
2.1.3 Loading dyes 
DNA loading dye 
15% Ficoll 
0.25% bromophenol blue 
0.25% xylene cyanol 
1% SDS 
1 mM EDTA (pH 8.0) 
 
Protein loading dye   
75 µl NuPAGE™ 4X LDS sample buffer (Invitrogen)  
15 µl β-mercaptoethanol 
 
RNA loading dye (2X) 
10% MOPS (10X) 
20% deionised formaldehyde 
50% deionised formamide 
0.02% bromophenol blue 
5% glycerol 
1 mM EDTA (pH 8.0) 
40 µg/ml ethidium bromide 
2.1.4 Staining solutions 
Coomassie Blue Stain 
2.5 g Coomassie Brilliant Blue R-250 
45% methanol 
10% acetic acid 
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Coomassie Blue Destain 
45% methanol 
10% acetic acid 
 
Eosin 1% solution 
1% eosin 
0.01% acetic acid 
Crystal of thymol 
 
Gills haematoxylin 
0.4% haematoxylin 
2 mM NaIO3 
100 mM Al2(SO4)3 
25% ethylene glycol 
4% glacial acetic acid 
 
Ponceau S stain 
0.1% (w/v) Ponceau S 
0.1% (v/v) acetic acid 
2.1.5 mATPase staining working reagents 
Acidic pre-incubation media  
3.90 g CH3COONa  
3.70 g KCl 
dH2O to 500 ml 
Adjust to pH 4.6 with 100% glacial acetic acid 
 
Basic pre-incubation media (pH 9.4) 
0.95 g NaOH  
1.90 g NaCl 
1.98 g glycine 
2.78 g CaCl2.2H2O 
dH2O to 500 ml 
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ATP Incubation media  
0.255 g ATP  
150 ml basic pre-incubation media (pH 9.4) 
Adjust to pH 9.4 with 1N NaOH 
 
Pre-incubation wash (pH 9.4) 
Basic pre-incubation media 
 
Ammonium sulphide  
1 ml 20% (NH4)2S 
dH2O to 200 ml  
 
1% CaCl2 
13.2 g CaCl2.2H2O 
dH2O to 1 L  
 
2% CoCl2 
36.6 g CoCl2.6H2O 
dH2O to 1 L 
2.1.6 Van Gieson solutions 
Van Gieson solution 
10 ml 1% aqueous acid fuchsin   
90 ml saturated Picric acid 
0.25 ml concentrated HCl 
 
Solution A 
1% haematoxylin in absolute alcohol 
 
Solution B 
4 ml 30% Ag ferric chloride 
1 ml concentrated HCl 
100 ml dH2O 
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2.1.7 Bacterial growth media 
LB media 
Bacteria were grown in LB Broth (Lennox L Broth) which was prepared 
by adding 20 g LB Broth base to 1 L H2O, then autoclaved and stored at 4°C. 
 
LB plates 
Bacterial colonies were grown on LB Agar (Lennox L Agar) plates. LB 
Agar plates were prepared by adding 32 g LB Agar to 1 L H2O, followed by 
autoclaving. Molten LB Agar (20 ml) was poured into Petri dishes (10 cm; Nunc) 
and left to set before storing at 4°C. 
2.1.8 Yeast two-hybrid media and buffers 
Yeast growth media 
Yeast peptone dextrose media (YPD; rich medium)  
20 g peptone  
10 g yeast extract  
20 g glucose  
0.1 g NaOH (if for plates) 
20 g agarose (if for plates) 
1 L H2O 
 
Yeast nitrogen base- (YNB) ura-his-leu-trp (selective medium)  
1.7 g YNB (without amino acids)  
0.6 g his-ura-trp-leu dropout mix  
20 g glucose (or 20 g galactose/10 g raffinose for X-5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-gal; if for plates) 
20 g agar (if for plates) 
1 L H2O 
 
Selective media  
Combinations of the following amino acids were added to the YNB-ura-
his-leu-trp media; 0.02 mg/ml ura, 0.02 mg/ml his, 0.06 mg/ml leu, and/or 0.04 
mg/ml trp  
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Buffers 
10X LiOAc 
1 M lithium acetate 
 
50% polyethylene glycol-3350 (PEG) 
250 g polyethylene glycol-3350  
500 ml H2O 
 
10X TE 
0.1 M Tris (pH 7.5) 
0.01 M EDTA 
 
1X TE/LiOAc 
1 part 10X TE, 1 part 10X LiOAc, and 8 parts H2O 
 
1X TE/LiOAc/PEG 
1 part 10X TE, 1 part 10X LiOAc, and 8 parts 50% PEG 
2.1.9 Cell culture media 
DMEM  
50 ml 2X DMEM  
8 ml HCO3- 
1 ml penicillin G (200 U/ml) and streptomycin (200 µg/ml) 
41 ml H2O 
 
Satellite cell proliferation media  
DMEM supplemented with 20% FBS (v/v), 10% HS (v/v), and 1% chick embryo 
extract (CEE) (v/v). 
2.1.10 Fixatives 
Ethanol Fixative 
15 ml 50 mM glycine 
35 ml absolute ethanol 
Adjust pH to 2.0 with HCl 
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10% buffered formalin 
32.5 g Na2HPO4 
20 g NaH2PO4.H2O 
500 ml formalin 
4.5 L H2O 
 
4% paraformaldehyde 
2 g paraformaldehyde 
50 ml PBS 
Heat to ~50°C then add 2 M NaOH until almost clear. Remove from heat, and add 
concentrated HCl until pH 7.2 once cooled. Filter with a 0.22 µm Millex-GP filter 
unit (Millipore) 
 
20:2:1 fixative 
20 parts ethanol 
2 parts formalin 
1 part acetic acid  
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2.2 Methods 
Standard molecular biology methods were performed as described by 
Sambrook et al. (1989) unless otherwise stated.  
2.2.1 RNA extraction 
Total RNA was isolated from tissues and cultured cells using TRIZOL 
reagent (Invitrogen) according to the manufacturer’s instructions. For muscle 
tissue, approximately 50-100 mg of sample was homogenised in 1 ml TRIZOL. 
After 5 min incubation at room temperature, 200 µl chloroform per 1 ml TRIZOL 
was added and the tubes were shaken for 15 s before incubating at room 
temperature for a further 2-3 min. The samples were centrifuged at 12,000 x g for 
15 min at 4°C, and the aqueous phase was transferred to a new tube. Total RNA 
was precipitated with 500 µl isopropanol per 1 ml TRIZOL, incubating for 10 min 
at room temperature. The samples were centrifuged at 14,000 x g for 10 min at 
4°C and the pellet was washed in 75% ethanol and re-spun, before resuspending 
in 25-60 µl DEPC-treated MQ H2O. 
For cultured cells, media was removed and the cells were washed twice 
with PBS. The cells were then lysed by adding 2 ml TRIZOL per 10 cm dish 
(Nunc), and the lysate was transferred into 1.5 ml tubes. After 5 min incubation at 
room temperature, 400 µl chloroform was added before shaking the tubes for 15 s. 
Following a further 3 min incubation at room temperature, the samples were 
centrifuged at 12,000 x g for 15 min, and the aqueous phase was transferred to a 
new tube before total RNA was precipitated with 1 ml isopropanol. Samples were 
then centrifuged at 14,000 x g for 10 min before the pellet was washed in 75% 
ethanol and resuspended in 40 to 60 µl of DEPC-treated MQ H2O.  
Total RNA was later quantified by UV spectrophotometry measuring at 
260/280 nm using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies).  
2.2.2 First-strand synthesis  
SuperScript II Reverse Transcriptase (Invitrogen) was utilised for all first-
strand synthesis for subsequent PCRs. Reverse transcriptase (RT) reactions were 
performed according to the manufacturer’s protocol. For each RT reaction, 0.5 µg 
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of Oligo(dT) was annealed to 5 µg of total RNA in a 10 µl reaction containing 1 
mM dNTPs. This annealing reaction was incubated at 65°C for 5 min followed by 
a 1 min incubation on ice. A 9 µl reaction mixture containing 1X RT Buffer, 10 
mM MgCl2, 20 mM dithiothreitol (DTT) and 40 U RNaseOUT was then added 
and the reaction was incubated at 42°C for 2 min. SuperScript II RT (50 U) was 
added to the mixture before incubating at 42°C for 50 min and 70°C for 15 min. 
Rnase H (2 U) was then added and the mixture was incubated for a further 20 min 
at 37°C. All RT reactions were stored at -20°C until subsequent use in PCR 
amplifications.  
2.2.3 PCR  
All PCR amplifications were performed using Taq DNA Polymerase 
(Roche) according to the manufacturer’s instructions. PCRs (50 µl) contained 0.2 
mM dNTPs, 0.2 µM forward primer, 0.2 µM reverse primer, 1X PCR buffer and 
varying concentrations of RT reaction. A Hybaid MBS 0.5S PCR System 
(Hybaid) was used for all PCR thermocycling. PCR cycling temperatures and 
times are described in relevant sections where PCR was performed. 
2.2.4 Electrophoresis of RNA  
Total RNA was fractionated by electrophoresis using agarose gels 
containing 1% agarose, 1X MOPS and 0.66 M formaldehyde. A volume of 10 µg 
of total RNA was mixed with an appropriate volume of RNA loading dye before 
incubating at 65°C for 5 min. Following RNA loading, electrophoresis was 
performed at 40-80 V at 4°C until the desired separation was achieved. Resulting 
gels were photographed with a Bio-Rad Gel Doc 2000 system (Bio-Rad) to assess 
the integrity of the RNA using the 28S and 18S ribosomal bands.  
2.2.5 Electrophoresis of DNA 
Depending on the size of the DNA fragments and the required separation, 
agarose gels contained 0.8-2% agarose and 300 ng/ml ethidium bromide in 1X 
TAE buffer. Electrophoresis was performed using an Owl electrophoresis system 
(Owl Separation Systems) containing 1X TAE. DNA samples were mixed with 
DNA loading dye and then loaded before electrophoresis at 30-100 V until the 
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desired separation was achieved. Fractionated DNA was visualised and 
photographed using the Gel Doc system described above. 
2.2.6 Recovery of DNA  
Following DNA separation by low melting point (LMP) agarose gel 
electrophoresis, the section of gel containing the desired DNA fragment was 
excised under UV light and incubated at 70°C until melted. The recovery of DNA 
was performed using the Wizard DNA Purification System (Promega) as follows. 
A volume of 1 ml DNA purification resin was added before the resin/DNA was 
passed through a Wizard Minicolumn, followed by 2 ml 80% isopropanol. The 
Minicolumns were then centrifuged at 10,000 x g for 2 min before the DNA was 
eluted in 50 µl MQ H2O with centrifugation at 10,000 x g for 20 s. 
2.2.7 DNA ligations 
The DNA and specific vectors were digested separately with the 
appropriate restriction endonucleases to generate complementary 3’ or 5’ 
extensions for cloning. Ligation reactions contained 25-50 ng vector, a 3- or 6-
fold molar excess of insert over vector, 1X ligation buffer (Invitrogen) and 1 U T4 
DNA ligase; ligations were performed at 16°C for 18 hr.  
2.2.8 Transformation of competent cells 
Transformation of DH5α and BL21 competent cells was performed using 
the following protocol. Plasmid DNA (1-20 ng) was added to 100 µl of the 
competent cells (Invitrogen) before incubating on ice for 30 min. The cells were 
heat shocked at 42°C for 45 s and then cooled on ice for 3 min before adding one 
volume of LB broth. The transformed cells were incubated at 37°C for 60 min 
without antibiotic before plating onto LB agar plates. 
2.2.9 Growth of bacteria 
Plated bacteria 
Transformed bacterial cells (approximately 100 µg/ml) were streaked 
across LB agar plates containing the appropriate antibiotic(s). Plates were 
incubated at 37°C for 12-18 hr until colonies were approximately 1-2 mm in 
diameter. 
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Liquid cultures 
Single colonies were picked using sterile tips and transferred to 3 ml of LB 
broth (for a miniprep culture) containing 100 µg/ml ampicillin. The cultures were 
then incubated at 37°C overnight with shaking (200 rpm). 
2.2.10 Plasmid DNA extraction 
Plasmid DNA from miniprep cultures of transformed bacteria was 
extracted and purified using the QIAprep Miniprep System (Qiagen) according to 
the manufacturer’s instructions. Cultures were initially centrifuged at 4,000 x g 
for 4 min. The resulting bacterial pellets were resuspended in 250 µl Buffer P1, 
followed by 250 µl Buffer P2 and 350 µl Buffer P3, inverting the tubes 4-6 times 
between buffer additions to mix thoroughly. The samples were then centrifuged at 
20,000 x g for 10 min before the supernatants were transferred to QIAprep spin 
columns. The columns were centrifuged at 20,000 x g for 1 min, washed with 0.75 
ml Buffer PE and centrifuged again. Plasmid DNA was eluted in 50 µl MQ H2O 
by centrifuging at 20,000 x g for 1 min. 
2.2.11 Restriction endonuclease digestions 
Plasmid DNA was digested with 5 U of the appropriate restriction 
endonuclease (specified in relevant sections) per µg DNA. Restriction digestions 
were performed in 1X restriction endonuclease buffer (as recommended by the 
supplier) in a volume such that the total enzyme concentration was less than 10%. 
Digestion reactions were performed 37°C (or temperature specified by supplier) 
for 1 hr. The resulting digest products were later used for agarose gel 
electrophoresis or purified for subsequent use. 
2.2.12 Northern and Southern blotting 
2.2.12.1 Northern blotting 
Following electrophoresis and assessment of RNA integrity (described in 
Section 2.2.4), the RNA gels were soaked in 10X SSC for 10 to 20 min to remove 
the formaldehyde. RNA was transferred to Hybond N+ membrane (Amersham) 
by capillary transfer as described in Sambrook et al. (1989), using 10X SSC as the 
transfer buffer. After the transfer, the membranes were washed and cross-linked 
using a UV Stratalinker 1800 (Stratagene). The membranes were pre-hybridised 
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with Church and Gilbert hybridisation buffer in Hybaid bottles at 55°C for 1 hr 
prior to hybridisation. After denaturing the prepared 32P-labelled cDNA probes 
with 4 M NaOH for 5 min, the radiolabelled probes were added to the membranes 
in fresh Church and Gilbert hybridisation buffer. Hybridisation was performed 
overnight in a Hybaid oven at 55°C. The following day the membranes were 
rinsed with 5X SSC, and washed at 55°C for 15 min with 2X SSC + 0.5% SDS 
and 1X SSC + 0.5% SDS. The membranes were then sealed in plastic before 
exposing to X-ray autoradiography (XAR) film (Kodak).  
2.2.12.2 Southern blotting 
Following DNA electrophoresis (as described in Section 2.2.5), the 
Northern blotting protocol (described above) was essentially performed, with the 
exception that after electrophoresis, the gels were soaked (and transferred) in 1.5 
M NaCl and 0.5 M NaOH for 30 min.  
2.2.13 Radiolabelling of probes 
Androgen receptor associated protein-70 (ARA70) cDNA for a Northern 
and Southern blot radioactive probe was generated as described in Section 3.2.4 of 
Chapter 3. Similarly, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
cDNA for a Southern blot radioactive probe was generated as described in Section 
3.2.7 of Chapter 3. The process of radiolabelling the cDNA was performed as 
follows. cDNAs were labelled using a Rediprime II random prime labelling 
system (Amersham) according to the manufacturer’s instructions. Initially, cDNA 
was diluted to 25 ng in a final volume of 45 µl, and then denatured by heating to 
100°C for 5 min before adding to a Rediprime random priming mix. A volume of 
2.5 µl of [α-32P]dCTP (25 µCi) was added and mixed before incubating at 37°C 
for 10 min.  
2.2.14 Suppressive subtraction hybridisation methods 
2.2.14.1 mRNA isolation 
Poly (A)+ RNA was purified from total RNA (TRIZOL) using a Fast 
Track 2.0 mRNA isolation kit (Invitrogen) according to the following protocol. 
Total RNA (2 mg) was dissolved in 15 ml DEPC-treated H2O before the sodium 
chloride concentration was adjusted to 0.5 M with 950 µl of 5 M NaCl. The RNA 
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mix was passed through an 18-gauge needle and incubated at 42°C for 10 min. A 
tube of Oligo(dT) (75 mg) was added per sample before incubating for 2 min at 
room temperature. Samples were then gently rocked for 1 hr before centrifuging at 
3,000 x g for 5 min. The Oligo(dT) was washed twice in binding buffer, followed 
by a wash in low salt wash buffer until the buffer was clear. After resuspending in 
800 µl of low salt wash buffer, the Oligo(dT) was transferred to a spin column and 
centrifuged at 5,000 x g for 10 s. This was repeated until all cellulose was 
transferred to the column. Steps using low salt wash buffer were performed until 
the flow-through was less than 0.05 (OD260). The Oligo(dT) was later 
resuspended in two aliquots of 200 µl elution buffer, with 30 s centrifugation 
spins in between. After collecting the 400 µl of eluate, 60 µl 2 M sodium acetate, 
1 ml 100% ethanol and 40 µg glycogen was added before storing at -80°C 
overnight. The following day, the solution was thawed and centrifuged at 15,000 
x g for 25 min at 4°C. The pellet was then air dried and resuspended in elution 
buffer. The mRNA concentration was determined by UV spectrophotometry at 
260 nm using a Heλios γ spectrophotometer (Thermo Scientific).  
2.2.14.2 Construction of subtracted libraries  
To perform suppressive subtraction hybridisation (SSH), cDNAs were 
synthesised from 2 µg of poly (A)+ RNA from m. biceps femoris (BF) of 
myostatin-null mice (‘driver’) and wild-type mice (‘tester’) using a PCR-Select 
cDNA subtraction kit (Clontech) as previously described by Diatchenko et al. 
(1996).   
To select for double-muscle-directed transcripts, cDNAs derived from 
myostatin-null muscle were ligated to oligonucleotide linkers and hybridised with 
excess cDNAs derived from wild-type muscle tissue. First and second strand 
cDNA was subtracted as described in the manufacturer’s protocol of the PCR-
Select cDNA subtraction kit (Clontech). After hybridisation, differential 
transcripts were selectively amplified by suppression.   
2.2.14.3 Cloning of cDNAs 
Amplified cDNAs were shotgun cloned into the pGEM-T Easy vector 
(Promega) and transformed into DH5α competent cells (Invitrogen) (as described 
in Section 2.2.8). Colonies containing inserts were grown overnight in LB broth 
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with ampicillin, from which 1 µl was used to seed PCR amplification of inserts 
with Nested primer 1 and 2R. PCR conditions were; 94°C for 30 s, followed by 25 
cycles of 95°C for 30 s and 68°C for 3 min. 
Nested primer 1 5’-TCGAGCGGCCGCCCGGGCAGGT 
Nested primer 2R 5’-AGCGTGGTCGCGGCCGAGGT 
2.2.14.4 Differential library screening 
PCR amplified transcripts were dot-blotted onto Hybond N+ membrane 
(Amersham) using a dot-blot apparatus (Bio-Rad) according to the manufacturer’s 
instructions. For each PCR, 50 µl of the following combined mixture was dot-
blotted onto duplicate membranes: 5 µl PCR product and 140 µl denaturing mix 
(0.3 M NaOH/15% Ficoll (Sigma) and 0.5% bromophenol blue). The membranes 
were autocross-linked in a UV Stratalinker 1800 (Stratagene) and pre-hybridised 
in Church and Gilbert hybridisation buffer at 60°C for 1 hr. Hybridisation with 
cDNA probes was performed overnight in a Hybaid oven at 55°. The following 
day, the membranes were washed with 2X SSC + 0.5% SDS for 15 min (x2) at 
55°C, followed by 1X SSC + 0.5% SDS for a further 15 min. The membranes 
were then sealed in plastic and exposed to XAR film (Kodak).  
2.2.14.5 cDNA probes  
The wild-type and myostatin-null cDNA probes were synthesised in a 20 
µl RT reaction from poly (A)+ RNA using a superscript pre-amplification kit 
(Invitrogen). Each poly (A)+ RNA (2 µg) was incubated at 70°C for 10 min with 1 
µl Oligo(dT) (0.5 mg), and MQ H2O to 7 µl. A further 12 µl of the following mix 
was then added: 2 µl 10X RT buffer, 2 µl 25 mM MgCl2, 1 µl 10 mM dNTP mix 
(-dCTP), 2 µl 0.1 M DTT and 5 µl [α-32P]dCTP, before incubating at 42°C for 5 
min. A volume of 1 µl (200 U) Superscript II RT was added per tube, which were 
then incubated at 42°C for 40 min before termination at 70°C for 15 min. A 
volume of 1 µl RNase H was added, and tubes were incubated at 37°C for 20 min 
before 29 µl MQ H2O was added to make a total of 50 µl. The cDNA probes were 
passed over a G-50 Sephadex column (Boehringer) to remove the unincorporated 
radioactive 32P according to the manufacturer’s instructions. 
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2.2.15 Yeast two-hybrid interactions 
For yeast two-hybrid studies, the DupLEX-A™ Yeast Two-Hybrid System 
(OriGene) was used to identify protein-protein interactions between the androgen 
receptor ligand binding domain (ARLBD) and ARA70. 
2.2.15.1 Cloning of ARLBD and ARA70  
The cDNAs for ARA70 (both full length and truncated) and ARLBD were 
obtained by reverse transcription-PCR (RT-PCR) (as described in Section 2.2.3). 
First-strand cDNA was synthesised in a 20 µl RT reaction from 5 µg total RNA 
(from murine tissue) using SuperScript II pre-amplification kit (Invitrogen). PCR 
was performed with 2 µl of the RT reaction under the following conditions: 
ARLBD; 94°C for 2 min, then 30 cycles of 94°C for 20 s, 55°C for 30 s, and 72°C 
for 1 min, followed by a final 75°C for 5 min step 
Full length ARA70; 94°C for 2 min, then 25 cycles of 94°C for 20 s, 55°C for 30 
s, and 72°C for 2 min, followed by a final 72°C for 5 min step 
Truncated ARA70; 94°C for 2 min, then 25 cycles of 94°C for 15 s, 60°C for 30 s, 
and 68°C for 1.5 min, followed by a final 68°C for 7 min step.  
The primers used for the amplification of ARA70 were: 
Forward 5’-GCGAATTCATGAACACATCCCTG  
Full length reverse 5’-GCGAATTCTCACATCTGTAGAGG  
Truncated reverse 5’-GAATTCTCAAAGCCACTCTGACAAGGA  
The primers used for ARLBD were: 
Forward 5’-GGGATCCGTATGACTCTGGGAGCA  
Reverse 5’-ACGGATCCCTCACTGTGTGTGGAA  
The following molecular manipulations were performed as described in 
the relevant sections of this Chapter. All amplicons were electrophoresed in LMP 
agarose gels, excised, and Wizard purified before ligating into pGEM-T Easy 
(Promega). DH5α cells were transformed by the ligation mixture and incubated at 
37°C before performing minipreps on each culture. The pEG202 bait plasmid and 
the pJG4-5 target plasmid were prepared by performing enzymatic digests using 
EcoR1 and BamH1 respectively. The ARA70 inserts were cloned into pEG202 as 
EcoR1 fragments, while the ARLBD was cloned into pJG4-5 as a BamH1 
fragment. DH5α cells were then transformed by ligation mixtures and all 
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constructs were sequenced to confirm the absence of mutations. In preparation for 
yeast transformations, the cultures were incubated at 37°C and later minipreped.  
2.2.15.2 Yeast transformation 
Interactions between the encoded fusion proteins were assessed by co-
transforming the bait and target plasmids together with the reporter plasmid, 
pJK103, into yeast strain EGY194 as follows. A 5 ml culture of yeast EGY194 
was grown in YPD overnight at 30°C (yeast were grown with shaking unless 
stated otherwise), and used to inoculate 60 ml YPD to an absorbance of 0.1 at 600 
nm. At an absorbance of 0.5-0.7, the cultures were centrifuged at 1,500 x g for 5 
min, and resuspended in 0.3 ml 1X TE/LiOAc. The resuspended cells were 
aliquoted into 1.5 ml tubes and 100 ng of each plasmid DNA (bait, target and 
reporter) along with 50 µg denatured carrier DNA was added. A volume of 0.3 ml 
1X TE/LiOAc/PEG was added and the tube was mixed by inversion. The cells 
were incubated at 30°C for 30 min, before the addition of 40 µl DMSO (dimethyl 
sulphoxide) and a further incubation at 42°C for 15 min (without shaking). The 
cells were then centrifuged at 12,000 x g for 10 s and resuspended in 0.5 ml H2O. 
To assess protein interactions, the transformed yeast cells were grown on selection 
plates as described in Section 3.2.3 of Chapter 3.  
2.2.16 In situ hybridisation 
2.2.16.1 Overview of the in situ hybridisation procedure 
In situ hybridisation experiments were performed to detect ARA70 mRNA 
in muscle tissues. Initially, an approximately 500 bp ARA70 fragment was cloned 
into a pGEM-T Easy vector (Promega) containing T7 and SP6 RNA polymerase 
promoters. After the vector was linearised by restriction enzymes, digoxigenin 
(DIG) -UTP-labelled, single-stranded RNA probes were generated using a DIG 
RNA labelling kit (Roche). RNA labelling with DIG-UTP by in vitro transcription 
with SP6 and T7 RNA polymerase permitted the generation of ‘sense’ and 
‘antisense’ transcripts with DIG-UTP being incorporated every 20-25 nucleotides. 
The DIG-labelled probes were then introduced to the muscle sections where the 
‘antisense’ probe (SP6 probe) could bind to any complementary ARA70 mRNA 
within the tissues. The probes were later immuno-detected with anti-DIG alkaline 
phosphatase fab fragments as a bound antibody conjugate, due to the enzyme 
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alkaline phosphatase catalysing a chemical reaction to produce a visible, dark 
indigo coloured, precipitate.  
2.2.16.2 Generation of DIG-labelled RNA in situ probes  
The sequences of the designed primers used for the generation of a 502 bp 
fragment were:  
Forward 5’-GCGAATTCATGAACACATCCCTG  
Reverse 5’-CCATCAGATGCTCAGGGATTTGA  
PCR was performed using 2 µl of RT reaction (from murine kidney RNA) (as 
described in Section 2.2.3), under the following conditions: 94ºC for 2 min, then 
35 cycles of 94ºC for 20 s, 55ºC for 30 s, and 72ºC for 2 min, followed by a 
termination step at 72ºC for 5 min. The amplicon was electrophoresed in a 1% 
LMP agarose gel before the fragment was excised and Wizard purified. The 
fragment was ligated into pGEM-T Easy (Promega), and transformed into DH5α 
cells. Endonuclear restriction digests were performed using EcoR1 and BamH1 to 
establish the presence and orientation of the insert respectively (refer to relevant 
sections within this Chapter for descriptions of these molecular manipulations). 
Additionally, the construct was sequenced to confirm the absence of mutations. A 
further restriction digest was performed using the restriction enzymes Sph1 and 
Sal1 to linearise the vector/ insert in preparation for the in situ probe making. The 
resulting digest products were mixed as follows: 57 µl linearised plasmid; 2 µl 
glycogen; 20 µl 3 M sodium acetate; 600 µl 100% ethanol; 143 µl H2O. Samples 
were incubated at -20°C for 2 hr before centrifuging for 10 min at 14,000 x g. The 
supernatant was removed, and after the addition of 600 µl 70% ethanol, the 
samples were spun for 10 min at 14,000 x g. The resulting pellet was dried and 
then resuspended in 20 µl H2O. The Roche DIG RNA labelling kit (SP6/T7) 
protocol was performed in order to generate DIG-labelled single-stranded RNA 
probes. For this, 2 µl of purified linearised plasmid was added to 11 µl DEPC-
treated H2O, before the following was added while incubating on ice. 
Plasmid linearised by Sal1   Plasmid linearised by Sph1 
10X NTP labelling mix 2 µl  10X NTP labelling mix 2 µl 
10X transcription buffer 2 µl  10X transcription buffer 2 µl 
RNase inhibitor  1 µl  RNase inhibitor  1 µl 
RNA polymerase T7  2 µl  RNA polymerase SP6  2 µl 
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Samples were mixed gently, centrifuged briefly, and incubated at 37ºC for 2 hr. 
The reaction was later terminated by the addition of 2 µl 0.2 M EDTA. The SP6 
and T7 probes were then precipitated with 2.5 µl 4 M LiCl, 5 µl, 10 mg/ml yeast 
tRNA, and 75 µl 100% ethanol. Samples were incubated at -70ºC for 30 min then 
centrifuged at 13,000 x g for 15 min. The pellet was washed in 70% ethanol and 
re-centrifuged for a further 5 min. Once the supernatant was removed, the pellet 
was dried before being resuspended in 15 µl premix hybridisation buffer. 
A dot-blot procedure was later performed to determine the relative 
concentrations of the SP6 and T7 probes. Both probes were diluted with TE buffer 
to the following dilutions: 1:100, 1:250, 1:500, 1:1,000, 1:2,000, and 1:3,000. A 
quantity of 1 µl of each probe dilution was spotted onto N+ nitrocellulose 
membrane (Amersham). The spots were dried and cross-linked before the 
membrane was submerged in 1X blocking buffer (diluted in TBS) for 45 min. 
Sheep anti-DIG alkaline phosphatase (Fab fragments) were then added to the 
blocking buffer at a dilution of 1:5,000 for 30 min. The membrane was washed in 
TBS-T for 10 min (x3), and incubated with a colour solution (1 ml 1 M Tris-HCl 
(pH 9.5), 0.2 ml 5 M NaCl, 0.5 ml 1 M MgCl2, 8.3 ml DEPC-treated H2O 
containing 45 µl nitroblue tetrazolium chloride (NBT) and 35 µl 5-bromo-4-
chloro-3-indoyl phosphate (BCIP)) for 5-10 min depending on colour 
development. 
2.2.16.3 De-waxing and pre-treatment   
TA muscle tissues and sections were prepared as described in Section 
2.2.18.2. Prepared muscle sections were washed in 2X SSC for 30 min, digested 
with Proteinase K (10 mg/ml in 100 mM Tris/HCl pH 8.0, 1 mM CaCl2) for 15 
min at 37°C, and washed with 2X SSC. Tissue sections were post-fixed with 
0.25% glutaraldhyde diluted to 1:100 in DEPC-treated PBS for 5 min, and then 
washed twice in DEPC-treated PBS for 5 min. Sections were treated with 1% 
acetic anhydride in 0.1 M triethanolamine for 5 min, rinsed in 2X SSC with 0.5 ml 
of acetic anhydride for 5 min, and then washed in 2X SSC for 5 min. 
2.2.16.4 Pre-hybridisation 
Approximately 50 µl pre-hybridisation solution (50% formamide, 2X 
SSC, 150 mM NaCl, 4 µg/ml bovine serum albumin (BSA), 5% dextran sulfate, 
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0.5 mg/ml salmon sperm DNA, and 0.25 mg/ml yeast tRNA) was added to each 
section and incubated for 60 min at 55°C in a humidified chamber equilibrated 
with 50% formamide in 2X SSC.  
2.2.16.5 Hybridisation 
The pre-hybridisation solution was later removed, and approximately 50 µl 
of either sense or anti-sense RNA probe diluted in pre-hybridisation solution (at 
equal molar concentrations) was added to each tissue section. The slides were 
then incubated overnight at 55°C in the equilibrated chamber. The following day 
the probes were removed and the slides were immersed in 50% formamide in 2X 
SSC (preheated to 60°C) for 10 min (x2). Slides were further washed in 2X SSC 
for 15 min (x2), 1X SSC for 15 min (x2) and 0.2X SSC for 30 min (x2) at 37°C. 
2.2.16.6 Immunological detection 
The slides were washed with TBS for 10 min (x2), after which, blocking 
buffer (TBS containing 0.1% Triton X-100 and 2% normal sheep serum (NSS)) 
was added for 30 min. The sections were then covered with TBS containing 0.1% 
Triton X-100, 1% NSS, and sheep anti-DIG alkaline phosphatase (Fab fragments) 
at 1:500 for 2 hr in a humid chamber. The slides were again washed with TBS for 
10 min (x2) before incubating for 10 min with a pre-colour solution (100 mM 
Tris-HCl (pH 9.5), 100 mM NaCl, and 50 mM MgCl2). A colour solution 
containing 1 ml pre-colour solution, 4.5 µl NBT (75 mg/ml), 3.5 µl/ml BCIP (50 
mg/ml), and 1 mM levamisole was then added to each section overnight. The 
following day the reaction was stopped by incubating in a stop buffer (10 mM 
Tris-HCl (pH 8.1), 1 mM EDTA) for 5 min, and dipping in dH2O. The slides were 
washed in PBS for 5 min before counterstaining with 4',6-diamidino-2-
phenylindole (DAPI; 1:1,000 in PBS; Molecular Probes) for 1 min. The sections 
were re-washed and mounted with aqueous mounting medium (Dako). Images 
were obtained using an Olympus BX50 microscope (Olympus) fitted with a Dage-
MTI DC-330 colour camera (Dage-MTI) and UV filter. 
2.2.17 Generation and purification of a myostatin truncation 
The truncated myostatin protein used in the antagonist experiments 
described in this thesis was generated and purified by Carole Berry and Dr Gina 
 109
Nicholas (AgResearch, Hamilton, New Zealand), according to a previously 
published protocol (Sharma et al., 1999). A pET protein expression system 
(Novagen) was used to express the truncated myostatin protein, referred to as 
Mstn-ant1. A portion of bovine myostatin cDNA spanning amino acids 267-350 
was PCR amplified as a BamHI fragment to produce a truncated portion of the 
processed region, and subsequently cloned into a pET 16-B vector. The myostatin 
coding sequence was placed in frame with the 10 histidine residues. PCR was 
performed at 94°C for 30 s, 50°C for 1 min, and 72°C for 1 min for 35 cycles, 
followed by a single 72°C extension step for 5 min. The primers used for the 
amplification of the truncated myostatin sequence were:  
Forward 5’-GAGGATCCGGATTTTGGGCTTGAT  
Reverse 5’-CGGATCCTCCATATTAATTGGACACAT  
The amplicon was excised from a LMP gel and Wizard purified before ligating 
into pGEM-T Easy (Promega). DH5α cells were transformed with the ligation 
mixture and incubated at 37°C before minipreping and sending for sequencing to 
confirm absence of mutations. The insert was cloned into a pET 16-B vector as a 
BamH1 fragment, and then transformed into DH5α cells, which were incubated at 
37°C and later minipreped. Plasmid DNA was transformed into BL21 E. coli 
(Invitrogen) competent cells (refer to relevant sections within this chapter for 
descriptions of these molecular manipulations). An overnight culture of cells 
transformed with the recombinant myostatin expression vector was diluted (1:50) 
and incubated at 37°C to an OD of 0.8 (595 nm) in 1 L of LB broth containing 50 
mg/L ampicillin. The fusion protein was induced by 0.5 mM isopropyl thio-β-
galactoside (IPTG) for 2 hr. The bacteria were collected by centrifugation (4,500 
x g for 30 min) and resuspended in 40 ml of lysis buffer (50 mM Tris (pH8.0), 
200 mM NaCl, 10% glycerol). The bacteria were then sonicated, and the resulting 
lysate was centrifuged at 10,000 x g for 30 min. The truncated protein was 
purified from the supernatant by Ni-Agarose (Qiagen) affinity chromatography. 
For this, the supernatant was bound to the Ni-Agarose for 2 hr at 4°C, then packed 
into a column and washed with lysis buffer containing 50 mM imidazole. Column 
fractions were eluted with lysis buffer containing 200 mM imidazole, and pooled 
and dialysed against two changes of 100 mM Tris-HCl (pH 8.0) containing 500 
mM NaCl for 2 hr. In order to test the purity of the truncated protein, 3 µg was 
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separated on a NuPAGE™ 4-12% Bis-Tris gel (Invitrogen), and stained with 
Coomassie Blue stain. 
2.2.18 Tissue preparation 
2.2.18.1 Freezing muscles for sectioning 
Dissected muscles were coated in Tissue-Tek OCT compound (Sakura) 
before dipping in liquid nitrogen-cooled isopentane for approximately 10 s. 
Tissues were then stored at -80°C until further use. Muscle sections were cut at 10 
µm using a Reich-Jung Cryocut 1800 cryostat (Leica), then air dried and stored at 
-20°C. Before staining, the slides were thawed in an airtight container at room 
temperature.  
2.2.18.2 Formalin fixing and paraffin embedding of tissues  
Excised fat pads and muscles were fixed in 10% formalin at room 
temperature for 48 hr and then washed in 70% ethanol until processing. A Leica 
TP 1050 tissue processor (Leica) was used to embed the fat pads with paraffin 
wax. This process involved an automated sequence described in Table 2.1.  
 
Table 2.1 Paraffin fixation of tissues 
Solution Temperature Time 
70% ethanol (x2) room temperature 30 min 
85% ethanol room temperature 60 min 
95% ethanol room temperature 60 min 
100% ethanol (x2) room temperature 60 min 
xylene (x3) room temperature 60 min 
paraffin (x3) 60°C 60 min 
 
A MQ H2O bath was preheated to 42°C before the sections were cut to a 
thickness of 7-10 µm using a Leitz Wetzlar microtome (Leica). Cut sections were 
floated in the water bath and allowed to flatten before transferring onto polysine-
coated slides (Esco). The slides were dried overnight on a warming tray before 
storing at room temperature. In preparation of haematoxylin and eosin (H & E) 
staining or in situ hyridisation, sections were first de-waxed by immersing slides 
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into clean xylene twice for 10 min each, and then re-hydrated through a 
descending ethanol series. The slides were then stained as described in Sections 
2.2.16 and 2.2.19.  
2.2.19 H & E staining 
H & E staining enabled the visualisation of the nuclei (haematoxylin, 
purple colouration) and cytoplasm (eosin, pink colouration) in both tissues and 
cells. The staining procedure for tissues and cells are described in Tables 2.2 and 
2.3 respectively.  
 
Table 2.2 H & E staining protocol for tissue sections 
Procedure Time 
Stain with Gills haematoxylin 5 min 
Rinse with tap water until clear 
Blue with Scott’s tapwater 2 min 
Rinse with tapwater 2 min 
Stain with 1% eosin Y 2 min 
Rinse in tapwater until clear, plus 2 min 
50% ethanol 3 dips 
70% ethanol 3 dips 
95% ethanol 2 min 
100% ethanol 2 min x2 
xylene 5 min x2 
Table 2.3 H & E staining protocol for myoblasts/myotubes  
Procedure Time 
Remove media and rinse cells with PBS  
Stain with Gill’s haematoxylin 5 min 
Wash with dH2O 2 min x2 
Blue with Scott’s tapwater 2 min 
Rinse with dH2O  
Stain with 1% eosin Y 2 min 
100% ethanol 5 min x3 
xylene 5 min x2 
 
 112
Once the slides dried, DPX mounting solution was applied before placing a 
coverslip over the specimens.  
2.2.20 Van Gieson staining 
Van Gieson staining enabled the visualisation of nuclei (purple 
colouration) cytoplasm (brown colouration) and collagen (pink colouration) 
within a muscle section. The staining procedure is described in Table 2.4. The 
Weigert’s iron haematoxylin was prepared by mixing equal parts of solution A 
and solution B (see Section 2.1.6). 
 
Table 2.4 Van Gieson staining protocol for muscle sections 
Procedure Time 
Stain in Weigert’s iron haematoxylin  10 min 
Rinse with H2O  until clear, plus 2 min 
Stain in Van Gieson solution  5 min 
Rinse with H2O  dip x3 
90% ethanol with 6 drops saturated picric acid 1 min 
100% ethanol with 6 drops saturated picric acid 1 min 
xylene  5 min (x2) 
 
Once the slides dried, DPX mounting solution was applied before placing a 
coverslip over the tissue sections.  
2.2.21 Fibre typing through mATPase 
For fibre type analysis, muscle sections were stained for mATPase activity 
using a modified method of Brooke and Kaiser (1970). The staining procedure is 
described in Table 2.5. Fresh tissue sections were required for the staining 
procedure. In addition, the ATP incubation medium and the ammonium sulphide 
solution (which was maintained in a dark environment) needed to be made fresh 
just prior to their use. 
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Table 2.5 Fibre typing staining protocol for muscle sections 
Procedure Time 
Acidic pre-incubation media (pH 4.6) (at 25°C)  6 min 
Pre-incubation wash  30 s x2 
ATP incubation medium (at 37°C, with shaking) 30 min 
1% CaCl2 1 min  
1% CaCl2 2 min 
1% CaCl2  3 min 
2% CoCl2  2 min x3 
Rinse in dH2O x15-25 
Rinse in ammonium sulphide 1 min 
Rinse in dH2O x25 
 
Once the slides dried, a 10% glycerol mounting solution was applied before 
placing a coverslip over the tissue sections.  
2.2.22 Immunocytochemistry  
2.2.22.1 Mac1 immunocytochemistry 
The analysis of macrophage infiltration into injured muscle was performed 
on muscle sections using a previously published immunocytochemistry (ICC) 
protocol (McCroskery et al., 2005). Muscle sections were fixed in 2% 
paraformaldehyde for 10 min at room temperature, rinsed in PBS (x3), then 
permeablised in 0.3% Triton X-100 in PBS for 30 min. The sections were blocked 
with 10% normal donkey serum (NDS) in TBS for 1 hr at room temperature 
before incubating overnight at 4˚C with a goat anti-Mac1 antibody (1:400; 
Integrin α M (m-19); Santa Cruz) in 5% NDS in TBS. The sections were washed 
for 4 min in PBS (x3) and incubated with a biotinylated donkey anti-goat 
secondary antibody (1:400; Amersham) in 5% NDS in TBS for 30 min at room 
temperature. The washes were repeated before adding streptavidin-conjugated 
Alexa Fluor 488 (1:400; Molecular Probes) in 5% NDS in TBS for 30 min at 
room temperature. The sections were washed with PBS, and later counterstained 
with DAPI (Molecular Probes) at 1:1,000 in PBS for 5 min. A final rinse in PBS 
was performed before mounting with fluorescent mounting medium (Dako). 
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2.2.22.2 PCNA ICC 
In order to detect proliferating satellite cells in isolated muscle fibre 
cultures, the following protocol was performed. After the required culturing time, 
the muscle fibres were fixed with 100% methanol and washed in PBS for 5 min 
(x3). The fibres were then permeablised in 0.5% TritonX-100 in PBS for 10 min 
and blocked with 10% normal goat serum (NGS) and 0.35% cλ in PBS for 1 hr at 
room temperature. Mouse anti-PCNA antibody (1:100; Dako) in 5% NGS and 
0.35% cλ in PBS was added overnight at 4°C. Fibres were re-washed before the 
primary antibody was detected using Alexa Fluor 546 goat anti-mouse IgG 
conjugated secondary (1:300; Molecular Probes) in 5% NGS and 0.35% cλ in 
PBS for 1 hr at room temperature. After re-washing, the fibres were 
counterstained with DAPI (1:1,000 in PBS; Molecular Probes) before mounting 
with fluorescent mounting media (Dako). 
2.2.22.3 CD34 ICC 
Satellite cells were detected with CD34 antibodies according to an adapted 
method of Beauchamp et al. (2000). After the required culturing time, fibres were 
fixed with 4% paraformaldehyde and rinsed with PBS (x3). The fibres were 
permeablised with 0.5% TritonX-100 in PBS for 10 min and blocked with 10% 
NGS in PBS for 30 min at room temperature. Fibres were then incubated 
overnight at 4°C with rat anti-mouse CD34 monoclonal antibody (1:100; clone 
RAM34, BD PharMingen) in 0.35% cλ in PBS. After washing in TBS-T for 5 min 
(x3), the primary antibody was detected using a biotinylated goat anti-rat 
secondary antibody (1:300; Amersham) in 0.35% cλ in PBS for 2 hr at room 
temperature. The washes were repeated before incubating with streptavidin-
conjugated Alexa Fluor 488 (1:400; Molecular Probes) in 0.35% cλ in PBS for 1 
hr at room temperature. Following a further washing, the fibres were 
counterstained with DAPI (Molecular Probes) at 1:1,000 in PBS for 5 min before 
mounting with fluorescent mounting media (Dako). 
2.2.22.4 Desmin and MyoD/Pax7 ICC 
For the detection of desmin or MyoD and Pax7 in primary myoblast 
cultures, the following protocol was performed. After the required culturing time, 
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the actively growing primary myoblasts were fixed with 20:2:1, rinsed with PBS 
(x3) and permeablised with 0.1% triton X-100 in PBS.  
For the detection of desmin, the myoblasts were blocked with 10% NSS 
and 0.35% cλ in PBS for 1 hr at room temperature before incubating overnight at 
4˚C with mouse anti-desmin (1:200; Sigma) in 5% NSS and 0.35% cλ in PBS. 
After washing in TBS-T for 5 min (x3), the fibres were incubated with 
biotinylated sheep anti-mouse secondary antibody (1:300; Amersham) in 5% NSS 
and 0.35% cλ in PBS for 1 hr at room temperature. The washes were repeated 
before incubating with streptavidin-conjugated Alexa Fluor 488 (1:400; Molecular 
Probes) in 5% NSS and 0.35% cλ in PBS for 1 hr at room temperature. The fibres 
were re-washed, then counterstained with DAPI (Molecular Probes) at 1:1,000 in 
PBS for 5 min before mounting with fluorescent mounting media (Dako). 
For the detection of MyoD/Pax7, the myoblasts were blocked in a blocker 
solution (5% NSS, 5% NGS and 0.35% cλ in PBS) for 1 hr at room temperature 
before incubating overnight at 4˚C with rabbit anti-MyoD (1:100; Santa Cruz) and 
mouse anti-Pax7 (1:100; ascites fluid obtained from the Developmental Studies 
Hybridoma Bank; DSHB) in blocker solution. After washing in TBS-T for 5 min 
(x3), the cells were incubated with biotinylated donkey anti-rabbit secondary 
antibody (1:300; Amersham) in blocker solution for 1 hr at room temperature. The 
washes were repeated before incubating with streptavidin-conjugated Alexa Fluor 
488 and Alexa Fluor 546 goat anti-mouse IgG conjugated secondary (1:300; 
Molecular Probes) in blocking media for 1 hr at room temperature. Following a 
further wash, the cells were counterstained with DAPI (Molecular Probes) at 
1:1,000 in PBS for 5 min and mounted with fluorescent mounting media (Dako). 
2.2.22.5 ARA70 ICC 
ARA70 was detected in primary myoblast cultures as follows. After the 
required culturing time, actively growing primary myoblasts were fixed with 4% 
paraformaldehyde for 5 min at 37ºC, rinsed with PBS (x3), and permeablised with 
0.1% Triton-X 100 in PBS for 10 min at room temperature. Cells were then 
blocked with 0.35% cλ in PBS for 1 hr at room temperature, before incubating 
with goat anti-ARA70 polyclonal antibody (1:25; Santa Cruz) in blocking buffer. 
Cells were washed in TBS-T for 5 min (x3), and incubated with biotinylated 
donkey anti-goat secondary antibody (1:300; Amersham) for 1 hr. The washes 
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were repeated before incubating with streptavidin-conjugated to fluorescein 
isothiocyanate (FITC; 1:300; Molecular Probes) for 1 hr at room temperature. 
After re-washing in TBS-T, the cells were counterstained with DAPI (Molecular 
Probes) at 1:1,000 in PBS, and rinsed in PBS before mounting with fluorescent 
mounting media (Dako). 
2.2.23 Isolation of cells and myofibres 
2.2.23.1 Satellite cell isolation by tissue dissociation and adherence to Matrigel-
coated plates 
The isolation of satellite cells described here was adapted from previously 
published protocols (Allen et al., 1997; Partridge 1997; Yablonka-Reuveni et al., 
1999). Hind-limb muscle from mice was dissected out and minced in PBS before 
being enzymatically digested in DMEM (without serum) containing 0.2% 
collagenase type 1A (w/v) (>125 CDU/mg). The minced muscle was incubated at 
37°C, with constant shaking for 90 min (70 rpm). The slurry was centrifuged at 
1,400 x g for 10 min, after which, 10 ml of PBS was added to the pellet before 
triturating the solution for 5 min. The slurry was then passed through a 100 µm 
cell strainer (BD Biosciences) before spinning at 1,000 x g for 10 min. The cell 
pellet was suspended in 8 ml warm satellite cell proliferation media and pre-plated 
on uncoated 10 cm plates (Nunc) for 2 hr at 37°C and 5% CO2. The cell 
suspension was later transferred to plates coated with 10% Matrigel (BD 
Biosciences), and incubated for 24 or 48 hr at 37°C and 5% CO2. Cells were later 
washed with PBS before trypsinising off for further usage.   
2.2.23.2 Satellite cell isolation by tissue dissociation and density centrifugation 
The isolation of satellite cells described here was adapted from a 
previously published protocol (Yablonka-Reuveni and Nameroff 1987). Satellite 
cells were isolated as described in Section 2.2.23.1; however, after passing the 
slurry through a 100 µm cell strainer (BD Biosciences), the filtering was repeated 
using a 70 µm cell strainer (BD Biosciences). The cell suspension was then spun 
at 1,000 x g for 10 min and resuspended in PBS. A 90% Percoll solution was 
prepared using 9 parts Percoll and 1 part 10X PBS. Both 70% and 40% gradient 
solutions were prepared by diluting the 90% Percoll solution with the required 
volume of PBS. The gradient was made by overlaying the 40% solution with the 
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70% solution. The cell suspension was placed on top of the gradient before 
spinning at 2,000 x g for 20 min at 4°C with the brake off. The layer of satellite 
cells was then transferred to a tube with PBS. Cells were again spun at 2,000 x g 
for 10 min, and later used for 5-bromo-2’-deoxy-uridine- (BrdU) labelling.  
2.2.23.3 Isolation of single myofibres 
The isolation of single myofibres described here was adapted from a 
previously published protocol (Rosenblatt et al., 1995). TA muscles were 
dissected out and digested in 0.2% (w/v) type 1A collagenase (>125 CDU/mg) in 
DMEM (without serum) for 60 min at 37ºC with rocking (70 rpm). The digested 
muscles were then transferred to DMEM containing 10% HS and 0.5% CEE 
before the fibres were separated by gentle trituration using a glass Pasteur pipette. 
Isolated fibres were transferred to 4- or 8-well chamber slides (BD Biosciences) 
coated with 10% Matrigel (BD Biosciences) and either cultured in fresh media for 
24 to 72 hr at 37°C and 5% CO2, or fixed immediately with relevant fixative.  
2.2.23.4 Isolation of peritoneal macrophages 
Macrophages were isolated by a peritoneal lavage technique. This 
involved freshly killed mice being injected intraperitoneally with 5 ml ice cold 
sterile PBS with a 23-gauge needle. The abdomen was massaged for 2 min before 
the fluid, containing macrophages, was withdrawn from the abdomen cavity. This 
cell solution was stored on ice while the process was repeated. Macrophages were 
kept on ice until subsequent use. 
2.2.23.5 Isolation of bone marrow-derived macrophages 
After killing the mice, hind-limb muscle was cut away from the bone 
before removing the bone by cutting the tibia just above the ankle, and the femur 
close to the hip socket. The bones were placed in DMEM media while using a 10 
ml syringe and 26-gauge needle to flush out the bone marrow by forcing the 
media through the bone cavity. Once all of the marrow was harvested, the cell 
solution was filtered through a 70 µm cell strainer (BD Biosciences) before 
spinning at 300 x g for 7 min at room temperature. The cell pellet was 
resuspended in medium (approximately 1 ml per mouse), and 10 µl of the cell 
suspension was mixed with 90 µl of red blood cell lysis buffer in order to count 
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the cells on a hemacytometer. The cells were then plated at 5 x 106 cells/plate in 
DMEM with 10% FBS and 10% L929 conditioned medium (containing colony 
stimulating factor-1 (CSF-1)), for 5 days to induce macrophage differentiation. 
For macrophage activation, approximately 1 x 107 cells were seeded onto 10 cm 
plates (Nunc) and left overnight to adhere to the plate surface.  
2.2.24 Culture of C2C12 myoblasts 
C2C12 myoblasts were grown according to standard techniques (Thomas 
et al., 2000). C2C12 myoblasts were cultured in DMEM containing 10% FBS, 
7.22 nM Phenol red, 1 x 105 U/L penicillin, and 100 mg/L streptomycin. The 
medium was buffered with 41.9 mM NaHCO3 and gaseous CO2. Myoblasts were 
cultured at 37oC and 5% CO2 in a ThermoForma Series II water jacketed 
incubator 3250 (Thermo Scientific). The culture dishes, seeding densities of cells, 
and treatments for specific experiments are described in the Materials and 
Methods of Chapters 3 and 6. 
2.2.25 Production of CEE  
The following protocol was adapted from the Gibco product sheet and Yu-
Li Wang’s Laboratory, Lab Protocols (http://ylwang.umassmed.edu/index.htm). 
Fertilised Cobb eggs (Bromley Park Hatcheries) were incubated at 37.5°C and 65-
70% humidity for 9 days. The eggs shells were wiped clean with sterile water, 
followed by 70% ethanol (x2). With sterile scissors, the wide end of the shell was 
cut open and the embryo was removed with a sterile surgical spoon. The embryos 
were weighed and 1 ml 1X Earles Balanced Salt solution (Invitrogen) per gram of 
embryo weight was added. The solution was blended on a high speed for 15 s, 3 
times, with 15 s rests on ice between blending. The solution was then centrifuged 
at 3,000 x g for 15 min at 4°C. The supernatant was later aliquoted out and stored 
at -80°C. Sterility of the CEE was checked by preparing DMEM containing 10% 
FBS and 1% CEE media and incubating for 48 hr at 37°C. Following the 
incubation period, the media was observed for any bacterial or fungal growth.  
2.2.26 Trypsinisation of cells 
The harvesting of all cell types was performed as follows. The culturing 
medium was removed before rinsing the cells with PBS (x3). Trypsin (1X) was 
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then added to the cells for 5-10 min at 37°C. Once the cells had lifted off the 
culturing dish, fresh media was added to inactivate the trypsin. The cell density 
was established using a haemacytometer before re-plating for further culturing, or 
alternatively, the cells were used for RNA or protein extraction.   
2.2.27 Fixation of single fibres and myoblasts   
4% paraformaldehyde fixing 
Approximately 0.5 ml 4% paraformaldehyde was added to the bottom of each 
chamber well before removing the majority of the top media layer. The slides 
were then incubated at 37ºC for 5-10 min. The fixative was removed before the 
fibres were rinsed repeatedly with PBS. 
 
100% methanol fixing   
The media was first removed before adding ice cold 100% methanol. The slides 
were incubated at 4ºC for 10 min and then air dried for a further 10 min. The 
muscle fibres were then rinsed repeatedly with PBS. 
 
Ethanol fixing 
Once the media was removed, the muscle fibres were left for approximately 30 s 
before adding 0.5 ml of ethanol fixative (Section 2.1.10). The slides were then 
incubated at -20ºC for 20 min. The fixative was later removed and the fibres were 
rinsed repeatedly with washing buffer (BrdU labeling and detection kit; Roche). 
 
20:2:1 fixing 
Once the media was removed, the cells were rinsed with PBS (x3). 20:2:1 fixative 
was added for 30 s, and then removed before re-rinsing the cells.   
2.2.28 BrdU-labelling  
2.2.28.1 Labelling of single fibres 
After incubating the isolated fibres for 48 hr in DMEM containing 10% 
HS, 0.5% CEE and 10 µM BrdU (Roche) at 37°C and 5% CO2, the fibres were 
fixed with ethanol fixative (refer to Section 2.1.10). A BrdU ICC was then 
performed according to the BrdU labeling and detection kit (Roche) protocol as 
follows. Fibres were incubated with mouse anti-BrdU antibody in incubation 
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buffer (1:10) for 30 min at 37ºC. Following 3 washes with the washing buffer 
solution, the fibres were incubated with anti-mouse-Ig-fluorescein in PBS (1:10) 
for 40 min at 37ºC. The fibres were then washed twice for 5 min with washing 
buffer before counterstaining with DAPI (Molecular Probes) at 1:1,000 in PBS for 
5 min at room temperature. A further two 5 min washes were performed, and the 
slides were then mounted with Dako fluorescent medium. 
2.2.28.2 Labelling of satellite cells  
Satellite cell proliferation was investigated by in vivo BrdU-labelling. 
Mice were intraperitoneally injected with BrdU (30 mg/kg; Roche) as a single 
pulse 2 hr before euthanizing. Satellite cells were isolated following the protocol 
described in Section 2.2.23.2. Cells were fixed in 70% ethanol for 30 min on ice, 
and then centrifuged at 1,200 x g for 10 min at 10ºC before treating with 2 M HCl 
and 0.5% TritonX-100 for 30 min at room temperature. After re-centrifuging, the 
acid treatment was neutralised with 0.1 M disodium tetraborate buffer (pH 8.5). 
The cells were again centrifuged before incubating in 70% ethanol at -20ºC 
overnight. The following day the cells were re-centrifuged and permeablised in 
0.5% Tween-20 in PBS at 4ºC for 10 min. After a further centrifugation, the cells 
were incubated for 45 min at 37ºC with a monoclonal anti-BrdU-FLUOS antibody 
(1:25, Roche) in incubation buffer (Roche). PBS was added before a final 
centrifuge. Cells were resuspended in PBS and analysed using a FACScan flow 
cytometer (BD Biosciences).  
2.2.29 Proliferation assay 
For all proliferation assays, the previously published photometric endpoint 
assay was performed (Oliver et al., 1989). After the required culturing time, the 
cells were fixed in 100 µl of 10% formaldehyde in 0.9% saline. The fixative was 
removed and 100 µl of methylene blue stain (1% methylene blue and 0.01 M 
borate buffer, pH 8.5) was added to each well for 30 min at room temperature. 
After the removal of the staining solution, the cells were washed four times with 
200 µl borate buffer, followed by the addition of 200 µl 0.1 M HCl:70% ethanol 
(1:1). The absorbance of the cells was read on a VersaMax microplate reader 
(Molecular Devices) at 655 nm, a measure directly proportional to cell number. 
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2.2.30 Chemotaxis assays 
Chemotaxis assays were performed using an adapted method previously 
described by McCroskery et al. (2005). For the analysis of myoblast and 
macrophage migration, the two cell types were isolated as described in Section 
2.2.23. Chemotaxis assays were performed using cell culture inserts (BD 
Biosciences), containing polyethylene terephthalate (PET) 0.8 µm membranes, in 
24-well plates (Corning). The insert membranes were treated with 1% Matrigel 
(BD Biosciences) in DMEM and then dried overnight at 37°C. The relevant test or 
control media (specified in Section 6.2.7 of Chapter 6) was added to the bottom 
wells, while 75,000 cells were added to the top wells (inserts). The plates were 
then incubated at 37ºC and 5% CO2 for 4 hr for macrophages or 7 hr for 
myoblasts. After the required incubation period, the top surfaces of the 
membranes were washed with pre-wet swabs to remove cells that did not migrate. 
The membranes were then fixed, stained in Gill’s haematoxylin and wet-mounted 
onto slides. Migrated cells were counted on four representative fields per 
membrane and the average number plotted. All assays were performed in 
duplicate. 
2.2.31 Protein isolation 
2.2.31.1 Cell protein 
Protein isolated from cell cultures was performed as follows. Cells 
harvested by typsinisation were spun down at 1,000 x g for 5 min and 
resuspended in approximately 200 µl PLB before freezing at -80ºC. Alternatively, 
cells were scraped off the culturing plate surface with 200 µl PLB and transferred 
to 1.5 ml tubes before freezing at -80ºC. Cell lysates were later thawed and 
repeatedly passed through a 20-gauge needle before centrifuging at 14,000 x g for 
5 min to pellet the cell debris. The supernatant (protein extract) was collected and 
stored at -80°C until further use. 
2.2.31.2 Muscle protein 
Required muscles were dissected out, frozen in liquid nitrogen, and stored 
at -80°C. To isolate the muscle protein, 50 mg of each muscle was homogenised 
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in 1 ml PLB. The muscle samples were spun at 14,000 x g for 5 min before 
collecting the supernatant and storing at -80°C until further use. 
2.2.32 Estimation of protein concentrations  
Total protein concentrations were estimated using the Bradford Assay 
(Bradford 1976). Total protein from each sample (1-2 µl) was added to dH2O to 
make up a final volume of 100 µl. The Protein Assay Dye Reagent (Bio-Rad) was 
diluted one in five before 1.2 ml was mixed with each protein sample. The 
absorbencies were then determined at 595 nm using a Heλios γ UV 
spectrophotometer (Thermo Scientific). The absorbances of BSA standards (0 to 
15 µg) were also measured to generate a standard curve with which the unknown 
samples were compared.  
2.2.33 SDS polyacrylamide gel electrophoresis and membrane transfer 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using precast NuPAGE™ 4-12% Bis-Tris gels (Invitrogen). The required amount 
of total protein (10 to 20 µg) was mixed with an appropriate volume of protein 
loading dye and boiled for 5 min prior to loading. Electrophoresis of the proteins 
was performed using 1X SDS Running Buffer (Invitrogen) at 40 mA until the 
desired separation was attained. After electrophoresis, the protein was transferred 
to nitrocellulose membrane (Bio-Rad) by electroblotting using a XCell II Blot 
Module (Invitrogen) which was run at 30 V for approximately 1 hr. Following 
transfer, the membranes were stained in Ponceau S to assess protein loading. 
Alternatively, gels were stained with Coomassie Blue stain to visualise the 
protein. 
 
Ponceau S staining  
Membranes were stained for 1 min and then rinsed in TBS-T until bands were 
clearly defined.  
 
Coomassie Blue staining 
Gels were stained for 30 min in Coomassie Blue stain, and then destained in 
Coomassie Blue destaining solution until bands were clearly defined.  
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2.2.34 Western blotting 
For the analysis of MyoD, membranes were blocked in BSA blocker 
(0.3% BSA, 1% PEG, and 1% poly vinyl perrolidone (PVP) in TBS-T) for 1 hr at 
room temperature, and then incubated with mouse anti-MyoD (BD PharMingen) 
at 1:10,000 overnight at 4°C. Alternatively, membranes were blocked in 5% milk 
in TBS-T overnight at 4°C, and then incubated with polyclonal rabbit anti-MyoD 
antibody (Santa Cruz) at 1:200 for 3 hr at room temperature. 
For the analysis of Pax7, myostatin and GAPDH, the membranes were 
blocked overnight at 4°C in 5% milk in TBS-T, and then incubated with one of 
the following: mouse anti-Pax7 antibody (ascites fluid obtained from the 
Developmental Studies Hybridoma Bank) at 1:500 for 3 hr; purified myostatin 
antibody (0.5 mg/ml; produced in house) at 1:2,000 for 3 hr; or mouse anti-
GAPDH (1:10,000; Research Diagnostics) for 1 hr at room temperature.  
All membranes were washed in TBS-T for 5 min (x5), then incubated with 
either goat anti-mouse IgG horseradish peroxidise (HRP) conjugate (Dako) 
(1:5,000, MyoD; 1:2,000, Pax7 and myostatin; or 1:10,000, GAPDH), or goat 
anti-rabbit IgG HRP conjugate (1:2,000; Dako) in their respective blocking 
solutions for 1 hr at room temperature. The washes were repeated before HRP 
activity was detected using Western Lightning™ Chemiluminescence Reagent 
Plus (PerkinElmer). XAR film (Kodak) was exposed to the membranes and the 
developed films were scanned and analysed using a GS-800 densitometer and 
Quantity One imaging software (Bio-Rad). 
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Chapter Three 
Myostatin negatively regulates the expression of the steroid 
receptor co-factor ARA70 
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3.1 Introduction 
The maintenance of adult skeletal muscle mass is the net result of the 
balance between muscle synthesis and degradation. When the equilibrium of 
molecular, physiological, and pathological determinants favours one mechanism 
over the other, the consequence is hypertrophy, or alternatively, atrophy of 
muscle. An extreme example of widespread skeletal muscle hypertrophy is 
dramatically illustrated in myostatin-deficient animals. The individual muscles of 
myostatin-null mice exhibit a 2-3 fold increase in size over wild-type, due to a 
combination of hypertrophy and hyperplasia (McPherron et al., 1997). Myostatin 
is a secreted member of the TGF-β family of signalling molecules (McPherron et 
al., 1997; McPherron and Lee 1997) that acts to restrict muscle growth via several 
mechanisms during embryonic, foetal and postnatal growth. Myostatin expression 
is predominately seen in skeletal muscle. Although myostatin mRNA levels do not 
differ between males and females, myostatin protein levels have been found to be 
sexually dimorphic. This was reported by McMahon et al. (2003) who showed 
that mature myostatin was 40-60% lower in males when compared to females. 
Furthermore, in an independent study, Reisz-Porszasz et al. (2003) indicated that 
over-expression of myostatin led to sex-specific (males only) atrophy in mice. 
During growth, myoblasts enter the cell cycle and proliferate until a 
cascade of signals, initiated by activatation of MyoD, causes myoblasts to 
permanently withdraw from the cell cycle (Crescenzi et al., 1990; Sorrentino et 
al., 1990), differentiate and fuse into multinucleated myotubes. However, in 
response to myostatin signalling there is an increase in p21 expression and a 
decrease in Cdk2 protein activity that results in an accumulation of 
hypophoshorylated Rb leading to the arrest of myoblasts in the G1 and G2 phases 
of the cell cycle (Thomas et al., 2000). When functional myostatin is absent, 
deregulated cell cycle control of myoblasts results in an increased number of 
myoblasts and, consequently, muscle fibres (hyperplasia) (Thomas et al., 2000). 
In addition to proliferation, myostatin also appears to regulate the differentiation 
step of myogenesis by regulating the activity and the expression levels of the 
MRF MyoD (Langley et al., 2002). 
Satellite cells are myogenic precursor cells that are mitotically quiescent in 
mature muscle (Schultz et al., 1978), but in response to injury are activated, re-
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enter the cell cycle, and are responsible for postnatal growth of muscle (Snow 
1977a; Snow 1977b; Bischoff 1989). Myostatin has been shown to maintain 
satellite cell quiescence by inhibiting the G1 to S progression and, moreover, 
negatively regulate satellite cell renewal (McCroskery et al., 2003). Increased 
satellite cell activation in myostatin-deficient animals leads to an increase in 
myonuclei, and thus myofibre size (hypertrophy) (McCroskery et al., 2003).  
A second well known example of hypertrophy is observed in individuals 
that have been administered testosterone. The effects of testosterone on skeletal 
muscle have been well documented and include increased type I and II muscle 
fibre volume, myonuclear number, protein synthesis and satellite cell number, 
decreased protein degradation, and increased myogenesis and decreased 
adipogenesis of pluripotent stem cells (review by Herbst and Bhasin, (2004)). The 
action of testosterone is mediated through the AR, a ligand-dependent 
transcription factor that is a member of the steroid hormone receptor superfamily 
(Chang et al., 1988b; Chang et al., 1988a). When testosterone binds, the AR 
undergoes a series of conformational changes that allows the AR to interact with 
AREs in various androgen target genes (Chang et al., 1995). ARA70, also known 
as nuclear receptor coactivator 4, RFG and ELE1, has been identified as a type II 
coregulator that stabilises the ligand-bound AR enhancing the transactivational 
potential of the AR (Yeh and Chang 1996; Yeh et al., 1998). AR coactivators, 
including ARA70, are recruited by the AR dimers on the ARE of DNA to 
facilitate further recruitment of histone acetylases and regulate chromatin structure 
and transcription (Spencer et al., 1997).  
In this study we demonstrate that murine ARA70 is expressed in myoblasts 
during myogenesis. We further demonstrate that myostatin is a potent negative 
regulator of ARA70 gene expression. Given that increased AR expression and 
reduced myostatin levels lead to hypertrophy, we propose a model where we 
hypothesize that the absence of myostatin, by increasing ARA70 expression, 
increases the activity of AR leading to the hypertrophy phenotype which is 
associated with male growth and driven by testosterone. 
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3.2 Materials and Methods 
3.2.1 Animals 
Myostatin-null mice (C57BL/10 background) were obtained from S.-J. Lee 
(The Johns Hopkins University, Baltimore, MD). Wild-type mice (C57BL/10) 
were bred at the Ruakura Small Animal Colony. Animal manipulations described 
in this paper were approved by the Animal Ethics Committee (AgResearch 
Ruakura) and the University of Waikato Animal Ethics Committee (University of 
Waikato, Hamilton, New Zealand). Male mice only were utilised in the 
experiments reported herein. 
3.2.1 SSH 
Total RNA from BF muscle of both wild-type and myostatin-null mice 
was prepared using TRIZOL reagent (Invitrogen) according to the manufacturer’s 
instructions. Poly (A)+ RNA was isolated from 2 mg of total RNA by Fast Track 
2.0 mRNA kit (Invitrogen) according to the manufacturer’s recommendations. To 
perform subtraction hybridisation, complementary DNAs were synthesised from 2 
µg of poly (A)+ RNA. SSH was then performed between myostatin-null mice 
(‘driver’) and wild-type mice (‘tester’) using the PCR-Select cDNA Subtraction 
Kit (Clontech) according to the manufacturer’s recommendations. Differentially 
expressed cDNAs were amplified and sub-cloned into the pGEM-T Easy vector 
(Promega) and transformed into DH5α competent cells (Invitrogen). Colonies 
containing inserts were grown overnight in LB broth (ampicillin), from which 1 µl 
was used for PCR amplification of inserts with Nested primer1 and 2R supplied 
with the kit (Clontech). PCR conditions were as stated in the manufacturer’s 
instructions. 
3.2.2 Differential library screening 
The PCR amplified differential transcripts were denatured and dot-blotted 
onto Hybond N+ membrane (Amersham), using dot-blot apparatus (Bio-Rad) 
according to the manufacturer’s instructions. For each PCR, 50 µl of the following 
combined mixture was dot-blotted onto duplicate membranes: 5 µl of PCR 
product and 140 µl of denaturing mix containing 0.3 M NaOH, 15% Ficoll 
(Sigma), and 0.5% bromophenol blue. The dot-blotted membranes were 
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autocross-linked by UV irradiation in a UV Stratalinker 1800 (Stratagene) then 
pre-hybridised in Church and Gilbert hybridisation buffer (0.5 M Na2HPO4, pH 
7.2, 7% SDS, 1 mM EDTA) at 60°C for approximately 1 hr prior to hybridisation. 
To compare relative levels of isolated differential transcripts between myostatin-
null and wild-type tissues, 32P-labelled cDNA probes were synthesised in a 20 µl 
RT reaction from 2 µg poly (A)+ RNA, using superscript pre-amplification kit 
(Invitrogen) according to the manufacturer’s instructions. The cDNA probes were 
passed over a G-50 Sephadex column (Boehringher) to remove unincorporated 32P 
according to the manufacturer’s instructions. One of the duplicate membranes was 
then hybridised with the myostatin-null cDNA probe, while the other was 
hybridised with the wild-type cDNA probe, overnight at 55°C. After 
hybridisation, membranes were washed twice with 2X SSC + 0.5% SDS for 15 
min at 55°C, then in 1X SSC + 0.5% SDS for a further 15 min at 55°C and 
exposed to XAR film (Kodak) and dot-blot duplicate intensities compared. 
Differentially expressed transcripts were identified via dot-blot intensity 
differences (the autoradiogram was scanned in a GS-800 Calibrated Densitometer 
(Bio-Rad) and the relative OD of the dots was measured using Quantity One 4.2.2 
software (Bio-Rad)), then sequenced by dye terminator sequencing. The partial 
sequences obtained were then compared with entries in the GenBank database 
using the BLAST homology search program.  
3.2.3 Yeast two-hybrid interactions 
The DupLEX™ Yeast Two-Hybrid System (OriGene) was used to detect 
protein-protein interactions. The open reading frame of mouse ARA70 (bp 35-
1912; amino acid residues 1-625; GenBank accession number NM_019744) 
encoding the full length ARA70 was cloned into the pEG202 bait plasmid 
(carrying the HIS3 gene) containing the Lex-A DNA binding domain using 
EcoR1 restriction sites (LexA-FL-ARA70). A truncated form of ARA70 (bp 35-
1564; amino acid residues 1-510) encoding amino-terminal region was also 
cloned in the pEG202 bait plasmid using EcoR1 restriction sites. A portion of the 
AR (bp 1842-2732 amino acid residues 604-899; GenBank accession number 
NM_013476) containing the LBD was cloned into the pJG4-5 target plasmid 
(carrying the TRP1 gene) containing the B42 DNA binding domain using BamH1 
restriction sites. Interaction between the encoded fusion proteins was assessed by 
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co-transforming the bait and target plasmids together with a reporter plasmid, 
pJK103, carrying the lacZ reporter gene under the control of LexA operators and 
the URA3 gene into yeast strain EGY194 (MATa trp1 his 3 ura3 leu2:4 LexAop-
LEU2). Transformed yeast cells were plated onto medium lacking histidine, uracil 
and tryptophan and grown at 30°C for 3 days to select for the presence of the three 
plasmids. Three independent colonies were then transferred to medium lacking 
histidine, uracil, tryptophan and leucine for 3 days at 30ºC to select for positive 
interactions. Positive clones were then tested for expression of the second reporter 
gene, lacZ, by growth on medium containing X-gal and lacking in histidine, 
uracil, and tryptophan. Expression of the target-B42 activation domain fusion 
protein, B42-ARLBD, is galactose-inducible in this system and therefore 
galactose growth-dependence was also tested. 
3.2.4 Northern blot analysis 
RNA was isolated from various mouse tissues using TRIZOL reagent 
according to the manufacturer’s instructions. Northern analysis was performed 
essentially as described by Sambrook et al. (1989). Total RNA (10 µg) was 
fractionated by 0.66 M formaldehyde, 1% agarose gel electrophoresis. RNA was 
transferred to Hybond N+ membrane (Amersham) by capillary transfer using 10X 
SSC. The membrane was pre-hybridised in Church and Gilbert hybridisation 
buffer at 55°C for 1 hr, followed by hybridisation with 32P-labelled cDNA probes 
in fresh Church and Gilbert hybridisation buffer at 55°C overnight. The 
membrane was washed at 55°C with 2X SSC + 0.5% SDS, and then 1X SSC + 
0.5% SDS. ARA70 was PCR amplified using an RT-PCR kit (Invitrogen). Five 
micrograms of total RNA from kidney was used in a RT reaction and PCR was 
performed with 2 µl of the RT reaction at 94°C for 20 s, 55°C for 20 s, and 72°C 
for 1 min for 35 cycles. This was followed by a single 72 °C extension step for 5 
min. The primers for ARA70 were:  
Forward  5’- CCATCAGATGCTCAGGGATTTGA  
Reverse  5’- GCGAATTCATGAACACATCCCTG  
Probe cDNAs were radioactively labelled using [α32P]dCTP (Amersham) and 
Rediprime II labelling kit (Amersham), according to the manufacturer’s 
instructions. 
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3.2.5 Isolation of mouse primary myoblasts and ICC  
Primary myoblasts from the entire hind-limb muscles were isolated and 
cultured according to the protocols of Allen et al. (1997) and Partridge (1997) 
with slight modifications. To detect ARA70 protein, isolated primary myoblasts 
were grown and then fixed on chamber slides (Nunc) coated with 10% Matrigel 
(BD Biosciences), and incubated with goat anti-ARA70 polyclonal antibody 
(1:25; Santa Cruz) for 1 hr. The primary antibody was detected using biotinylated 
anti-goat secondary antibody (1:300; Amersham) followed by streptavidin-
conjugated to FITC (1:300; Molecular Probes). All nuclei were counterstained 
with DAPI (Molecular Probes) and slides visualised under fluorescence 
illumination. 
3.2.6 In situ hybridisation 
Mouse TA muscle tissue was fixed in 4% paraformaldehyde in PBS for 16 
hr at room temperature, washed, dehydrated through an ascending ethanol series, 
and embedded in paraffin wax. Sections were then cut at 7 µm and mounted on 
microscope slides (Esco). For the generation of DIG probes, a 502 bp fragment of 
ARA70 cDNA (bp 46-597; GenBank accession no. NM_019744) was cloned into 
the pGEM-T Easy vector (Promega) and transcribed according to the 
manufacturer’s recommendation (DIG RNA Labeling Kit; SP6/T7; Boehringer). 
Paraffin-embedded sections were dewaxed, and in situ hybridisations were 
performed according to the method of Greiwe et al. (2001) with slight 
modifications. All nuclei were counterstained with DAPI (Molecular Probes).  
3.2.7 Semi-quantitative RT-PCR and Southern blotting 
Total RNA was isolated from wild-type or myostatin-null mouse muscle 
tissues or C2C12 myoblast cells using TRIZOL reagent according to the 
manufacturer’s instructions, then used as template in a RT reaction using 
Oligo(dT) primers and SuperScript II First-Strand Synthesis System for RT-PCR 
(Invitrogen), according to the manufacturer’s instructions. The resulting cDNA 
was used as template in semi-quantitative PCR conditions for ARA70 and GAPDH 
were 94°C for 20 s, 55°C for 30 s, and 72°C for 2 min for 20 cycles and a final 
extension at 72°C for 5 min. The primers used for the PCRs were:  
 
 133
ARA70 
Forward  5’ - GCGAATTCATGAACACATCCCTG  
Reverse  5’ - GCGAATTCTCACATCTGTAGAGG  
GAPDH (GenBank accession number NM_008084) 
Forward  5’-GTGGCAAAGTGGAGATTGTTGCC  
Reverse  5’-GATGATGACCCGTTTGGCTCC  
Thirty microlitres of the semi-quantitative PCR products were fractionated on a 
0.8% or 1.2% agarose gel, transferred to a Hybond N+ membrane (Amersham) in 
SB solution (1.5 M NaCl, 0.5 M NaOH) and hybridised to an ARA70 or GAPDH 
[α32P]dCTP -labelled probe (prepared as above) in Church and Gilbert buffer at 
55ºC. After washes in 2X SSC + 0.5% SDS and 1X SSC + 0.5% SDS at 55°C, the 
membranes were exposed to XAR film (Kodak). The autoradiogram was scanned 
and the relative OD of bands was measured as above. 
3.2.8 C2C12 myoblast culture 
C2C12 myoblasts were grown prior to assay in DMEM buffered with 41.9 
mM NaHCO3 and 5% gaseous CO2. Phenol red (7.22 nM) was used as a pH 
indicator, and 1X 105 IU/l penicillin, 100 mg/l streptomycin, and 10% FBS were 
added to media. For assaying, C2C12 myoblasts were seeded on a 10 cm plate 
(Nunc) at a density of 25,000 cells/cm2. Following a 16 hr attachment period, 
differentiation media consisting of DMEM containing 2% HS and 0 or 15 µg/ml 
recombinant myostatin (prepared as described by Thomas et al. (2000) were 
added. Cells were collected for RNA extraction after 0, 12, 24, 48 and 72 hr and 
processed for semi-quantitative RT-PCR as above. Cells cultured without 
myostatin were also collected for protein extraction after 0, 12, 24, 48 and 72 hr. 
3.2.9 Western blot analysis 
Cell extracts were prepared and total protein estimated exactly as 
described by Thomas et al. (2000). Fifteen micrograms of total protein was 
resolved by 4-12% SDS-PAGE (Invitrogen) then transferred to nitrocellulose 
membrane (Bio-Rad) by electroblotting. Equal protein loadings were confirmed 
with Ponceau S staining. Western blots were performed using standard 
procedures. Polyclonal rabbit anti-MyoD (Santa Cruz) was used at a 1:200 
dilution. Detection of the primary antibody was carried out with a HRP 
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conjugated anti-rabbit IgG (Dako) at a 1:2,000 dilution. Peroxidase activity was 
detected using Western Lightning™ Chemiluminescence Reagent Plus 
(PerkinElmer). The autoradiogram was scanned and the relative OD of bands was 
measured as above. 
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3.3 Results 
3.3.1 ARA70 is a downstream target of myostatin 
Myostatin is a powerful inhibitor of muscle growth with both hypertrophy 
and hyperplasia of muscle observed in the absence of myostatin (Kambadur et al., 
1997; McPherron et al., 1997). At embryonic and foetal myogenic stages, 
myostatin appears to function by regulating cell cycle progression (Thomas et al., 
2000). Key transcriptional regulators of muscle development, such as Pax3, 
MyoD, and Myf5, are known to be down-regulated in response to myostatin 
signalling in myogenic cells resulting in inhibition of both proliferation and 
differentiation of muscle (Amthor et al., 2002). To further elucidate the molecular 
mechanisms by which myostatin affects myogenesis, SSH was performed to 
investigate differential gene expression patterns postnatally. For this analysis total 
RNA from BF muscle was isolated from wild-type and myostatin-null mice and a 
library of cDNA representative of differentially expressed mRNAs was generated. 
Around 400 cDNA clones were dot-blotted and analysed using reverse Northern 
blotting techniques. Genes that were differentially expressed were selected for 
sequencing and the derived sequences were used to search GenBank. Results 
revealed several known and well characterised genes that were regulated by 
myostatin in addition to various genes of unknown function (Table 3.1). Here we 
describe a murine cDNA clone that contained sequence homology to a human 
gene known as nuclear receptor coactivator 4, or ARA70. This gene was 
significantly up-regulated in the myostatin-null muscle (Figure 3.1). 
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Table 3.1. Genes up-regulated in myostatin-null mice.  
Differentially expressed genes in wild-type and myostatin-null mice were 
identified by SSH and a selection is tabulated below. 
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Figure 3.1 ARA70 is revealed as a downstream target of myostatin by SSH   
Total RNA from BF muscle was isolated from wild-type (WT) and myostatin-null 
(KO) mice and a library of cDNA representative of expressed mRNAs was 
generated. Individual PCR-amplified products were gridded on nitrocellulose 
membranes as dot-blot arrays after two SSHs were performed. Membranes were 
hybridised against 32P-labelled cDNA probes from wild-type and myostatin-null 
poly (A)+ RNA. (A) The reverse Northern dot-blot for the cDNA clone 
subsequently identified by DNA sequencing and BLAST analysis as ARA70 is 
shown. (B) Autoradiogram of the dot-blot shown in panel A was analysed by 
densitometry. 
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3.3.2 Murine ARA70 is highly homologous to human ARA70 
GenBank sequence analysis revealed that there are two identical entries for 
putative murine ARA70 (NM_019744 and AF159461), which correspond to the 
gene we identified in the SSH analysis, and another extremely homologous 
sequence that differs by only 1 amino acid substitution (AK129020). These 3 
entries we have designated as the α-form of ARA70. A further entry, (BC031528), 
is also highly homologous excepting 6 amino acid substitutions and a 27 bp 
inframe deletion resulting in the loss of 9 amino acids in the carboxyl-terminal 
portion of the protein. This we have designated the β-form of ARA70 (Figure 
3.2). Two additional entries show significant sequence homology to the above 
sequences, one has an amino-terminal 66 amino acid truncation (AK032951) and 
the other, 1 internal amino acid substitution and a carboxyl-terminal 242 amino 
acid truncation (AK014479). Murine ARA70α is 82% homologous to human 
ARA70 at DNA level. When protein sequences were compared, it was revealed 
that murine ARA70α shared approximately 79% sequence homology to human 
ARA70 (Figure 3.2). The form of ARA70 used for experiments reported herein is 
the α-form, identical to the NM_019744 and AF159461 entries. 
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Figure 3.2 Murine ARA70 shows high homology to human ARA70   
Amino acid sequence comparison between murine ARA70α (NM_019744), 
murine ARA70β (BC01528), and human ARA70 (L49399) are depicted. Amino 
acid residues differing between the murine α- and β-forms are highlighted in bold 
boxes and differences between the human and murine α-form are boxed. 
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3.3.3 Murine ARA70 interacts directly with the ARLBD 
To confirm and characterise the putative murine ARA70 as an AR 
coactivator, we used the yeast two-hybrid system to determine if mouse ARA70 
binds to the LBD of mouse AR. Previously, the binding between human ARA70 
and ARLBD has been characterised using the yeast two-hybrid system where it 
was shown that ARA70 amino acid residues 321-441 bound to ARLBD with 
highest binding affinity (Zhou et al., 2002). Furthermore, the carboxyl-terminal 
region of ARA70 is thought to contain a repression domain that influences protein 
folding and decreases the binding affinity to ARLBD. Deletion of this region 
(amino acid residues 499-614) increased binding to ARLBD 4-fold (Zhou et al., 
2002). We therefore expressed both of these forms of ARA70 as a bait fusion 
protein to the LexA activation domain: the full length ARA70 (LexA-FL-ARA70) 
and the truncated form with the carboxyl-terminal region deleted (LexA-1-510-
ARA70). These fusion proteins were tested for interaction in the yeast two-hybrid 
system with the LBD (amino acids residues 604-899) of the AR expressed as a 
target fusion protein to the B42 activation domain (B42-ARLBD) (Figure 3.3). In 
yeast co-transformed with LexA-FL-ARA70 and B42-ARLBD there was no 
transactivation of either lacZ or LEU2 reporters and hence no growth of yeast was 
observed on leucine deficient agar plates. These data indicate that full length 
ARA70 did not bind to ARLBD. In contrast, when yeast were co-transformed 
with the truncated form of ARA70, LexA-1-510-ARA70, and B42-ARLBD, 
transactivation of the lacZ reporter occurred when yeast were grown on agar 
containing galactose but not when the carbohydrate source was glucose. This 
result is consistent with the galactose dependency of the GAL1 promoter used to 
drive the expression of the B42-ARLBD fusion protein. Similarly, transactivation 
of LEU2 in yeast co-transformed with LexA-1-510-ARA70 and B42-ARLBD 
expression plasmids grown on medium deficient in leucine occurred only in the 
presence of galactose. These data, therefore, clearly indicate that 1-510-ARA70 
and ARLBD can interact directly in the yeast cells.   
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Figure 3.3 ARA70 interacts directly with ARLBD   
Interactions between pairs of fusion proteins containing either an amino-terminal 
LexA DNA-binding domain or B42 transactivation domain were determined by 
yeast two-hybrid assay using lacZ and LEU2 reporter genes under the control of 
LexA operators. (A) Numbers below the schematic layout of ARA70 indicate the 
nucleotide numbers correctly corresponding to the GenBank mouse entry 
NM_019744 (b) and residue numbers of the amino acid sequence (aar). Similarly 
for ARLBD GenBank mouse entry NM_013476. Bars indicate the positions of the 
cDNAs used for the bait plasmids LexA-FL-ARA70 and LexA-1-510-ARA70 and 
the target plasmid B42-ARLBD. (B) Three independent transformants were tested 
for their ability to transactivate the lacZ locus as visualised by X-gal staining on 
plates containing either galactose (Gal) or glucose (Glu), to either induce or 
repress, respectively, expression of the B42 fusion protein. Similarly, 
transactivation of the LEU2 locus, which enables yeast to grow in the absence of 
leucine, was tested on plates containing either galactose (Gal) or glucose (Glu).   
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3.3.4 ARA70 is expressed in various tissues 
To analyse the expression profile of the ARA70 gene we performed 
Northern blot analysis. Northern analyses in mouse indicated that ARA70 is 
expressed as an mRNA of approximately 3.3 kilobases in many tissues, including 
brain, heart, intestine, kidney, liver, lung, testis and skeletal muscle (Figure 3.4A). 
To assess if ARA70 protein was present in primary myoblasts we performed 
immunofluorescent staining on primary myoblast cell cultures. 
Immunofluorescence revealed ARA70 protein was localised throughout the 
myoblast cytoplasm (Figure 3.4Bi). Counterstaining with DAPI to identify cell 
nuclei showed ARA70 protein was consistently present in all cells (Figure 3.4Bii). 
Immunofluorescence was not detected in the absence of primary antibody (Figure 
3.4Biii). To assess the distribution and level of ARA70 expression in muscle cells 
we performed in situ hybridisation on paraffin-embedded transverse sections of 
TA muscle (Figure 3.4C). A fragment from the ARA70 open reading frame 
sequence was used to generate sense and anti-sense DIG-labelled RNA in situ 
probes. Expression of ARA70 mRNA was clearly detectable in muscle tissue 
(Figure 3.4Ci). Control sections hybridised with the sense probe displayed only 
background signal verifying specificity of the antisense probe (Figure 3.4Cii). 
ARA70 expression did not appear to be fibre type specific as the staining intensity 
was uniform throughout the muscle section. Furthermore, the pattern of staining 
within the individual fibres indicated that ARA70 mRNA was localised throughout 
the cytoplasm. These data are in agreement with previous studies showing ARA70 
protein localised in the cytoplasm of human breast cancer cells (Kollara et al., 
2001). 
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Figure 3.4 ARA70 is expressed in various mouse tissues   
(A) Northern analysis of the tissue distribution of ARA70. Total RNA (15 µg) 
extracted from mouse BF muscle; Br, brain; T, testes; I, intestine; Lu, lung; H, 
heart; K, kidney; L, liver; was fractionated by gel electrophoresis and transferred 
to Hybond N+ membrane and probed with an ARA70 32P-labelled cDNA probe. 
Ethidium bromide-stained 18 S and 28 S rRNA bands from the gel were assessed 
to have equal loading and showed RNA integrity (data not shown). (B) 
Immunofluorescent staining of ARA70 in primary myoblasts. (i) Primary 
myoblasts isolated from hind-limb muscle of 4-week-old mice were cultured and 
immunostained for ARA70. (ii) DAPI staining of myonuclei of the corresponding 
field is shown. (iii) Background immunofluorescence when anti-mouse secondary 
antibody was used in the absence of primary antibody is shown. (iv) DAPI 
staining of negative control. (C) Expression of ARA70 in TA muscle. (i) In situ 
hybridisation of transverse TA muscle sections was performed using a DIG-
labelled ARA70 antisense probe. (ii) Negative control using a DIG-labelled 
ARA70 sense probe. Slides were counterstained with DAPI.   
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3.3.5 ARA70 expression is negatively regulated by myostatin 
SSH results revealed differential expression of ARA70 between wild-type 
and myostatin-null mice. In the absence of myostatin, increased expression of 
ARA70 was observed. To further analyse the effect of myostatin on ARA70, we 
used two independent gene expression analyses. Northern analysis was performed 
on the total RNA from BF muscle of wild-type and myostatin-null mice (Figure 
3.5A). The results indicate that wild-type BF muscle exhibited a lower level of 
ARA70 expression than myostatin-null muscle. Similarly, semi-quantitative RT-
PCR analysis also confirmed that there is increased expression of ARA70 in 
myostatin-null as compared to wild-type BF muscle (Figure 3.5B-C). Thus the 
Northern and semi-quantitative RT-PCR analyses together corroborated the 
original observation in SSH that in BF, in the absence of myostatin, ARA70 
expression was up-regulated. 
3.3.6 Myostatin inhibits the expression of ARA70 in C2C12 cells  
Three independent techniques, SSH, Northern, and semi-quantitative RT-
PCR, of wild-type and myostatin-null mice strongly indicated a down-regulation 
of ARA70 expression in muscle in the presence of myostatin. To further 
investigate this phenomenon we used an in vitro muscle model. C2C12 myoblasts 
were cultured under differentiating conditions for up to 72 hr in the presence or 
absence of exogenous myostatin. Semi-quantitative RT-PCR showed ARA70 
expression was initiated between 12 and 24 hr under differentiating conditions in 
myoblasts that were cultured without the addition of exogenous myostatin (Figure 
3.6A-B). ARA70 expression was maximal after 72 hr under differentiating 
conditions in the control myoblasts. Expression of MyoD protein was also 
measured in control myoblasts and was significantly increased during early 
differentiation, by 12 h, (Figure 3.6C-D) as previously shown (Langley et al., 
2002) and was maximal at 24 hr. These data clearly demonstrate that initiation of 
ARA70 expression was delayed by approximately 12 hr relative to increases in 
MyoD protein. ARA70 expression was not detected by semi-quantitative RT-PCR 
in C2C12 myoblasts cultured under differentiating conditions in the presence of 
exogenous myostatin at any of the time points investigated. These in vitro data 
confirm in vivo tissue results, that myostatin down-regulates expression of ARA70. 
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Figure 3.5 ARA70 mRNA expression is increased in myostatin-null muscle 
(A) Northern analysis of ARA70 in wild-type (WT) and myostatin-null (KO) mice. 
Total RNA (15 µg) extracted from BF muscle was fractionated by gel 
electrophoresis and transferred to Hybond N+ membrane and probed with an 
ARA70 32P-labelled cDNA probe. Ethidium bromide-stained 18 S and 28 S rRNA 
bands from the gel were assessed to have equal loading and showed RNA 
integrity (data not shown). (B) Semi-quantitative RT-PCR analysis of ARA70 
from BF muscles from WT and KO mice. Primers specific for full length ARA70 
amplify the expected 1878 bp product in a sequential RT then PCR amplification. 
Amplicons were then transferred to nitrocellulose membrane and probed with an 
ARA70 32P-labelled cDNA probe. (C) Autoradiogram of the Southern blot shown 
in panel B was analysed by densitometry and normalised to GAPDH.   
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Figure 3.6 Myostatin down-regulates ARA70 in differentiating C2C12s  
(A) Semi-quantitative RT-PCR analysis of ARA70 derived from myoblasts 
cultured in differentiating medium with (+) or without (-) exogenous myostatin 
for 0, 12, 24, 48 or 72 hr. Primers specific for full length ARA70 amplify the 
expected 1878 bp product in a sequential RT then PCR amplification. Amplicons 
were then transferred to nitrocellulose membrane and probed with an ARA70 32P-
labelled cDNA probe. Amplicons were not detected in the absence of template 
(negative control). (B) Autoradiogram of the Southern blot shown in panel A was 
analysed by densitometry and normalised to GAPDH. (C) Western blot analysis of 
MyoD. Total protein (15 µg) derived from myoblasts cultured in differentiating 
medium without exogenous myostatin for 0, 12, 24 or 72 hr were resolved by 4-
12% SDS-PAGE, transferred to nitrocellulose membrane, and probed with 
polyclonal rabbit anti-MyoD, goat anti-rabbit IgG HRP and detected using 
chemiluminescence. (D) Autoradiogram of the Western blot shown in panel C 
was analysed by densitometry.    
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3.4 Discussion 
Myostatin is a potent negative regulator of myogenesis and it was recently 
demonstrated that myostatin functions by regulating both the proliferation and 
differentiation steps of myogenesis by different mechanisms. Myostatin has been 
shown to regulate myoblast cell cycle progression through Retinoblastoma-
dependent (Thomas et al., 2000) and independent (Langley et al., 2004) 
mechanisms. However, during differentiation, myostatin has been shown to 
function by regulating the activity and expression of MyoD (Langley et al., 2002). 
To further analyse the molecular mechanism by which myostatin functions, we 
performed a molecular genetic screen and describe here that myostatin could 
potentially regulate muscle growth by controlling the expression of a steroid 
receptor coactivator, ARA70. 
To isolate downstream target genes of myostatin, we performed SSH on 
total RNA from 4- to 6-week-old wild-type and myostatin-null mice, by which 
stage we observe generalised heavy muscling in the myostatin-null mice. We have 
recovered several novel, as well as some known, genes in this subtraction; 
however, here we chose to characterise ARA70 as a downstream target gene of 
myostatin. Sequence analysis revealed that in addition to the expected canonical 
ARA70, there is an internally deleted variant (Figure 3.2). When compared to the 
canonical isoform, the β-form displays 6 amino acid substitutions and a 9 amino 
acid deletion in the carboxyl-region of the peptide. At this stage it is not known if 
both proteins are encoded by two non-allelic genes with different expression 
patterns or if these differences are due to RNA processing. The homology search 
revealed that murine ARA70 is highly homologous to human ARA70. We tested 
the ability of the murine ARA70 α-isoform to interact with ARLBD in the yeast 
two-hybrid system. The result indicated that full length α-isoform of ARA70 did 
not interact with the ARLBD (Figure 3.3). This result is consistent with the 
previous observation that the interaction between the full length human AR and 
human ARA70 is ligand-dependent in yeast (Yeh and Chang 1996). Thus the lack 
of interaction seen here between full length ARA70 and ARLBD could be due to 
lack of availability of the ligand or may also be due to incorrect folding of murine 
ARA70 in yeast. Mapping experiments with human ARA70 have clearly 
indicated that the carboxyl-terminal region of ARA70 has an inhibitory effect on 
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ARA70 binding to AR in yeast (Zhou et al., 2002). Thus we conducted further 
yeast two-hybrid studies with ARA70 in which the carboxyl-terminal portion was 
deleted. The results indicated that the truncated ARA70 did specifically interact 
with ARLBD (Figure 3.3), confirming that the murine ARA70 behaves much like 
human ARA70 with respect to its interactions with AR.   
The expression analysis indicates that ARA70 is expressed ubiquitously 
(Figure 3.4A). Since ARA70 is highly expressed in muscle, we further monitored 
the expression of ARA70 in myoblasts during myogenic differentiation of C2C12 
myoblasts (Figure 3.6). The peak expression of ARA70 was detected much later 
during differentiation (72 hr), subsequent to peak expression of MyoD (24 hr). 
This result suggests that ARA70 could be involved in regulating the late 
differentiation events of myogenesis, such as increased protein synthesis, in 
combination with AR.   
The major finding of this study is the identification of ARA70 as a 
downstream target gene of the potent negative regulator of muscle growth, 
myostatin. Several independent lines of evidence suggest ARA70 expression is 
negatively regulated by myostatin; reverse Northerns, Northern blot analysis and 
semi-quantitative RT-PCR analysis using RNA from wild-type and myostatin-null 
mice indicate that in the absence of myostatin there are increased levels of 
expression of ARA70. In corroboration of these data, when myoblasts were treated 
with exogenous myostatin there was reduced expression of ARA70, confirming 
that the ARA70 gene is either directly or indirectly repressed by myostatin. What 
might be the physiological consequences of myostatin regulating the ARA70 gene 
expression? Studies have shown that both AR (Inoue et al., 1993; Inoue et al., 
1994) and testosterone (Ferrando et al., 1998) induce skeletal muscle hypertrophy 
by inducing protein synthesis. In contrast, lack of myostatin also leads to 
generalised hypertrophy of muscles. Since increased levels of ARA70 are 
observed in the myostatin-null muscles, it is quite possible that the up-regulated 
ARA70 protein could increase the activity of AR, therefore leading to increased 
protein synthesis.   
Thus, we propose that the hypertrophy seen in animals that lack myostatin 
could not only be due to increased satellite cell activation (McCroskery et al., 
2003) but also a result of increased protein synthesis due to enhanced AR activity 
owing to increased expression of ARA70. Currently efforts are underway to 
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generate an ARA70 over-expressing transgenic mice line to assess the hypertrophy 
phenotype since transient over-expression of ARA70 in C2C12 cells has failed to 
induce hypertrophy in the myoblasts. 
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Chapter Four 
Prolonged absence of myostatin reduces sarcopenia 
 
This work has been published in the Journal of Cellular Physiology, Volume 209, 
p866-873 (2006). A PDF of the paper has been copied to the CD attached to the 
back cover of this thesis. 
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4.1 Introduction 
Myostatin, a TGF-β superfamily member, is a negative regulator of muscle 
growth (McPherron et al., 1997). It is expressed in both embryonic and adult 
skeletal muscle, suggesting that myostatin acts as a regulator of both prenatal and 
postnatal myogenesis. Myostatin-null mice are significantly larger than their wild-
type counterparts due to a two- to three-fold increase in muscle mass resulting 
from both muscle cell hyperplasia and hypertrophy (McPherron et al., 1997). 
Studies indicate myostatin regulates cell cycle progression and MRF levels, 
thereby controlling myoblast proliferation and differentiation during 
developmental myogenesis (Thomas et al., 2000; Langley et al., 2002). In 
addition, myostatin also influences postnatal muscle growth. Recently it was 
shown that myostatin regulates myogenesis through the inhibition of satellite cell 
activation in mice (McCroskery et al., 2003). Furthermore, myostatin levels 
increased with muscle atrophy due to unloading in mice (Carlson et al., 1999), 
and with severe muscle wasting in HIV patients (Gonzalez-Cadavid et al., 1998). 
Cachexia, induced by systemic administration of myostatin, has also been shown 
to cause muscle wasting in mice, suggesting that myostatin may be directly 
involved in cachetic-type conditions in humans (Zimmers et al., 2002). Together, 
these studies suggest that increased levels of myostatin lead to muscle wasting. 
Possible mechanisms of wasting through myostatin include the inhibition of 
satellite cell activation and proliferation, and inhibition of differentiation or 
myoblast fusion.  
Studies measuring myostatin levels during aging (Kawada et al., 2001; 
Baumann et al., 2003) have yielded conflicting results regarding the role of 
myostatin in age-related muscle wastage, or sarcopenia. Sarcopenia is the 
profound loss of skeletal muscle mass and strength (Brooks and Faulkner 1994) 
associated with normal aging in mammals. This atrophy has previously been 
attributed to various factors including a decrease in muscle fibre number, an 
alteration in the fibre type, atrophy of existing fibres (Alnaqeeb and Goldspink 
1987), loss of motor innervation (Carry et al., 1993), and defective muscle 
regeneration (Grounds 1998) which involves muscle satellite cells (Schultz and 
Jaryszak 1985; Schultz and McCormick 1994). Aged muscle appears restricted in 
its ability to promote satellite cell activation, proliferation and differentiation, 
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therefore impairing its ability to regenerate (Welle 2002). It has been suggested 
that this reduced satellite cell activation is a function of the environment of aged 
muscle (Carlson and Faulkner 1989). Furthermore, using parabiotic pairing 
experiments, Conboy et al. (2005) recently showed that systemic factors from 
young mice promote the proliferation and regenerative capacity of satellite cells in 
aged mice. In addition, we believe that negative regulators, such as myostatin, are 
essential in the regulation of satellite cell-mediated muscle regeneration. 
Therefore, to observe the effects of prolonged absence of myostatin and muscle 
wasting during the aging process we compared young and old wild-type and 
myostatin-null muscle and its regeneration. 
Here we show that, irrespective of age, a lack of functional myostatin 
resulted in muscle fibre hyperplasia and hypertrophy, and alterations in the fibre 
types. Myostatin-null muscle fibres had an increased number of associated 
satellite cells which demonstrated a greater propensity to undergo activation. In 
addition, muscle regeneration following notexin damage was accelerated in 
myostatin-null mice.  
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4.2 Materials and Methods 
4.2.1 Animals 
Myostatin-null mice (C57BL/10 background) were obtained from Se-Jin 
Lee (Johns Hopkins University, Baltimore, MD). Wild-type C57BL/10 mice were 
bred at the Ruakura Small Animal Colony. All animals were handled in 
accordance with the guidelines of the Ruakura Animal Ethics Committee 
(AgResearch, Hamilton, New Zealand) and the University of Waikato Animal 
Ethics Committee (University of Waikato, Hamilton, New Zealand).  
4.2.2 Tissue processing 
Mice were euthanized by CO2 inhalation followed by cervical dislocation. 
TA and BF muscles were dissected out and frozen in isopentane cooled in liquid 
nitrogen. Frozen 10 µm transverse sections were cut from the mid-belly region of 
the muscles and used for histochemical analysis. For total fibre number, muscle 
sections were stained with H & E while for fibre type analysis, muscle sections 
were either immunostained using monoclonal antibodies specific for MHC types 
or stained for mATPase activity using a modified method of Brooke and Kaiser 
(1970). For immunostaining, muscle sections were blocked in 0.2% TritonX-100, 
0.2% BSA and 10% NSS in PBS for 1 hr at room temperature followed by an 
overnight incubation at 4˚C with antibodies against type I (BA-D5, 1:100), type 
IIA (SC-71, 1:50) or type IIB (BF-F3, 1:100) MHC (Schiaffino et al., 1989) 
(American Type Culture Collection) in 0.2% BSA and 5% NSS in PBS-T. The 
sections were then washed with PBS and fixed in 10% buffered formalin for 5 
min before incubating with a biotinylated sheep anti-mouse immunoglobulin 
secondary antibody (1:300, Amersham) in 0.2% BSA and 5% NSS in PBS-T for 1 
hr at room temperature. The sections were then washed and incubated with 
streptavidin-conjugated Alexa Fluor 488 (1:400, Molecular Probes) in 0.2% BSA 
in PBS-T for 1 hr. After washing, the sections were counterstained with DAPI at 
1:1,000 (Molecular Probes) in PBS before mounting with fluorescent mounting 
medium (Dako) and viewing under fluorescent illumination using an Olympus 
BX50 microscope (Olympus) and SPOT RT camera and software (Diagnostic 
Instruments). 
 158
For mATPase staining, sections were incubated in an acid pre-incubation 
medium (pH 4.6) (95 mM CH3COONa, 99 mM KCl) followed by an ATP 
incubation medium (pH 9.4) (2.8 mM ATP, 47.5 mM NaOH, 65 mM NaCl, 52.75 
mM glycine, 37.8 mM CaCl2). Fibre types were distinguished by the intensity of 
staining (type I > type IIX > type IIB > type IIA).  
4.2.3 In vivo BrdU-labelling of satellite cells  
Satellite cell proliferation was investigated by in vivo BrdU-labelling. 
Wild-type and myostatin-null mice were intraperitoneally injected with BrdU (30 
mg/kg; Roche) as a single pulse 2 hr before euthanizing. Satellite cells were 
isolated following an adapted protocol of Yablonka-Reuveni and Nameroff 
(1987). Briefy, 1- and 6-month-old wild-type and myostatin-null mice (n = 10 per 
group) were killed by CO2 gas followed by cervical dislocation. Hind-limb 
muscles were dissected out, minced and digested in 0.2% (w/v) type 1A 
collagenase (>260 CDU/mg) in DMEM for 90 min at 37ºC. The muscle slurry 
was triturated then passed through a 70 µm cell strainer (BD Biosciences) before 
loading onto 70% and 40% Percoll gradients (Sigma) and centrifuged at 2,000 x g 
for 20 min at 25ºC. The interface between the two gradient solutions was 
recovered and cells were resuspended in PBS. In order to detect BrdU-
incorporation, an In Situ Cell Proliferation Kit, FLUOS (Roche) was used. Cells 
were fixed for 30 min in 70% ethanol on ice and treated with 2N HCL and 0.5 % 
TritonX-100 for 30 min at room temperature before neutralising in 0.1 M 
disodium tetraborate buffer (pH 8.5). Cells were permeablised in 0.5% Tween-20 
in PBS and incubated for 45 min at 37ºC with a monoclonal anti-BrdU-FLUOS 
antibody (1:25, Roche) in incubation buffer (Roche). Cells were analysed by a 
FACScan (BD Biosciences) flow cytometer. The Percoll isolated cells purified by 
this method were >95% myogenic (McCroskery et al., 2003). 
4.2.4 Single myofibre isolation and culture 
Single fibres were isolated as previously described by Rosenblatt et al. 
(1995). Briefly, 1- and 24-month-old wild-type and myostatin-null mice were 
euthanized by CO2 gas followed by cervical dislocation. TA muscles were 
dissected out and digested in 0.2% (w/v) type 1A collagenase (>260 CDU/mg) in 
DMEM for 60 min at 37ºC. Muscles were transferred to DMEM containing 10% 
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HS and 0.5% CEE and fibres were separated by gentle trituration. Isolated fibres 
were transferred to 4-well chamber slides (BD Biosciences) coated with 10% 
Matrigel (BD Biosciences) and either fixed immediately after isolation at 37ºC for 
10 min in 4% paraformaldehyde in PBS (for the detection of CD34) or cultured in 
DMEM containing 10% HS, 0.5% CEE and 10 µM BrdU (Roche) for 48 hr at 
37ºC in 5% CO2 (for the detection of BrdU-incorporation). 
Satellite cells were detected with CD34 antibodies according to an adapted 
method of Beauchamp et al. (2000). Briefly, fibres were fixed with 4% 
paraformaldehyde, washed in PBS, permeablised in 0.5% TritonX-100 in PBS for 
10 min and blocked in 10% NGS in PBS for 30 min at room temperature. Rat 
anti-mouse CD34 monoclonal antibody (clone RAM34; BD PharMingen) at 1:100 
in 0.35% cλ in PBS was incubated overnight. Primary antibody was detected 
using biotinylated goat anti-rat IgG polyclonal antibody (Amersham) at 1:300 in 
0.35% cλ in PBS for 2 hr at room temperature followed by streptavidin-
conjugated Alexa Fluor 488 (Molecular Probes) at 1:400 in 0.35% cλ in PBS for 1 
hr at room temperature. Fibres were counterstained with DAPI (Molecular 
Probes) at 1:1,000 in PBS for 5 min before mounting.  
To detect BrdU-incorporated cells, the BrdU labeling and detection kit 
(Roche) protocol was followed. Fibres were counterstained with DAPI (Molecular 
Probes) at 1:1,000 in PBS for 5 min before mounting.  
CD34- or BrdU-positive nuclei were counted as a percentage of total 
myonuclei in order to normalise the data and exclude any discrepancies in the 
lengths of the fibres analysed. 
4.2.5 Muscle regeneration following notexin injury 
Twenty four-month-old male mice were anaesthetised with 
Ketamine/Rompun (10% ketamine hydrochloride at 100 mg/ml, 5% Rompun 2% 
at 20 mg/ml) at 0.1 ml/7 g body weight. A small incision over the right TA muscle 
was made before 10 µl of Notexin (10 µg/ml) was injected into the muscle. The 
incision was then closed using a Michelle clip. Mice were euthanized on days 1, 
7, 10 or 28 following the notexin administration. Both right and left (regenerating 
and control respectively) TA muscles were removed, weighed, and then frozen in 
isopentane cooled in liquid nitrogen. Frozen 10 µm transverse sections were cut 
from the mid-belly region of the TA and stained with H & E or immunostained 
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using monoclonal antibodies specific for type I, IIA and IIB MHCs as described 
previously.  
4.2.6 Statistical analysis 
All data are presented as means and SEM. Angular transformed data 
(percentages of type IIA fibres and BrdU-positive cells) and untransformed data 
(fibre numbers and areas and percentages of CD34-positive cells) were analysed 
by analysis of variance (ANOVA) to assess the effects of age and the myostatin-
null genotype. The pooled residual standard deviation from these analyses was 
used to assess particular comparisons of interest, the wild-type versus myostatin-
null difference at each age and changes between ages. 
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4.3 Results 
4.3.1 Lack of myostatin alters fibre morphology 
In order to assess the effect of myostatin and aging on muscle, three 
different parameters of muscle fibre physiology (fibre number, fibre type and fibre 
size) were determined in young and aged wild-type and myostatin-null muscle.   
Aging muscle generally undergoes varying degrees of muscle fibre 
atrophy. Hence, the extent of muscle atrophy was assessed by measuring cross-
sectional areas of various fibre types of 6- and 24-month-old wild-type and 
myostatin-null TA muscle. The TA muscle was chosen because a number of 
previous studies concerning age-related muscle wasting suggest that TA muscle is 
consistently affected by aging (Rowe 1969; Hooper 1981; Alnaqeeb and 
Goldspink 1987; Marsh et al., 1997a). Furthermore, lack of myostatin is known to 
affect the physiology of TA muscle (McPherron and Lee 2002). Histochemical 
staining of type I, IIA, B and X fibres in TA and BF muscles, indicated that 
typically, type IIB was the largest fibre type, type IIX being an intermediate, 
while type IIA and type I were generally the smallest fibres (Figure 4.1A). 
Analysis of 6- and 24-month-old wild-type TA type IIB/X cross-sectional areas 
clearly suggested a significant decrease in the fibre areas due to atrophy resulting 
from increasing age (Figure 4.1B) (P < 0.001). In contrast, measurements of 
myostatin-null type IIB/X fibres indicated significant fibre hypertrophy in both 6- 
and 24-month-old TA muscle suggesting the hypertrophy observed was not only 
maintained in the aged muscle, but also little fibre atrophy had occurred during 
the aging process (Figure 4.1B). 
During aging, murine muscle undergoes a switch in fibre type from fast 
glycolytic to fast oxidative fibre type. To investigate fibre type changes, 
immunostaining using antibodies against type I, IIA, and IIB MHCs were 
performed. Our results indicate that between 6- and 24-months, an increase of 
over 54% in type IIA fibres occurred in the wild-type TA muscle (Figure 4.1C) (P 
< 0.05). In contrast, myostatin-null TA indicated no significant increase in type 
IIA fibres with age. Moreover, type IIA fibres were minimally represented in 1-, 
6- and 24-month-old myostatin-null TA in comparison to wild-type muscle. For 
example, at 24-months of age, type IIA fibres occupied close to 9% of the wild-
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type TA, while just over 1% in myostatin-null TA (Figure 4.1C) (P < 0.001). 
Although a previous report suggested a very low number of type I fibres in mouse 
TA (Wang and Kernell 2001), we found no fibres of this type in any of the TA 
muscles tested. However type I fibres were found to be abundant in BF muscles, 
and therefore provided a positive control for both immuno- and histochemical 
staining procedures.  
Fibre number was also measured during aging in both genotypes. One-
month-old myostatin-null TA displayed a high degree of hyperplasia with a 57% 
increase in total fibre number compared to 1-month-old wild-type TA (Figure 
4.1D) (P < 0.001). Six-month-old myostatin-null TA muscle contained fewer 
fibres than 1-month-old myostatin-null muscle but 40% more fibres than 6-month-
old wild-type muscle (P < 0.001). Within genotypes, no statistically significant 
change in fibre number was observed between 6- and 24-months of age.  
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Figure 4.1 Long term absence of myostatin alters muscle fibre morphology  
(A) Example of mATPase stained BF muscle cross-section. Fibre types were 
determined by staining intensity, type I > type IIX > type IIB > type IIA (from 
darkest to lightest). Scale bar, 20µm. (B) Averages of type IIB/X fibre areas in TA 
cross-sections from 6- and 24-month-old wild-type (WT) (empty bars) and 
myostatin-null (KO) (solid bars) muscle (n = 5 per group). ** = P < 0.001 when 
WT is compared to KO and when WT 6m is compared to WT 24m. (C) Percent of 
type IIA fibres in TA cross-sections from 1-, 6- and 24-month WT and KO mice 
(n = 5 per group). ** = P < 0.001 when WT groups are compared to KO groups, * 
= P < 0.05 when WT 1m and WT 6m is compared to WT 24m. (D) Number of 
fibres in TA cross-sections from 1-, 6-, and 24-month-old WT and KO muscles (n 
= 5 per group). ** = P < 0.01 when WT is compared to KO, and when KO 1m is 
compared to KO 6m. All data are expressed as mean ± SEM.  
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4.3.2 Myostatin decreases satellite cell number and activation  
Satellite cell numbers and or their activation are believed to be adversely 
affected by progressive aging leading to a reduction in regeneration capabilities 
(Carlson and Faulkner 1989; Bockhold et al., 1998; Conboy and Rando 2002). 
Myostatin is expressed in satellite cells and lack of myostatin in young mice leads 
to a greater number of satellite cells per unit fibre length as well as an increase in 
their propensity to become activated during in vitro studies (McCroskery et al., 
2003). To elucidate the effects of myostatin and aging on satellite cell behaviour, 
the total number of satellite cells and their ability to become activated was 
quantified from 1- and 24-month-old wild-type and myostatin-null mice.  
In order to analyse satellite cell numbers per unit fibre length, satellite 
cells attached to single fibres isolated from 1- and 24-month-old wild-type and 
myostatin-null TA muscle were counted using the cell surface marker CD34. The 
mean percentage of fibre nuclei that were satellite cells in 1-month-old wild-type 
fibres was 5% compared to 11% in 1-month-old myostatin-null fibres (Figure 
4.2A) (P < 0.001). Aging appeared to have little effect on satellite cell number as 
no significant change in the satellite cell number was observed between 1- and 24-
month-old wild-type and myostatin-null fibres.  
Since not only the number of satellite cells but also the activity of satellite 
cells is relevant to the ability of a muscle to regenerate, satellite cell activation 
was investigated using in vitro and in vivo BrdU-labelling. In vitro BrdU-labelled 
satellite cells attached to isolated fibres indicated the average percentage of 
activated satellite cells per fibre in 1-month-old wild-type TA was 6.5% as 
opposed to 10% in 1-month-old myostatin-null TA muscle (Figure 4.3A) (P < 
0.001). However, during aging, satellite cell activation was reduced in both the 
wild-type and myostatin-null 24-month-old mice (P < 0.001). It is noteworthy that 
at 24-months, there was still twice the number of activated satellite cells per fibre 
in myostatin-null muscle fibres as compared to wild-type fibres (P < 0.05). As an 
independent measure, the number of fibres with one or more activated satellite 
cell attached was also counted. On average, 80 to 90% of 1-month-old wild-type 
and myostatin-null fibres in explant cultures contained activated satellite cells 
(Figure 4.3B). In contrast, only 16% of 24-month-old wild-type fibres and 31% of 
myostatin-null contained BrdU-positive nuclei (P < 0.001).   
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Finally, the propensity of satellite cells to become activated was also 
measured using in vivo BrdU-incorporation. FACS analysis of BrdU-labelled 
satellite cells indicated similar trends to the in vitro labelled satellite cells. The 
percentage of activated satellite cells from 1-month-old wild-type muscle was 
8.5% as opposed to 14.8% in 1-month-old myostatin-null muscle (Figure 4.3D) (P 
< 0.001). With increasing age the percentage of activated satellite cells in both 
wild-type and myostatin-null 6-month-old muscle dropped significantly to 2% and 
5% respectively (P < 0.001).    
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Figure 4.2 Satellite cell number is increased in myostatin-null mice 
(A) Percent of satellite cells per 100 myonuclei on fibres isolated from 1- and 24-
month-old wild-type (WT) and myostatin-null (KO) TA muscle. Satellite cells 
were visualised by immunostaining for CD34 and total nuclei by DAPI 
counterstaining. Fibres were isolated from 3 animals per group and in excess of 
1,000 nuclei per group were counted. ** = P < 0.001 when WT is compared to 
KO. Data are expressed as mean ± SEM. (B) Example of a CD34-positive satellite 
cell attached to an isolated muscle fibre. Scale bar, 20 µm.  
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Figure 4.3 Increased cell activation is retained in the myostatin-null fibres 
(A) Percent of activated satellite cells per 100 myonuclei on fibres isolated from 
1- (empty bars) and 24- (solid bars) month-old wild-type (WT) and myostatin-null 
(KO) TA muscle. Activated satellite cells were represented by in vitro BrdU-
incorporation and total nuclei by DAPI counterstaining. Fibres were isolated from 
3 animals per group and over 1,000 nuclei per group were counted. ** = P < 0.001 
when WT 1m is compared to KO 1m or WT 24m and when KO 1m is compared 
to KO 24m, * = P < 0.01 when WT 24m is compared to KO 24m. (B) Percent of 
fibres with activated satellite cells attached. Fibres were isolated from 1- and 24-
month-old WT and KO TA muscle and in excess of 100 fibres per group were 
assessed. ** = P < 0.001 when WT 1m is compared to WT 24m, when KO 1m is 
compared to KO 24m, and when WT 24m is compared to KO 24m. (C) Example 
of a BrdU-labelled satellite cell attached to an isolated TA fibre (i). The fibre was 
counterstained with DAPI to visualise all myonuclei (ii). Scale bar, 20 µm. (D) 
Percent of BrdU-positive cells determined through flow cytometry. Satellite cells 
were BrdU-labelled in vivo and isolated from 1- and 6-month-old WT and KO 
hind-limb muscle using Percoll gradients. A minimum of 10,000 cells per sample 
group were analysed in triplicate. ** = P < 0.001 when WT 1m is compared to 
WT 6m or KO 1m and when KO 1m is compared to KO 6m, * = P < 0.05 when 
WT 6m is compared to KO 6m. All data are expressed as mean ± SEM.  
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4.3.3 Lack of myostatin enhances muscle regeneration  
Notexin, a potent myotoxin, causes muscle necrosis, which induces 
regeneration. Compared to young muscle, aged muscle has a reduced capacity to 
regenerate. Recent work from our laboratory has shown that young myostatin-null 
mice have a greater capacity to regenerate than their wild-type counterparts 
(McCroskery et al., 2005). It is unknown however, whether aged myostatin-null 
mice retain this greater ability to regenerate. Therefore, muscle regeneration in 24-
month-old wild-type and myostatin-null mice were compared. 
Histochemically stained day-1 wild-type and myostatin-null TA muscle 
sections displayed substantially damaged muscles indicated by necrotic fibres 
interspersed with surviving fibres. At this stage, an increased number of 
infiltrating cells were observed in myostatin-null TA compared to wild-type TA. 
In contrast, by day 7, greater amounts of infiltrating cells were present in wild-
type TA relative to the myostatin-null muscle. However, unlike the wild-type 
muscle, the myostatin-null TA contained a large number of nascent myotubes and 
centrally located nuclei, indicating earlier regeneration than in the wild-type 
muscle. These nascent myotubes and centrally located nuclei were not largely 
observed until day 10 in the wild-type muscle (Figure 4.4Ai). By day 10, 
remaining non-regenerated areas were larger and the nascent myotubes within 
these areas were less advanced in wild-type TA relative to myostatin-null TA 
(Figure 4.4Ai-ii). At days 7 and 10, a greater number of original fibres appeared 
to survive the notexin damage in myostatin-null TA as compared to the wild-type 
muscle. In both wild-type and myostatin-null muscles, smaller fibres within less 
extensively damaged areas had centrally located nuclei at days 7 and 10 whereas 
larger fibres did not. Assessment of fibre areas indicated original and nascent 
myotubes were substantially larger in myostatin-null TA compared to those 
observed in wild-type TA. Early collagen formation was observed by day 7 in 
wild-type TA and remained high in day-10 and -28 muscles (Figure 4.4Ai, iii). In 
contrast, little collagen was observed in myostatin-null TA at each time point 
(Figure 4.4Aii, iv). By day 28, wild-type and myostatin-null TA appeared largely 
regenerated (Figure 4.4Aiii-iv). Immunohistochemical analysis of wild-type day-
28 TA indicated a significant increase of type IIA fibres in regenerated TA 
(148%) compared to non-injured TA (Figure 4.4B) (P < 0.001). In contrast, a 
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slight (statistically insignificant) increase was observed between day-28 
regenerated and non-injured myostatin-null muscles. In addition, a low percentage 
of type I fibres (0.15%; P < 0.05, data not shown) were detected in day-28 
regenerated wild-type muscle. No type I fibres were observed in the myostatin-
null muscle.  
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Figure 4.4 Muscle regeneration is enhanced in the myostatin-null muscle  
(A) H & E stained cross-sections of day-10 wild-type (i) and myostatin-null (ii), 
and day-28 wild-type (iii) and myostatin-null (iv) TA muscles following notexin 
administration. Scale bar, 50 µm. (B) Percentage increase of type IIA fibres in 
muscle cross-sections from day-28 wild-type (WT) and myostatin-null (KO) 
notexin injured TA muscles (n = 3 per group). Data are expressed as mean ± 
SEM. ** = P < 0.001.  
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4.4 Discussion 
One of the most striking effects of aging in muscle is the associated loss in 
muscle mass resulting in loss of strength and endurance. Furthermore, aging 
muscle has a marked reduction in its regenerative capabilities after muscle 
damage. It has been difficult to establish a primary cause and to formulate a 
unified theory explaining the molecular basis behind the aging muscle phenotype. 
Although the roles of several positive regulators have been extensively studied 
(Mezzogiorno et al., 1993; Allen et al., 1995; Marsh et al., 1997b; Barton-Davis 
et al., 1998; Yablonka-Reuveni et al., 1999), the role of negative regulators during 
age-related muscle wasting is not known. In the current study we explored the 
involvement of myostatin, a known negative regulator of muscle growth, during 
the aging process.  
Well established effects of aging on muscle are atrophy of the muscle and 
its individual fibres, a shift towards oxidative fibres, and impairment of satellite 
cell activation and subsequent muscle regeneration. In this current study, we show 
that the prolonged absence of myostatin in mice reduces fibre atrophy associated 
with aging (Figure 4.1B).  
Currently, satellite cells are believed to be largely responsible for muscle 
growth and maintenance throughout life (see Hawke and Garry (2001) for 
review). Previously it has been suggested that satellite cell numbers decline during 
aging (Gibson and Schultz 1983; Shefer et al., 2006) while others report no 
change (Nnodim 2000; Conboy et al., 2003). Here we report that satellite cell 
activation rather than number is adversely affected during the aging process. 
We have previously shown in young mice that myostatin is involved in the 
maintenance of satellite cell quiescence (McCroskery et al., 2003) and that a lack 
of myostatin results in increased activation of satellite cells. Myostatin acts by 
inhibiting cell cycle progression from G0 to S phase. In its absence, cell cycle 
progression can proceed resulting in an increase in satellite cell activation and 
proliferation as observed in the myostatin-null mice. This increased cell number 
and activation would provide a mechanism for greater myoblast recruitment and 
subsequent fibre formation and enlargement leading to the fibre hypertrophy 
observed in the young myostatin-null mice. We now show that the prolonged 
absence of myostatin maintains the increased satellite cell number and activation 
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even in aged muscle (Figure 4.2A, 4.3A). The increased cell number and 
activation would provide an essential resource during aging, when a significant 
pressure on the maintenance of the fibres would be present in response to the 
aging process. Therefore we propose that lack of myostatin, from prenatal through 
to old age, leads to increased self-renewal of satellite cells and efficient 
replacement of lost muscle fibres, leading to increased muscle growth and reduced 
muscle wasting. However, at this time, it is not known whether a prolonged lack 
of myostatin provides increased resistance to the loss of muscle mass also. 
With aging, murine muscle undergoes specific fibre type switches, with 
functional and metabolic consequences. Specifically, numerous reports suggest a 
shift from glycolytic fibres to oxidative fibres with increasing age (Grimby et al., 
1982; Alnaqeeb and Goldspink 1987; Larsson et al., 1993). Myostatin also 
influences fibre type composition, as an increase in type II fibres, possibly at the 
expense of type I, can be observed in myostatin-null muscle (Holmes and 
Ashmore 1972; Girgenrath et al., 2005). This in itself would lead to muscle 
hypertrophy due to the larger size of the type II fibres. In agreement with previous 
findings of Alnaqueeb and Goldspink (1987) and Larsson et al. (1993), the 
number of type IIA fibres in this current study increased with age within the wild-
type muscle (Figure 4.1C). Assessment of the total fibre number indicated that 
they remained constant between 6- and 24-month-old muscles. Similar studies are 
somewhat conflicting as to whether a loss of fibres occurs during aging in rodents 
(Hooper 1981; Alnaqeeb and Goldspink 1987; Brown 1987; Timson and 
Dudenhoeffer 1990) and it has been suggested that the occurrence of fibre 
splitting complicates the analysis of fibre number (Alnaqeeb and Goldspink 
1987). However, as the fibre number did not change with aging, it was concluded 
that the observed increase in type IIA fibres was at the expense of either type IIB 
or X fibres through fibre type shifts in the wild-type muscle. In contrast, all 
myostatin-null muscles displayed minimal type IIA fibres. This indicates an 
alteration in the fibre type composition with the loss of myostatin, as well as a 
resistance to an increase of type IIA fibres, which was associated with aging in the 
wild-type mice (Figure 4.1C). The role played by myostatin in the determination 
of fibre types is still unclear, although Girgenrath et al. (2005) have suggested that 
myostatin may influence the fibre type during prenatal myogenesis and postnatal 
terminal differentiation, therefore playing a role in the determination of the adult 
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fibre type. One mechanism Girgenrath et al. (2005) proposed is that an absence of 
myostatin inhibits the proliferation or differentiation of primary myoblasts leading 
to a decline in the number of slow fibres, or conversely, increases the proliferation 
or differentiation of secondary myoblasts, resulting in a higher number of fast 
fibres. Regardless of the mechanism, increased type IIB fibres would cause the 
muscle to remain predominantly glycolytic during aging. 
Aging is also thought to negatively influence satellite cell behaviour. 
These cells are heavily involved in the regenerative process after muscle injury. 
Aging has a significant effect on the muscle regenerative capacity, since the 
proliferative potential of satellite cells in skeletal muscles of aged rodents is 
decreased as compared with young adults (Schultz and Lipton 1982). 
Furthermore, some reports also suggest that the poor regenerative capacity of 
skeletal muscle is also due to a decrease in the number of satellite cells (Snow 
1977). Since we observed that lack of myostatin maintains the increased number 
of satellite cells and activation propensity in 24-month-old myostatin-null mice 
compared to 24-month-old wild-type mice (Figure 4.2A, 4.3A), it was questioned 
whether aged myostatin-null muscle would demonstrate an increased propensity 
to regenerate following notexin damage. Overall, findings suggested a lack of 
myostatin did result in a more efficient regeneration, even in the aged mice. 
Nascent fibres formed faster, muscle and fibre hypertrophy and fibre type 
composition were preserved, and the formation of scar tissue was greatly reduced 
(Figure 4.4A). Interestingly, senescent myostatin-null mice were virtually able to 
recapitulate the enhanced regeneration seen in young adult myostatin-null mice. 
This is in agreement with a recent study by Wagner et al. (2005), who have shown 
that regeneration after injury in senescent myostatin-null muscle was more robust 
than the wild-type controls. In common with the prevention of fibre atrophy 
during the aging process, the subsequent muscle regeneration following notexin 
damage would be heavily reliant on satellite cell availability and activation. 
Undoubtedly, an increased number of satellite cells and activation propensity, as 
observed in the myostatin-null mice, would be advantageous during this 
regenerative process.  
Recently, Conboy et al. (2005), using a parabiosis model, have suggested 
that systemic factors contribute to the aging process. Indeed the results presented 
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here clearly supports that, in addition to the positive acting factors, negative 
regulators of myogenesis also play a role in the aging of skeletal muscle. 
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Chapter Five 
Enhanced myogenic potential of myoblasts is maintained in 
aged myostatin-null mice 
 
This study will be communicated as a manuscript to the Journal of Cellular 
Physiology. 
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5.1 Introduction 
The progressive loss of skeletal muscle mass and strength associated with 
aging is referred to as sarcopenia. Sarcopenia can have a profound effect on a 
person’s quality of life due to reduced mobility and independence and increased 
risk of falls (Grimby and Saltin 1983; Harris 1997; Roubenoff and Hughes 2000; 
Roubenoff 2001). A substantial factor related to this loss is a decreased 
regenerative capacity reported to occur in aged muscle (Carlson and Faulkner 
1989; Grounds 1998). Essential to muscle regeneration is the involvement of 
quiescent satellite cells associated with the muscle fibres (Zammit et al., 2002). In 
response to various stimuli, satellite cells become activated, leading to myoblasts 
fusing to existing fibres or the formation of new fibres (Schultz and McCormick 
1994). With increasing age, the activation potential of satellite cells is thought to 
decrease, thus contributing to the impaired muscle regeneration (Schultz and 
Lipton 1982; Conboy et al., 2005). It has been suggested that this reduced satellite 
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cell activation is a function of the environment of aged muscle (Carlson and 
Faulkner 1989; Conboy et al., 2005) indicating that various factors within the 
environment may positively or negatively regulate myogenesis and muscle 
regeneration.  
A potent inhibitor of muscle growth is myostatin, a TGF-β superfamily 
member (McPherron et al., 1997). Postnatally, myostatin has been shown to be 
expressed in adult skeletal muscle (McPherron et al., 1997) and satellite cells 
(McCroskery et al., 2003). In addition, myostatin is known to inhibit myoblast 
proliferation and differentiation (Thomas et al., 2000; Taylor et al., 2001), as well 
as inhibit satellite cell activation, thus maintaining the quiescent status of satellite 
cells (McCroskery et al., 2003). Increased myostatin protein levels have 
frequently been correlated to the loss of muscle associated with aging (Schulte 
and Yarasheski 2001; Yarasheski et al., 2002; Baumann et al., 2003) suggesting 
myostatin has a significant role in the reduced muscle regeneration observed 
during sarcopenia. In accordance with these findings, recently we (Chapter 4), and 
others, have shown that a prolonged absence of myostatin reduced sarcopenia in 
mice (Wagner et al., 2005).  
In addition, myostatin also influences adipogenesis as animals lacking 
functional myostatin have significantly reduced fat accumulation (Arthur 1995; 
Lin et al., 2002; McPherron and Lee 2002; Short et al., 2002; Wiener et al., 
2002). Generally in animals, fat accumulates with increasing age until old age 
when a decline occurs. The accumulation of adipose tissue is through the 
formation of new adipocytes from precursor cells, which occurs throughout life 
(Bertrand et al., 1978; Miller et al., 1984), and adipocyte hypertrophy. 
Although the role of myostatin in aging has been researched, to date the 
biology of myostatin-null myoblasts derived from aged satellite cells has not been 
investigated. Here we describe how a prolonged absence of functional myostatin 
affects the aging process in regards to the myogenic nature of satellite cells as 
well as adipose tissue. We found that the muscle hypertrophy, increased myoblast 
proliferation and differentiation, and decreased fat accumulation observed in 
young myostatin-null mice, was retained in aged myostatin-null mice.   
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5.2 Materials and Methods 
5.2.1 Animals and tissue processing 
Myostatin-null mice (C57BL/10 background) were obtained from S.-J. Lee 
(The Johns Hopkins University, Baltimore, MD). The wild-type mouse strain 
C57BL/10 was bred at the Ruakura Small Animal Colony. All animals were 
handled in accordance with the guidelines of the Ruakura Animal Ethics 
Committee (AgResearch, Hamilton, New Zealand) and the University of Waikato 
Animal Ethics Committee (University of Waikato, Hamilton, New Zealand). Male 
wild-type and myostatin-null mice aged 1-, 6- and 24-months, were killed by CO2 
gas followed by cervical dislocation. Individual muscles: BF; TA; Gas; and the 
Quad muscle group were dissected out and weighed. Gas was then frozen in liquid 
nitrogen for protein isolation. Epididymal fat pads were dissected and weighed 
before fixing in formalin and embedding in paraffin. Ten micrometer sections of 
each fat pad were cut and stained with H & E.    
5.2.2 Primary myoblast assays  
Satellite cells were isolated from the hind-limb muscles from 1-, 6- and 
24-month-old wild-type and myostatin-null mice according to published protocols 
(Allen et al., 1997; Partridge 1997; Yablonka-Reuveni et al., 1999; McCroskery 
et al., 2005). After 48 hr culturing, the cells were trypsinised off and utilised in a 
proliferation assay as previously described (Oliver et al., 1989; McCroskery et al., 
2003), plated on 8-well chamber slides (BD Biosciences) for ICC analysis 
(described below) or plated on 6-well plates (Nunc) for differentiation assays. 
After a 3 hr attachment period, the culturing media was replaced with DMEM 
with 2% HS. The differentiating myoblast cultures were used for protein isolation 
or stained with H & E for histological analysis after culturing for 0, 6, 12, 24, 48 
or 72 hr.  
5.2.3 ICC analysis 
Actively growing primary myoblasts were fixed with 20 parts 70% 
ethanol/2 parts 37% formaldehyde/1 part glacial acetic acid for 30 s and 
permeablised in 0.1% triton X-100 in PBS for ICC analysis of desmin or MyoD 
and Pax7. For desmin, the myoblasts were blocked with 10% NSS and 0.35% cλ 
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in PBS for 1 hr at room temperature before incubating overnight at 4˚C with 
mouse anti-desmin (1:200; Sigma) in 5% NSS and 0.35% cλ in PBS. Biotinylated 
sheep anti-mouse secondary antibody (1:300; Amersham) and streptavidin-
conjugated Alexa Fluor 488 (1:400; Molecular Probes) were used as secondary 
and tertiary antibodies respectively. For MyoD/Pax7 staining, the myoblasts were 
blocked with 5% NSS, 5% NGS and 0.35% cλ in PBS (blocking solution) for 1 hr 
at room temperature before incubating overnight at 4˚C with rabbit anti-MyoD 
(1:100; Santa Cruz) and mouse anti-Pax7 (1:100; ascites fluid obtained from the 
Developmental Studies Hybridoma Bank) in blocking solution. The cells were 
incubated with biotinylated donkey anti-rabbit secondary antibody (1:300; 
Amersham) for 1 hr before incubating for a further hour with streptavidin-
conjugated Alexa Fluor 488 (1:400) and Alexa Fluor 546 goat anti-mouse IgG 
conjugated secondary (1:300) (Molecular Probes). All cells were stained with 
DAPI (Molecular Probes) for 5 min and mounted with fluorescent media (Dako) 
before viewing under fluorescent illumination.  
5.2.4 Protein analysis of Gas muscle and primary myoblasts  
Gas muscles were homogenised in 1 ml PLB (0.05 M Tris pH 7.5, 0.25 M 
NaCl, 5 mM EDTA, Complete™ protease inhibitor tablet (Roche) and 0.1% 
NP40). Protein was collected from differentiating primary myoblasts isolated 
from 6- and 24-month-old wild-type and myostatin-null mice as previously 
published (McCroskery et al., 2003). Bradford’s reagent (Bio-Rad) was used to 
estimate total protein. Total protein (10 µg for muscle, 15 µg for myoblasts) was 
separated on a NuPAGE™ 4-12% Bis-Tris gel (Invitrogen) and transferred to 
nitrocellulose membranes (Bio-Rad). The membranes were stained in Ponceau S 
to visually assess equal protein loading. A Western blot for myostatin was 
performed as previously published (Sharma et al., 1999). For MyoD, BSA blocker 
(0.3% BSA, 1% PEG, and 1% PVP in TBS-T) was added for 1 hr at room 
temperature before incubating with mouse anti-MyoD (1:10,000; BD 
PharMingen) overnight at 4°C. For GAPDH, 5% milk in TBS-T was added 
overnight at 4°C before incubating with mouse anti-GAPDH (1:10,000; Research 
Diagnostics) for 1 hr at room temperature. Both membranes were incubated with 
goat anti-mouse IgG HRP conjugate (1:5,000 for MyoD, 1:10,000 for GAPDH; 
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Dako) for a further hour at room temperature. HRP activity was detected using 
Western Lightning™ Chemiluminescence Reagent Plus (PerkinElmer).  
5.2.5 Image and statistical analysis 
Images of fat pads and primary myoblasts and myotubes were obtained 
using an Olympus BX50 microscope (Olympus) and a SPOT-RT 4.01 camera and 
software (Diagnostic Instruments). The images were then analysed using ImageJ 
software (National Institutes of Health; NIH). All data are presented as means ± 
SEM. To determine the significance (P < 0.05) of differences between groups, 
comparisons were made using Student’s t test.  
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5.3 Results 
5.3.1 Lack of functional myostatin increases muscle weights  
Lack of functional myostatin has been shown to result in muscle 
hypertrophy, as observed in both Belgian blue cattle and myostatin-null mice 
(Kambadur et al., 1997; McPherron et al., 1997; McPherron and Lee 1997). 
Conversely, aging can cause loss of muscle mass in both animals and humans 
(Alnaqeeb and Goldspink 1987; Lexell et al., 1988; Holloszy et al., 1991; 
Gallegly et al., 2004). In order to determine any correlation between a lack of 
myostatin and muscle mass during aging, wet muscle weights of BF, Gas, TA and 
Quad from 1-, 6- and 24-month-old wild-type and myostatin-null mice were 
measured (Figure 5.1A). From the outset, 1-month-old myostatin-null muscle 
weights were significantly increased from that of 1-month-old wild-type muscle. 
For example, 1-month-old myostatin-null BF and Quad muscles were 50 and 72% 
heavier than their respective wild-type muscles (P < 0.001). Both wild-type and 
myostatin-null muscle weights increased significantly from 1- to 6-months of age. 
However, the myostatin-null muscles increased significantly more than the wild-
type. For example, myostatin-null Quad and TA increased 300% and 170% 
respectively compared to a 250% and 130% increase observed in the wild-type 
muscles (P < 0.001). With further aging, a significant decrease in wet weight was 
only observed in the wild-type and myostatin-null Quad muscles (16% and 24% 
loss respectively) (P < 0.05). However, all myostatin-null muscle weights were 
significantly larger than their wild-type counterparts irrespective of age. 
5.3.2 Age alters MyoD levels in myostatin-null & wild-type muscles 
MyoD expression has been shown to indicate the level of myogenesis 
occurring within a muscle (Grounds et al., 1992). To investigate MyoD protein 
levels in 1-, 6- and 24-month-old wild-type and myostatin-null muscles, Western 
blot analyses were performed (Figure 5.1B). The results indicated that in the wild-
type muscle there was a gradual increase in the expression levels of MyoD during 
postnatal growth. In the myostatin-null muscle, no significant up-regulation of 
MyoD levels was seen in the muscles of the mice between 1- and 6-months of 
age.  
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When relative comparisons were made between the two genotypes, it was 
discovered that MyoD levels were significantly higher in 1-month-old myostatin-
null muscle compared to 1-month-old wild-type muscle (Figure 5.1C) (P < 0.05). 
However, at 6-months of age, MyoD was significantly higher in the wild-type 
muscle compared to the myostatin-null muscle (P < 0.05) of the same age. The 
level of MyoD increased significantly between 6- and 24-months of age (P < 
0.05). Of note, no significant difference was observed between the two genotypes 
at 24-months of age.   
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Figure 5.1 Lack of myostatin alters muscle weights and MyoD levels  
(A) Gastrocnemius (Gas), tibialis anterior (TA), quadriceps (Quad) and biceps 
femoris (BF) muscle weights were measured in 1-, 6-, and 24-month-old wild-
type (empty bars) and myostatin-null (solid bars) mice (n = 10). P < 0.001 when 
wild-type is compared to myostatin-null and when 1-month is compared to 6-
month, P < 0.05 when 6-month Quad is compared to 24-month Quad. (B) Western 
blot analysis was performed on 1-, 6-, and 24-month-old wild-type (WT) and 
myostatin-null (KO) mice muscles to determine MyoD protein levels. The 
Western blot was analysed by densitometry and normalised to GAPDH protein 
levels. Normalised data were used to generate the MyoD (C) graph shown (empty 
bars = wild-type, solid bars = myostatin-null) (n = 5). P < 0.001 when 1-month 
WT is compared to 6-month WT, P < 0.05 when 1- and 6-month WT is compared 
to 1- and 6-month KO respectively, and when 6-month is compared to 24-month. 
All data are expressed as mean ± SEM. 
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5.3.3 Aged myostatin-null myoblasts display an increased proliferation  
Previously, it has been shown that exogenous myostatin inhibits the 
proliferation of C2C12 myoblasts (Thomas et al., 2000) and that myostatin-null 
myoblasts from young mice proliferate significantly faster than their wild-type 
counterparts (McCroskery et al., 2003). To determine if this greater proliferative 
capacity of the myostatin-null myoblasts is maintained with age, myogenic cells 
were isolated from 24-month-old wild-type and myostatin-null mice, and a 
proliferation assay was later performed. The myogenic purity of the 1- and 24-
month-old wild-type and myostatin-null primary myoblast cultures were first 
assessed through ICC using an antibody for desmin, a marker expressed 
specifically on muscle precursor cells (Kaufman and Foster 1988). Analysis of the 
immunostaining indicated that each culture was 90-94% myogenic as determined 
by the percentage of desmin-positive cells (Figure 5.2A) (P < 0.001). The 
proliferation assay indicated that indeed, the myostatin-null myoblasts possessed 
greater proliferation rates compared to the wild-type cultures (Figure 5.2B) (P < 
0.05). 
5.3.4 Differentiation and fusion is increased in myostatin-null cultures 
Myostatin has been shown to strongly inhibit myoblast differentiation 
(Langley et al., 2002; Rios et al., 2002; Joulia et al., 2003). In support of these 
reports, myotube hypertrophy was observed in the differentiating myostatin-null 
cultures in relation to the wild-type cultures irrespective of age (Figure 5.3A). In 
addition, aging has been correlated with a decrease in the differentiation potential 
of myoblasts (Charge et al., 2002; Lees et al., 2006). Analysis of cell fusion 
within each culture indicated that fusion was significantly greater in the 
myostatin-null cultures (Figure 5.3B). For example, the fusion index for 6-month 
myostatin-null cultures was 71% as opposed to 56% in the wild-type cultures (P < 
0.001). Aging had a minimal effect on the fusion index as any observed decreases 
were not statistically significant.  
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Figure 5.2 Aged myostatin-null myoblasts display increased proliferation   
(A) The number of desmin-positive cells in 1- and 24-month wild-type (empty 
bars) and myostatin-null (solid bars) myoblast cultures were determined to assess 
myogenic purity. Myoblasts were isolated from 3 mice of each age and genotype, 
cells were plated in duplicate, and a minimum of 1,000 cells per culture were 
counted. (B) A proliferation assay was performed with primary myoblasts isolated 
from 24-month-old wild-type (empty bars) and myostatin-null (solid bars) mice. 
Cell proliferation was determined using a methylene blue photometric endpoint 
assay. Proliferation after 48 and 72 hr is graphically shown. Assays were 
performed in triplicate using cells isolated from 6 animals. ** = P < 0.05 when 
wild-type is compared to myostatin-null. All data are expressed as mean ± SEM. 
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Figure 5.3 Increased differentiation is retained in myostatin-null myoblasts 
(A) Examples of wild-type 6- (i) and 24- (ii) month, and myostatin-null 6- (iii) 
and 24- (iv) month H & E stained differentiating myotubes after 96 hr culturing. 
(B) The fusion indexes (number of myotube nuclei/total nuclei) of wild-type 
(empty bars) and myostatin-null (solid bars) differentiating myotubes was 
determined after 96 hr culturing. Myoblasts isolated from 6 mice per age group 
and genotype were plated in triplicate and 10 images per plate were obtained for 
analysis. ** = P < 0.001 when 6-month wild-type is compared to 6-month 
myostatin-null, * = P < 0.05 when 24-month wild-type is compared to 24-month 
myostatin-null. All data are expressed as mean ± SEM. 
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5.3.5 Myostatin levels are altered with age during differentiation  
To determine whether aging would influence myostatin protein levels, 
Western analysis of differentiating myoblasts isolated from 6- and 24-month-old 
wild-type mice was performed over 72 hr of incubation (Figure 5.4A). The 6-
month-old differentiating myoblasts displayed a consistent level of processed 
myostatin until 48 hr of differentiation, after which, the level decreased (Figure 
5.4B). In contrast, the 24-month-old differentiating myoblasts displayed a low 
level of processed myostatin at 0 hr, relative to the 6-month-old myoblasts, and 
slowly increased until 48 hr.  
5.3.6 MyoD & Pax7 are differentially expressed in myoblasts cultures 
Activated satellite cells have been shown to co-express Pax7 with MyoD 
(Zammit et al., 2004; Nagata et al., 2006). However, later the cells may down-
regulate Pax7 or MyoD depending on the myogenic fate of the cells. To assess the 
ratio of MyoD-only, Pax7-only, and MyoD/Pax7-positive cells within the primary 
myoblast cultures isolated from 1- and 24-month-old wild-type and myostatin-null 
mice, MyoD and Pax7 co-immunostaining was performed (Figure 5.4C). 
Although the percentage of MyoD/Pax7-positive cells was similar in the 1-month-
old cultures, a greater percentage of MyoD-only cells were observed in the wild-
type cultures (~16%) compared to the myostatin-null cultures (~6%) (P < 0.001). 
This corresponded to a greater percentage of Pax7-only cells observed in the 
myostatin-null cultures (~16%) compared to the wild-type cultures (~3%) (P < 
0.001). With age, a significant decrease in MyoD-only cells (~13%) (P < 0.05) 
and a corresponding increase in Pax7-only cells (~19%) (P < 0.001) was observed 
in the 24-month-old wild-type cultures compared to the 1-month-old wild-type 
cultures. In contrast, the percentage of MyoD/Pax7 cells decreased (~18%) (P < 
0.05), while the percentage of Pax7-only cells increased (~16%) (P < 0.001), in 
the 24-month-old myostatin-null cultures compared to the 1-month-old myostatin-
null cultures. 
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Figure 5.4 Myostatin levels and MyoD/Pax7 expression is altered with age  
(A) Western blot analysis was performed on differentiating myoblasts isolated 
from 6- and 24-month-old wild-type mice to determine myostatin (MSTN) protein 
levels. The Western blot was analysed by densitometry and normalised to 
GAPDH protein levels. Normalised data were used to generate the graph shown 
(B) (solid dots = 6-month, empty dots = 24-month) (n = 6). (C) The percentage of 
myoblasts positive for MyoD/Pax7 (black bars), MyoD-only (grey bars), or Pax7-
only (white bars) within 1- and 24-month-old wild-type and myostatin-null 
cultures was determined by MyoD and Pax7 co-immunostaining. Myoblasts were 
isolated from 3 mice of each age and genotype, cells were plated in triplicate, and 
a minimum of 1,000 cells per culture were counted. For MyoD/Pax7, P < 0.001 
when 1-month compared to 24-month KO, P < 0.05 when 24-month WT 
compared to 24-month KO. For MyoD-only, P < 0.001 when 1-month WT is 
compared to 1-month KO, P < 0.05 when 1-month WT compared to 24-month 
WT. For Pax7-only, P < 0.001 when 1-month WT is compared to 1-month KO or 
24-month WT, and when 1-month KO compared to 24-month KO. All data are 
expressed as mean ± SEM. 
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5.3.7 Epididymal fat is decreased in the myostatin-null mice 
In addition to influencing myogenesis, myostatin is also known to alter 
adipogenesis, as decreased body fat is observed in myostatin-null mice 
(McPherron and Lee 2002). To investigate the effect of the presence or absence of 
myostatin on body fat in aged mice, epididymal fat pads from 1-, 6- and 24-
month-old wild-type and myostatin-null mice were weighed (Figure 5.5A). Both 
genotypes indicated an increase of adipose tissue during development from 1- to 
6-months of age. However, the increase observed in the wild-type mice was 
significantly greater than in the myostatin-null mice (1900% and 500% 
respectively, P < 0.001). The effect of further aging on the fat pad weights 
appeared minimal as no significant weight gain or loss was observed in either 
genotype. Visual assessment of H & E stained fat pad sections revealed a 
significant variation between the two genotypes in regards to the fat cell sizes 
(Figure 5.5B). Of note, the 1-month-old wild-type fat pad contained cells which 
were very irregular in size with the majority being very small. This differed 
considerably from the 6-month-old wild-type fat pad which contained large 
similar sized cells throughout the fat pad. In contrast to the 1-month-old wild-type 
fat pad, fat cells within the 1-month-old myostatin-null fat pads appeared very 
similar to that of the adult myostatin-null fat pads, though smaller in size. The 
average fat cell size from both wild-type and myostatin-null fat pads increased 
significantly from 1- to 6-months of age though the increase was substantially 
larger in the wild-type mice (1,000% and 100% respectively, P < 0.001) (Figure 
5.5C). Although no significant change in cell size was observed in the myostatin-
null mice between 6- and 24-months of age, the wild-type mice showed a small 
significant decrease (10%, P < 0.05).  
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Figure 5.5 Myostatin-null mice display a decreased fat accumulation  
(A) Epididymal fat pads were measured in 1-, 6-, and 24-month-old wild-type 
(empty bars) and myostatin-null (solid bars) mice (n = 10). P < 0.001 when 1-
month is compared to 6-month, and when 6- and 24-month wild-type is compared 
to 6- and 24-month myostatin-null. P < 0.05 when 6-month wild-type is compared 
to 24-month wild-type. (B) Examples of wild-type 1- (i) and 6- (ii) month, and 
myostatin-null 1- (iii) and 6- (iv) month H & E stained epididymal fat pads. (C) 
Average fat cell sizes within 1- and 24-month wild-type (empty bars) and 
myostatin-null (solid bars) fat pads are graphically shown (n =5). Approximately 
2,000 cells were measured per age group and genotype. P < 0.001 when WT is 
compared to KO or when 1-month is compared to 6- and 24-month, P < 0.05 
when 6-month WT is compared to 24-month WT. All data are expressed as mean 
± SEM. 
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5.4 Discussion 
Sarcopenia in elderly humans is known to contribute to frailty and falls, 
however the exact mechanism for the associated loss of muscle mass remains 
undetermined. Alternatively, it is well established that animals lacking functional 
myostatin have greater muscle mass (Grobet et al., 1997; McPherron et al., 1997; 
Zhu et al., 2000). To address how a prolonged absence of myostatin would affect 
the normal aging process, the myogenic nature of aged wild-type and myostatin-
null muscle was examined in mice. In agreement with previous studies, myostatin-
null mice displayed significantly larger muscles compared to wild-type mice 
(Figure 5.1A), a difference retained in the aged mice. The greater muscle weights 
in the 1-month myostatin-null muscles corresponded to increased MyoD protein 
levels (Figure 5.1C), however higher MyoD levels were observed in the 6-month 
wild-type muscle compared to the age-matched myostatin-null muscle. This may 
suggest a lengthier period of myogenesis in the wild-type muscle due to a slower 
rate of myogenesis relative to the myostatin-null muscle. It is possibly that in 
young myostatin-null mice, the greater MyoD protein level reported here, and the 
increased satellite cell number and activation previously described (McCroskery 
et al., 2003) leads to the establishment of the upper muscle mass limit earlier than 
the wild-type muscle. Conversely, an increased level of MyoD in the wild-type 
muscle at 6-months may indicate an earlier onset of age-related muscle wasting 
and associated myogenesis. Of note, a similar level of MyoD was observed in the 
24-month wild-type and myostatin-null muscle, however, the level was 
significantly greater than at 1-month. As aging is known to impair satellite cell 
activation (Conboy et al., 2003; Gallegly et al., 2004), it is possible that an 
increased level of MyoD occurs in response to the poor satellite cell activation 
potential in the aged animals. Regardless, the similar MyoD level in the 24-month 
wild-type and myostatin-null muscles suggests a greater level of MyoD is not 
required to maintain the increased mass muscle observed in the myostatin-null 
muscle. It is possible that the increased muscle mass established in the young 
mice could be of more significance. Furthermore, the greater proliferation rate 
(Figure 5.2B) and differentiation fusion index (Figure 5.3B) observed in the 
myostatin-null myoblast cultures would theoretically equate to more efficient 
myogenesis in the aged myostatin-null mice.  
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Quiescent satellite cells have been shown to express Pax7 (Seale et al., 
2000), however, when they become activated, they co-express Pax7 with MyoD 
(Zammit et al., 2004; Nagata et al., 2006). Cells may down-regulate Pax7 and 
progress along the myogenic pathway, or maintain Pax7 and down-regulate 
MyoD, thereby withdrawing from the cell cycle and returning to a quiescence-like 
state (Zammit et al., 2004; Nagata et al., 2006). MyoD and Pax7 co-stained wild-
type and myostatin-null myoblast cultures indicated a higher percentage of Pax7-
only cells in the 1-month myostatin-null cultures compared to the 1-month wild-
type cultures (Figure 5.4C). This would suggest a higher proportion of myostatin-
null cells returning to a quiescence-like state, thus resulting in a larger satellite 
cell pool via increased self-renewal. The greater proportion of Pax7-only cells in 
the myostatin-null cultures appears to be at the expense of MyoD-only cells 
suggesting a decreased number of cells progress along the myogenic pathway. 
However, theoretically this would be compensated by the increased proliferation 
rate reported to occur in the myostatin-null cultures (McCroskery et al., 2003), 
thus resulting in an increased number of myoblasts destined to terminally 
differentiate. Interestingly, the proportion of Pax7-only cells increased in both the 
wild-type and myostatin-null 24-month myoblast cultures. This may suggest that a 
higher proportion of aged myoblasts return to a quiescence-like state. 
Alternatively, it may be due to the decreased activation potential observed in aged 
satellite cells, which would result in a lower percentage of MyoD-positive cells. 
Interestingly, 24-month-old wild-type differentiating myoblasts displayed 
significantly reduced levels of processed myostatin. It is possible that due to aged 
myoblasts becoming refractory to proliferation and differentiation, a reduced level 
of myostatin is processed as a compensatory mechanism.   
An alteration in adipogenesis is another characteristic of the aging process. 
Fat deposits are thought to increase until middle to early old age followed by a 
decline with increasing age. Fat cells are continually formed (Bertrand et al., 
1978; Miller et al., 1984), though the overall number of cells may change 
throughout the lifespan depending on the rate of gain and loss of fat cells 
(Kirkland and Dax 1984; Silver et al., 1993; Kirkland and Dobson 1997). 
Myostatin also influences adipogenesis as myostatin-null mice have demonstrated 
a significant decrease in fat accumulation compared to wild-type mice (Lin et al., 
2002; McPherron and Lee 2002). In agreement with this finding, results reported 
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here indicated that the increase in fat pad weight from 1- to 6-months of age was 
significantly greater in wild-type mice compared to myostatin-null mice (Figure 
5.5A). Further aging appeared to have a minimal effect on wild-type and 
myostatin-null fat pad weights. Interestingly, fat cells within the 1-month-old 
myostatin-null fat pad were significantly larger than wild-type cells of the same 
age (Figure 5.5C), suggesting greater fat accumulation at this age. The average fat 
cell size increased significantly with age, however, the increase was substantially 
smaller in the myostatin-null mice indicating a reduced fat accumulation with 
increasing age. Further aging appeared to have little effect on the myostatin-null 
fat pad in regards to fat cell size, though an expected reduction was observed in 
the wild-type mice. Although the exact mechanism by which myostatin regulates 
fat metabolism is yet to be elucidated (and whether it is a direct or indirect effect 
of myostatin), it is intriguing how myostatin-null mice display a consistently low 
level of fat accumulation even in the aged mice.   
Collectively our findings show that a prolonged absence of myostatin results in 
the retention of muscle hypertrophy even in aged animals. In vitro results indicate 
this is brought about through increased myoblast proliferation and differentiation.   
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6.1 Introduction 
Mammalian skeletal muscle mass is dependent on numerous factors 
including muscle fibre number, type and size. All three aspects are believed to be 
influenced by a variety of conditions, including aging, which can lead to atrophy 
of the individual muscle fibres, loss of fibre numbers and fibre type switches 
(Gutmann and Hanzlikova 1966; Rowe 1969; Alnaqeeb and Goldspink 1987; 
Lexell et al., 1988; Holloszy et al., 1991). A prominent influence on muscle fibre 
size is the involvement of satellite cells, a population of myogenic precursor cells 
associated with the muscle fibres. Satellite cells are located between the basal 
lamina and sarcolemma (Mauro 1961) and exist predominantly in a mitotically 
quiescent state (Schultz et al., 1978). These cells are believed to be largely 
responsible for muscle regeneration (Partridge 2002) by giving rise to myoblasts, 
thereby enabling additional nuclei to fuse to existing fibres or form new myofibres 
(Bischoff 1994; Schultz and McCormick 1994). For the progression of this 
process, satellite cells must enter the cell cycle from the quiescent state and 
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undergo myogenesis. Clearly, the number of satellite cells as well as their 
proficiency to undergo this process would impact the degree to which muscle 
regeneration can occur. One factor thought to severely impact satellite cell 
behavior is aging. Satellite cells isolated from aged animals have demonstrated a 
significant lag when entering the cell cycle (Johnson and Allen 1995), a decreased 
proliferation and differentiation potential (Schultz and Lipton 1982; Lees et al., 
2006), and an increased susceptibility to apoptosis (Jejurikar et al., 2006; Krajnak 
et al., 2006). Additionally, various studies indicate that aged muscle is restricted 
in its ability to promote satellite cell activation (Decary et al., 1997; Bockhold et 
al., 1998; Conboy et al., 2003). Using cross-age muscle transplantation it has been 
demonstrated that the poor regeneration associated with old animals is a function 
of the aged environment (Carlson and Faulkner 1989). In addition, it has also been 
suggested that insufficient up-regulation of Notch signaling is directly responsible 
for the impaired activation propensity of the aged satellite cells (Conboy et al., 
2003). More recently, parabiotic pairing experiments have indicated that systemic 
factors from young mice restored the activation of Notch signaling as well as 
promoted the proliferation and regenerative capacity of satellite cells in aged mice 
(Conboy et al., 2005). Alternatively, negative regulators, such as myostatin, may 
inhibit satellite cell activity in the aged environment.  
Myostatin is a TGF-β superfamily member functioning as a potent 
inhibitor of muscle growth (McPherron et al., 1997). It is expressed both 
prenatally in the developing myotome and post-natally in adult skeletal muscle 
(McPherron et al., 1997) suggesting myostatin plays a continual role in 
myogenesis. Indeed, myostatin-null animals display significantly greater muscle 
mass resulting from muscle fibre hyperplasia and hypertrophy (McPherron et al., 
1997). Studies indicate that myostatin influences myogenesis in C2C12 myoblast 
cultures through the regulation of cell cycle progression and MRFs (Thomas et 
al., 2000; Langley et al., 2002). Moreover, myostatin has been shown to inhibit 
satellite cell activation in mice (McCroskery et al., 2003), which would have 
significant consequences during age-related muscle wasting and regeneration. 
Interestingly, increased myostatin has been correlated with muscle atrophy during 
unloading in mice (Carlson et al., 1999), muscle wasting in HIV patients 
(Gonzalez-Cadavid et al., 1998) and cachexia induced by systemic administration 
of myostatin (Zimmers et al., 2002). Although the exact role of myostatin during 
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age-related muscle wasting remains unclear, a prolonged absence from prenatal 
stage as seen in myostatin-null mice, has demonstrated an overall reduction in 
sarcopenia (Wagner et al., 2005). This being the case, the antagonism of 
myostatin has serious therapeutic potential in the alleviation of sarcopenia and 
impaired muscle regeneration observed in aged animals. In fact, we report here 
that a short term blockade of myostatin function through the administration of a 
truncated protein was able to significantly enhance muscle regeneration in aged 
mice. This regeneration occurred via a restoration of the myogenic and 
inflammatory responses in the aged mice, leading to increased satellite cell 
activity and enhanced macrophage and myoblast migration.  
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6.2 Materials and Methods 
6.2.1 Generation of Mstn-ant1 and testing during C2C12 proliferation 
An E. coli expression system was used to produce the truncated myostatin 
protein. Amplified cDNA, from the carboxyl-terminal region of myostatin, was 
purified and subsequently inserted into the cloning vector pET 16-B (Novagen) as 
previously described (Sharma et al., 1999). For the generation of Mstn-ant1, the 
cDNA was truncated at the amino acid 350 to produce a truncated portion of the 
processed region. The protein was purified utilising a Ni-NTA agarose (Qiagen) 
affinity column (Sharma et al., 1999). In order to test the purity of the antagonist, 
3 µg was separated on a NuPAGE™ 4–12% Bis-Tris gel (Invitrogen), stained 
with Coomassie blue then destained. C2C12 myoblasts were grown (Thomas et 
al., 2000) in uncoated 96-well microtitre plates (Nunc) at 1000 cells/well. 
Following a 16 hr attachment period, test media containing Mstn-ant1 was added 
to the actively growing cells before incubating for a further 48 or 72 hr. Cell 
proliferation was later assessed using a methylene blue photometric endpoint 
assay as previously described (Oliver et al., 1989). 
6.2.2 Animals 
The wild-type mouse strain C57BL/10 was bred at the Ruakura Small 
Animal Colony. All animals were handled in accordance with the guidelines of 
the Ruakura Animal Ethics Committee (AgResearch, Hamilton, New Zealand) 
and the University of Waikato Animal Ethics Committee (University of Waikato, 
Hamilton, New Zealand).  
6.2.3 Administration of Mstn-ant1 to notexin injured and aged mice 
On day 0, 1-year-old mice were anaesthetised with 10% ketamine 
hydrochloride (100 mg/ml)/5% Rompun (20 mg/ml) at 0.1 ml/7 g body weight. A 
small incision was made over the left TA before 10 µl of notexin (10 µg/ml; 
Venom Supplies) was injected into the muscle. On days 1, 3 5 and 7, the 
antagonist treatment group received Mstn-ant1 at 6 µg/g body weight 
subcutaneously, while the control group received the equivalent volume of saline. 
Mice were euthanized on days 1, 2, 3, 7, 10 and 28 (4-6 mice per group per day) 
for tissue collection.  
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Additionally, mice aged 13- to 16-months were injected subcutaneously 3 
times a week with Mstn-ant1 at 6 µg/g body weight, or the equivalent volume of 
saline, for 6 weeks (10 per group). TA and Gas muscles were collected for single 
fibre isolations and muscle protein respectively, while the remaining hind-limb 
muscle was collected for myoblast isolation. Bone marrow was also collected for 
macrophage cultures used in the chemotaxis assays. 
6.2.4 Assessment of muscle regeneration and strength 
TA muscles were dissected from each notexin injured mouse, weighed and 
frozen for protein isolation or tissue sectioning. Transverse sections (10 µm) were 
cut from the mid-belly region of each muscle. Muscle sections were stained with 
H and E to visualise and measure unregenerated and regenerated areas. To 
visualise areas of collagen deposited 10 and 28 days after injury, muscle sections 
were stained with Van Gieson. The amount of collagen was then measured within 
each section as a percentage of the total section area. Day-2, -3, -7 and -10 
muscles sections were immunostained for Mac1, an antibody specific for 
infiltrating peripheral macrophages, as previously described (McCroskery et al., 
2005). Muscle strength was measured in a double-blind fashion in the aged mice 
injected with saline or Mstn-ant1 for 6 weeks at the commencement and 
completion of the trial using a grip strength apparatus measuring fore- and hind-
limb strength) (MK-380S, Muromachi). The mice were pulled backward by the 
tail while the maximal force exerted by the mouse was digitally recorded. The 
mean of three grip tests for each animal was calculated and the mean maximal 
force of 10 animals per group was determined and expressed in Newtons as mean 
± SEM.  
6.2.5 Single fibre isolation and analysis of satellite cell activation 
TA muscles collected from the Mstn-ant1 or saline injected mice were 
used to isolate single fibres following an adapted protocol of Rosenblatt et al. 
(1995) previously described (refer to Section 2.2.23.3). Isolated fibres were then 
cultured for 24 or 48 hr at 37ºC in 5% CO2. In addition, single fibres were isolated 
from non-treated 1- and 24-month-old mice. These fibres were cultured with or 
without Mstn-ant1 at 5 µg/ml for 24, 48, or 72 hr at 37ºC in 5% CO2. After the 
required culturing time, all fibres were fixed with 100% methanol, washed in 
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PBS, permeablised in 0.5% TritonX-100 in PBS for 10 min and blocked in 10% 
NGS and 0.35% cλ in PBS for 1 hr at room temperature. Mouse anti-PCNA 
antibody (Dako) at 1:100 in 5% NGS and 0.35% cλ in PBS was then added 
overnight. The primary antibody was detected using Alexa Fluor 546 goat anti-
mouse IgG conjugated secondary (Molecular Probes) at 1:300 in 5% NGS and 
0.35% cλ in PBS for 1 hr at room temperature. Fibres were counterstained with 
DAPI (Molecular Probes) before mounting with fluorescent mounting media 
(Dako) and viewing under fluorescent illumination. PCNA-positive nuclei were 
counted as a percentage of total myonuclei in order to normalise the data and 
exclude any discrepancies in the lengths of the fibres analysed. 
6.2.6 Isolation of primary myoblasts and macrophages 
Satellite cells were isolated from the hind-limb muscles from the Mstn-
ant1 or saline injected mice according to published protocols (Partridge 1997; 
Yablonka-Reuveni et al., 1999; McCroskery et al., 2005). After 48 hr of culturing, 
the pooled cells were collected for protein isolation. In addition, primary 
myoblasts were isolated from non-treated 1- and 24-month-old mice for 
proliferation and chemotaxis assays. For a proliferation assay, the myoblasts were 
cultured with or without Mstn-ant1 at 10 µg/ml for 96 hr. Bone marrow derived 
macrophages were obtained by plating bone marrow cells at 5x106 cells/plate in 
DMEM with 10% FBS and 10% L929 conditioned medium (containing CSF-1) 
for 5 days to induce macrophage differentiation (Suresh and Sodhi 1991). 
Peritoneal macrophages were obtained by lavage of the peritoneal cavity of 1- and 
24-month-old non-treated mice with cold PBS. 
6.2.7 Myoblast and macrophage chemotaxis assays 
Chemotaxis assays were performed using cell culture inserts, containing 
PET 0.8 µm membranes (BD Biosciences) as previously described (McCroskery 
et al., 2005). For macrophage chemotaxis, DMEM with Zymosan A (Sigma) 
activated mouse serum (ZAMS) was used as a chemoattractant at 33, 22 and 11%. 
For myoblast chemotaxis, DMEM with 2% HS and 5% CEE (optimal), DMEM 
with 2% HS (suboptimal) or DMEM with 5% CEE (suboptimal) were used as 
chemoattractants. Rescue experiments were performed with either 2.5 or 5 µg/ml 
of recombinant myostatin in the presence or absence of Mstn-ant1 at 5x the 
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myostatin concentration. The cells were incubated for 4 or 7 hr for macrophages 
and myoblasts respectively. Migrated cells were counted on four representative 
fields per membrane and the average number plotted. All assays were performed 
in duplicate. 
6.2.8 Protein analysis 
TA muscles from notexin injured mice were homogenised in 1 ml PLB 
(0.05 M Tris pH 7.5, 0.25 M NaCl, 5 mM EDTA, Complete™ protease inhibitor 
tablet (Roche) and 0.1% NP40). Bradford’s reagent (Bio-Rad) was used to 
estimate total protein. Total protein (10 µg) was separated on NuPAGE™ 4-12% 
Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose membrane (Bio-Rad). 
Membranes were stained in Ponceau S to visually assess equal protein loading. 
For analysis of MyoD, membranes were blocked in BSA blocker (0.3% BSA, 1% 
PEG, and 1% PVP in TBS-T) for 1 hr at room temperature then incubated with 
mouse anti-MyoD (BD PharMingen) at 1:10,000 overnight at 4°C. For analysis of 
Pax7, membranes were blocked in 5% milk in TBS-T overnight at 4°C, and then 
incubated with mouse anti-Pax7 antibody (ascites fluid obtained from the 
Developmental Studies Hybridoma Bank) at 1:500 for 3 hr at room temperature. 
The membranes were then incubated with goat anti-mouse IgG HRP conjugate 
(Dako) at 1:5,000 (MyoD) or 1:2,000 (Pax7) for 1 hr at room temperature. HRP 
activity was detected using Western Lightning™ Chemiluminescence Reagent 
Plus (PerkinElmer). 
In addition, protein was collected from the primary myoblasts 
(McCroskery et al., 2003) and Gas muscle isolated from the aged mice injected 
with saline or Mstn-ant1 for 6 weeks. Total protein (15 µg) was used for Western 
blot analyses of MyoD and Pax7.  
6.2.9 Image and statistical analysis 
Unregenerated/regenerated areas and collagen deposition was analysed 
using an Olympus SZ-PT stereomicroscope (Olympus), a 3 CCD camera (Dage-
MTI) and Scion Image software (Scion). The obtained images were then 
measured using ImageJ software (NIH). Positive Mac1 staining was viewed under 
fluorescent illumination using an Olympus BX50 microscope (Olympus), SPOT-
RT 4.01 camera and software (Diagnostic Instruments Inc.), and images of each 
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section were obtained for analysis. The number of Mac1-positive cells was 
counted per unit area from four images per muscle section. All data are presented 
as means ± SEM. ANOVA with Tukey test was used to determine the significance 
(P < 0.05) of data between groups. 
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6.3 Results 
6.3.1 Antagonist production and biological activity 
Previously we have shown that a prolonged absence of myostatin reduced 
sarcopenia in myostatin-null mice (refer to Chapter 4). We elected to test whether 
a specific molecule, a truncated version of myostatin, could antagonise myostatin 
and potentially offer a therapeutic option for treating sarcopenia. Myostatin 
protein is proteolytically processed at amino acid 266, thereby giving rise to the 
biologically active mature myostatin (McPherron et al., 1997) which spans from 
amino acid 266-375. This 110 amino acid protein binds to Activin type IIB 
receptor as a dimer to transduce signalling (Lee and McPherron 2001). To 
antagonise myostatin, we produced a carboxyl-terminal truncation, spanning from 
amino acid 266 to 350, as a dominant negative protein. This carboxyl-terminal 
truncation, named Mstn-ant1, along with its amino acid length, is illustrated in 
Figure 6.1A. The Mstn-ant1 protein was expressed in an E. coli expression system 
and purified to homogeneity (Figure 6.1B). The biological activity of the 
antagonist Mstn-ant1 was determined by a C2C12 myoblast proliferation assay. 
The results indicated that Mstn-ant1 was able to significantly increase the 
proliferation rate of the treated myoblasts above the control myoblast level after 
48 (Figure 6.1C) and 72 (data not shown) hr in culture (P < 0.05).   
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Figure 6.1 Structural representation and biological activity of Mstn-ant1 
(A) Mstn-ant1 and processed myostatin are depicted, illustrating the length of the 
truncated protein (C = cysteine, numbers = amino acid number). (B) The Mstn-
ant1 protein was separated on a SDS gel showing as a 17 kDa molecule, and later 
screened for its biological activity in a proliferating C2C12 cell culture. (C) 
C2C12 myoblasts were cultured with or without 1 µg/ml (1) or 5 µg/ml (5) of 
Mstn-ant1 for 48 hr. ** = P < 0.001 and * = P < 0.05 when control compared to 
antagonist treated myoblasts. Data are expressed as mean ± SEM. 
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6.3.2 Mstn-ant-1 enhances muscle regeneration following injury 
Next we tested the utility of Mstn-ant1 in a regenerating model in mice. 
Typically after a notexin type injury, the injured muscle initially increases in 
weight due to a resulting oedema, followed by a decrease due to necrosis of the 
damaged muscle fibres which are cleared from the site of injury. The muscle 
weight then begins to increase again as regeneration of the fibres occur. The 
results indicated a trend in which the loss in muscle weight was less pronounced 
in the Mstn-ant1 treated muscles compared to the saline treated muscles at days 7 
and 10 (Figure 6.2A). It is possible that the observed trend was due to a decreased 
muscle loss during the necrosis period, or conversely, due to advancement in new 
fibre formation resulting from the in vivo antagonism of myostatin by the Mstn-
ant1 treatment. In support of this, analysis of the TA muscle sections indicated 
earlier nascent muscle fibre formation (regenerated areas) and an associated 
reduction in necrotic areas (unregenerated areas) in the muscles treated with Mstn-
ant1 compared to saline treated muscles at days 7 and 10 (Figure 6.2B-C) (P < 
0.05).  
Since a measure of fibre areas can indicate the progression of regeneration 
occurring within a recovering muscle, individual fibre areas were measured to 
assess fibre regeneration 28 days after injury. Results indicated that the 
regenerated fibres from Mstn-ant1 treated mice were significantly larger than the 
saline treated muscles (Figure 6.3B) (P < 0.05).  
Furthermore, following notexin injury, collagen deposits can be observed 
within the regenerated muscle (McCroskery et al., 2005). Van Gieson staining of 
the saline and Mstn-ant1 treated muscles (Figure 6.3A) indicated reduced levels of 
collagen in the Mstn-ant1 treated muscles as compared to saline treated muscles at 
days 10 and 28 (Figure 6.3C) (P < 0.05). 
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Figure 6.2 Antagonism of myostatin enhances muscle regeneration 
(A) After notexin injury and treatment with Mstn-ant1, the percentage of muscle 
weight gain or loss from saline (Sal) and Mstn-ant1 treated muscles was analysed 
on days 3, 7 & 10 (d3, 7 & 10) (n = 4). (B) Sections were cut from each TA 
muscle and stained with H & E to visually determine the extent of muscle injury 
and regeneration in day-7 saline (i) and Mstn-ant1 (ii) and day-10 saline (iii) and 
Mstn-ant1 (iv) muscles (n = 4, * denotes unregenerated areas) (scale bar, 1 mm). 
(C) Using the H & E stained sections, the percentage of unregenerated and 
regenerated areas within each muscle were measured (n = 4). * = P < 0.05 when 
Sal compared to Mstn-ant1 treated. All data are expressed as mean ± SEM.  
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Figure 6.3 Mstn-ant1 increases fibre area and decreases collagen deposition  
(A) Representative images of Van Gieson stained saline (i) and Mstn-ant1 (ii) 
treated muscle sections are shown (scale bar = 20 µm). Collagen is identified by 
pink staining (indicated by arrow). Individual regenerated fibre areas (B) as well 
as the percentage of collagen within each section (C) was measured in the saline 
(Sal) and Mstn-ant1 treated day-28 muscles using the Van Gieson stained sections 
(n = 4). *P < 0.05 when Sal is compared to Mstn-ant1 treated. All data are 
expressed as mean ± SEM. 
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6.3.3 MyoD and Pax7 levels are altered by Mstn-ant1 treatment 
Both Pax7 and MyoD have been established as potent markers of 
myogenesis. While Pax7 levels can signify the satellite cell pool as well as 
satellite cell self-renewal (Seale et al., 2000; Oustanina et al., 2004), MyoD can 
signify the level of myogenesis occurring within a muscle (Grounds et al., 1992). 
To investigate Pax7 and MyoD protein levels in the notexin injured muscles, 
Western blot analyses were performed. Analysis of the saline and Mstn-ant1 
treated muscles indicated that Pax7 protein levels were higher with Mstn-ant1 
treatment at days 3, 7, 10, and 28 (Figure 6.4A-B) (P < 0.05). Similarly, MyoD 
levels were also higher with Mstn-ant1 treatment compared to the saline treated 
muscles at days 3, 7, and 10 (Figure 6.4A,C) (P < 0.05). Comparable levels of 
MyoD were seen between the treatment groups at day 28, in contrast to the greater 
level of Pax7 observed at the same time point with the administration of Mstn-
ant1.  
Similar to a notexin injury, though to a lesser extent, aged muscle also 
displays a level of ongoing myogenesis due to muscle maintenance and repair in 
association with the aging process. Therefore, Pax7 and MyoD were also analysed 
in the muscles isolated from the aged mice treated for 6 weeks with saline, or 
Mstn-ant1. Protein isolated from Gas muscle at the completion of the trial 
indicated significantly higher Pax7 and MyoD protein levels in the Mstn-ant1 
treated mice compared to the saline treated mice (Figure 6.5A,C,E) (P < 0.05). In 
addition, protein isolated from actively growing primary myoblasts also displayed 
increased levels of both Pax7 and MyoD (Figure 6.5B,D,F) with Mstn-ant1 
treatment. 
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Figure 6.4 MyoD & Pax7 are increased by Mstn-ant1 treatment after injury 
(A) Western blot analysis was performed on days 1, 3, 7, 10 & 28 saline (Sal) and 
Mstn-ant1 treated notexin injured muscles to determine Pax7 and MyoD protein 
levels. Each blot was analysed by densitometry and normalised to GAPDH 
protein levels. Normalised data were used to generate the Pax7 (B) and MyoD (C) 
graphs depicted (n = 4). ** = P < 0.001, * = P < 0.05 when Sal compared to Mstn-
ant1. All data are expressed as mean ± SEM. 
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Figure 6.5 MyoD & Pax7 levels in aged muscle is increased by Mstn-ant1  
Western analysis was performed on muscles (A) and pooled primary myoblasts 
(B) isolated from aged mice treated for 6 weeks with saline (Sal) or Mstn-ant1 to 
determine Pax7 and MyoD protein levels during sarcopenia-related muscle 
regeneration. Each blot was analysed by densitometry and normalised to GAPDH 
protein. Normalised data were used to generate the Pax7 (C-D) and MyoD (E-F) 
graphs shown (n = 10). * = P < 0.05 when Sal compared to Mstn-ant1. All data 
are expressed as mean ± SEM. 
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6.3.4 Satellite cell activation and proliferation and muscle strength is 
increased in response to Mstn-ant1 treatment 
To investigate how Mstn-ant1 would affect satellite cell activation, 
isolated single fibres from 1- and 24-month-old mice were cultured with or 
without Mstn-ant1. Satellite cell activation was determined through ICC using an 
antibody for PCNA (Figure 6.6A), a marker for DNA replication. The fibres 
cultured with Mstn-ant1 consistently displayed a higher percentage of activated 
satellite cells per fibre than fibres cultured in media alone (Figure 6.6B-C) (P < 
0.05).  
Myostatin is also known to affect cell proliferation, thus to investigate the 
efficacy of the antagonist to increase myoblast proliferation, primary myoblasts 
from 1-month-old mice were cultured with or without Mstn-ant1. The result 
indicated that culturing with Mstn-ant1 increased myoblast proliferation by 15% 
(Figure 6.6D) (P < 0.001). 
In addition to culturing isolated fibres with Mstn-ant1, satellite cell 
activation was also investigated in the fibres isolated from the aged mice injected 
with saline or Mstn-ant1 for 6 weeks. The fibres isolated from the Mstn-ant1 
treated mice displayed a significantly increased percentage of activated satellite 
cells per fibre when compared to the saline treated mice (Figure 6.7A) (P < 0.05). 
Furthermore, to test whether the 6 week treatment could increase muscle 
strength, grip tests were performed at the commencement and completion of the 
treatment period. The results indicated that the administration of Mstn-ant1 
significantly increased the grip strength of the aged mice by 12% (P < 0.05) 
(Figure 6.7B). In contrast, no significant change was observed in the saline treated 
mice.  
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Figure 6.6 Mstn-ant1 increases satellite cell activation and proliferation  
(A) Activated satellite cells on isolated single fibres were visualised by 
immunostaining for PCNA (i) and total nuclei by DAPI (ii) (scale bar = 20 µm). 
The number of satellite cells per 100 myonuclei was determined in fibres isolated 
from 24-month-old (B) and 1-month-old (C) mice after culturing for 48 or 24 hr 
respectively with or without (c = control) Mstn-ant1. Fibres were isolated from 12 
animals and in excess of 1,000 nuclei per group were counted. * = P < 0.05 when 
Mstn-ant1 compared to control. (D) A proliferation assay was performed with 
primary myoblasts isolated from 1-month-old mice. The myoblasts were cultured 
with or without Mstn-ant1 and cell proliferation was determined using a 
methylene blue photometric endpoint assay. Proliferation after 96 hr is graphically 
shown. Assays were performed in triplicate using cells isolated from 4 animals. ** 
= P < 0.001. All data are expressed as mean ± SEM. 
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Figure 6.7 Cell activation and grip strength are increased by Mstn-ant1  
(A) Satellite cell activation was assessed in single fibres isolated from aged mice 
treated for 6 weeks with saline (Sal) or Mstn-ant1. Single fibres were cultured for 
24 and 48 hr (t24, t48). Activated satellite cells were visualised by 
immunostaining for PCNA and total nuclei by DAPI. The number of satellite cells 
per 100 myonuclei was then determined. Fibres were isolated from 10 animals in 
each treatment group and in excess of 1,000 nuclei per group were counted. * = P 
< 0.05 when Sal is compared to Mstn-ant1 treated. (B) Grip strength was assessed 
in aged mice treated for 6 weeks with Sal or Mstn-ant1. Grip strength was 
assessed on each animal at the trial commencement and completion (n = 10 per 
treatment group) giving a measurement in Newtons. The percentage of change 
between the commencement and completion grip strengths was then determined. 
* = P < 0.05. All data are expressed as mean ± SEM. 
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6.3.5 Antagonist treatment alters macrophage migration 
Myostatin is believed to inhibit macrophage migration (McCroskery et al., 
2005). Therefore, the presence of macrophages was examined in the notexin 
injured muscles treated with saline or Mstn-ant1 using anti-Mac1 antibodies to 
determine the efficacy of the antagonist to enhance macrophage migration (Figure 
6.8A). Indeed, a greater percentage of infiltrated nuclei were Mac1-positive in 
day-2 injured muscles which had been treated with Mstn-ant1, compared to saline 
treated muscles (Figure 6.8B) (P < 0.05). By day 3, the percentage had dropped in 
the Mstn-ant1 treated muscles below that of the saline treated day 3 muscles, and 
continued to be lower in day 7 and 10 muscles. This is indicative of a decreased 
macrophage requirement in the Mstn-ant1 treated muscles due to the earlier and 
increased number of macrophages observed at day 2. 
6.3.6 Cell migration is altered with age and Mstn-ant1 treatment 
Both myoblasts and macrophages are known to be influenced by 
chemotactic signals which affect their movement (Bischoff 1997; Jones 2000). To 
elucidate the effect of myostatin and aging on both myoblast and macrophage 
migration, a series of chemotaxis assays were performed. Results suggested that 
migration was significantly retarded in the myoblasts isolated from 24-month-old 
mice as compared to 1-month-old mice when in the presence of 5% CEE or 2% 
HS (Figure 6.9A) (P < 0.05). Similarly, migration of macrophages isolated from 
24-month-old mice was also reduced compared to 1-month-old mice, irrespective 
of the chemoattractant concentration (Figure 6.9B) (P < 0.05). The efficacy of the 
Mstn-ant1 to rescue cell migration in response to myostatin treatment was then 
examined using primary myoblasts isolated from 24-month-old mice. With the 
addition of Mstn-ant1, cell migration was able to be rescued by hindering the 
chemo-inhibitory effect of myostatin (Figure 6.9C) (P < 0.05). To test the efficacy 
of Mstn-ant1 to enhance cell migration after prolonged in vivo treatment, bone 
marrow derived macrophages were isolated from mice injected for 6 weeks with 
saline or Mstn-ant1. Indeed, the macrophages from Mstn-ant1 treated mice were 
able to migrate more efficiently than macrophages from saline treated mice 
(Figure 6.9D) (P < 0.05).  
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Figure 6.8 Antagonism of myostatin enhances macrophage infiltration  
Representative images of Mac1 immunostained day-2 saline (A) and Mstn-ant1 
(B) treated muscle sections after notexin injury are shown (scale bar = 50 µm). 
(C) The number of macrophages per unit area in regenerating muscle after notexin 
injury in saline (Sal) and Mstn-ant1 treated muscle sections was determined at day 
2, 3, 7, & 10 (n = 4 per day and treatment group). * = P < 0.05 when Mstn-ant1 
treatment is compared to Sal treatment.  
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Figure 6.9 Aging decreases while Mstn-ant1 enhances cell migration  
(A) Primary myoblasts isolated from 1- and 24-month-old mice were utilised in a 
migration assay using three concentrations of chemoattractant, 2% HS + 5% CEE 
(optimum concentration), 5% CEE, or 2% HS (suboptimal), while DMEM alone 
was a negative control (-ve control). ** = P < 0.001, * = P < 0.05 when 1-month-
old is compared to 24-month-old. (B) Peritoneal macrophages isolated from 1- 
and 24-month-old mice were utilised in a migration assay using three 
concentrations of the chemoattractant ZAMS (Z), 33% (optimum concentration), 
22% and 11% (suboptimal) and DMEM alone as a negative control. ** = P < 
0.001, * = P < 0.05 when 1-month-old is compared to 24-month-old. (C) Primary 
myoblasts isolated from 24-month-old mice were used in a chemotaxis assay. 
CEE medium was a positive control, while CEE + myostatin (Mstn; 2.5 µg/ml) 
was a negative control. Mstn-ant1 was added to wells containing CEE medium + 
Mstn to rescue the chemo-inhibitory effect of Mstn. ** = P < 0.001 when CEE 
compared to CEE + Mstn, or CEE + Mstn compared to CEE + Mstn + Mstn-ant1. 
(D) Bone marrow derived macrophages from the saline (Sal) and Mstn-ant1 
treated mice were used to assay macrophage migration after treatment. ** = P < 
0.001, * = P < 0.05 when Mstn-ant1 treatment compared to Sal treatment. For all 
migration assays, migrated cells were counted on four representative fields per 
membrane and the average number was plotted. All data are expressed as mean ± 
SEM. 
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6.4 Discussion 
Numerous studies indicate that aging considerably influences myogenesis 
through the muscle environment or systemic factors (Carlson and Faulkner 1989; 
Conboy et al., 2005), expression of MRFs (Welle et al., 2000) and satellite cell 
behaviour (Bockhold et al., 1998; Conboy et al., 2003). Recently, it has been 
shown that a prolonged absence of myostatin reduces sarcopenia in myostatin-null 
mice (Wagner et al., 2005). However, as these mice lack functional myostatin 
from a prenatal stage, it was necessary to determine the effects of short term 
inhibition of myostatin during old age. A previous study has indicated that an 
increase in skeletal muscle mass and strength occurs following treatment with a 
myostatin inhibitory antibody (Whittemore et al., 2003). In this study, we show 
that a short term administration of a myostatin antagonist restores the regenerative 
and myogenic capacity of aged muscle. 
In order to examine the effect of a short term antagonism of myostatin, 
Mstn-ant1 was screened for its ability to neutralise myostatin function. Cultured 
myoblasts express and secrete myostatin, which regulates the proliferation rate of 
myoblasts (Thomas et al., 2000; McFarlane et al., 2005). Thus, antagonism of 
myostatin by Mstn-ant1 would result in an increase in the myoblast proliferation 
rate. Indeed, a C2C12 myoblast proliferation assay indicated that Mstn-ant1 
effectively increased the proliferation of the myoblasts above that of the control 
(Figure 6.1C), thus confirming its biological activity.  
In agreement with past studies showing that a lack of myostatin 
significantly enhances muscle regeneration and reduces fibrosis (McCroskery et 
al., 2005; Wagner et al., 2005), results reported here suggest that a blockade of 
myostatin through the administration Mstn-ant1 immediately after notexin injury 
can replicate this effect. Muscle weights, histology, greater regenerated areas at 
days 7 and 10, as well as significantly larger individual fibre areas at day 28 all 
indicated advancement of regeneration with Mstn-ant1 treatment (Figure 6.2, 
6.3B). In addition, Mstn-ant1 treated muscles also displayed reduced levels of 
collagen (Figure 6.3C) suggesting myostatin is involved in fibrosis and collagen 
formation. In support of this, during fibroblast migration assays, myostatin can 
behave as a fibroblast chemoattractant (data not shown). Collectively, these 
results indicate that a prolonged absence of myostatin, as observed in the 
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myostatin-null mice, is not required to obtain enhanced muscle regeneration and 
reduced fibrosis. Rather, a short term blockade of myostatin during the 
regeneration period is sufficient to enhance the regeneration process. 
During muscle regeneration, MyoD is expressed earlier and at higher 
levels in myostatin-null muscle as compared with wild-type muscle (McCroskery 
et al., 2005). Similarly, Western blot analysis performed on the regenerating 
muscle from mice treated with Mstn-ant1 showed increased levels of MyoD 
during regeneration, suggesting increased myogenesis directly resulting from a 
myostatin blockade by Mstn-ant1 (Figure 6.4C). In addition, Pax7, which is 
expressed in quiescent and proliferating cells (Seale et al., 2000), was higher with 
Mstn-ant1 treatment throughout the trial period suggesting an increase in satellite 
cell number, activation and/or self renewal compared to saline treated mice 
(Figure 6.4B). These higher Pax7 and MyoD levels could be due to increased 
numbers of satellite cells and the subsequent myogenesis, and increased satellite 
cell self renewal. Of note, while similar levels of MyoD were observed in the 
Mstn-ant1 and saline treated day 28 regenerated muscles, higher levels of Pax7 
were seen in the Mstn-ant1 treated muscles compared to the saline treated muscle. 
Since Pax7 is a marker for satellite cell self-renewal (Oustanina et al., 2004; 
Zammit et al., 2004), the higher level of Pax7 indicates that Mstn-ant1 enhanced 
this self-renewal process. This is in accordance with an earlier finding that 
indicates myostatin inhibits satellite cell self-renewal (McCroskery et al., 2003). 
Similarly, an extended treatment with Mstn-ant1 to aged mice for 6 weeks also 
resulted in increased MyoD and Pax7 protein levels in both Gas muscle and 
primary myoblasts (Figure 6.5C-F). Aged muscle can undergo wasting due to a 
loss of fibres and atrophy of existing fibres (Alnaqeeb and Goldspink 1987), 
therefore a level of continued myogenesis is required to maintain and repair the 
muscle. Correspondingly, MyoD expression has been shown to be high in young 
animals, significantly decreasing in the adult, and later increasing again as the 
animal continues to age (Dedkov et al., 2003). However, although the level of 
MyoD, as well as other MRFs, increases in the aged muscle, this does not restore 
the muscle’s myogenic ability to that seen in a young muscle (Grounds 1998; 
Welle 2002; Conboy et al., 2005). As myostatin is known to reduce the expression 
of MyoD (Langley et al., 2002), it would be expected that myostatin would 
negatively regulate this age-related myogenesis. Indeed, by antagonising 
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myostatin, we were able to increase the level of myogenesis, as reflected by the 
increase in both MyoD and Pax7 protein levels. In support of these results, 
increased satellite cell activation was observed in 1- and 24-month-old single 
fibres when cultured in the presence of Mstn-ant1 (Figure 6.6B-C). Furthermore, 
in vivo administration of Mstn-ant1 to aged mice was able to increase the 
percentage of activated satellite cells per fibre (Figure 6.7A). This would suggest 
that antagonism of myostatin through subcutaneous injections of Mstn-ant1 can 
provide a means for increased myogenesis possibly by increasing satellite cell 
number or by priming the satellite cells to continue along the myogenic pathway. 
If indeed this is the case, then potentially, antagonism of myostatin in aged 
animals could positively contribute to the reversal of the decline in satellite cells 
and/or their activation potential that has been reported to occur in the aged muscle 
environment (Conboy et al., 2003; Shefer et al., 2006). Increasing satellite cell 
activation and number would be expected to result in an augmentation in force 
strength. As Figure 6.7B indicates, after a 6 week treatment of Mstn-ant1, grip 
strength was increased in the treated animals (P < 0.05).  
As previously stated, a major component of the regeneration process is the 
inflammatory response. After injury, both macrophages and myoblasts migrate to 
the site of injury in response to signalling from inflammatory cytokines and 
various growth factors. In corroboration with a study using myostatin-null mice 
(McCroskery et al., 2005), an accelerated migration and enhanced accretion of 
macrophages was observed with Mstn-ant1 treatment (day 2, Figure 6.8B), 
suggesting Mstn-ant1 rapidly and effectively antagonised the inhibitory effect of 
myostatin on macrophage migration. These findings were also recapitulated in 
chemotaxis assays whereby Mstn-ant1 effectively blocked the inhibitory effect of 
myostatin, thus rescuing the cell migration (Figure 6.9C). Aging also displayed a 
significantly negative effect on both primary myoblast and macrophage migration 
(Figure 6.9A-B). This could be due to a reduced propensity of the 24-month-old 
myoblasts and macrophages to respond to their respective chemoattractants or a 
reduced expression of receptors. Interestingly, after 6 weeks of Mstn-ant1 
treatment, the migratory ability of macrophages was restored (to an unknown 
extent) in the aged mice (Figure 6.9D).  
Collectively, the results presented here suggest that short term blockade of 
myostatin and its function through antagonist treatment can effectively enhance 
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muscle regeneration in aged mice after injury and during age-related muscle 
wasting. The ramifications of antagonist treatment for human health are 
potentially extensive. In addition, the efficacy of an antagonist treatment has been 
demonstrated here, as only four doses of an antagonist during the critical period of 
regeneration after injury was sufficient to significantly improve muscle recovery. 
Therefore, we propose that antagonism of myostatin is a viable option for 
treatment of deficient muscle regeneration and sarcopenia in humans, through a 
restoration of myogenic and inflammatory responses and decreased fibrosis.  
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Chapter Seven 
Perspectives and future directions 
Since the discovery of myostatin, a significant amount of research has 
been undertaken to understand the biological mechanism and function of 
myostatin during prenatal and postnatal myogenesis. Initially much of this work 
focused on the phenotype of myostatin-null animals, followed by in vitro studies 
with myogenic cell lines to determine the mechanism by which it regulates the 
cell cycle. More recently, studies have concentrated on the action of myostatin on 
satellite cell regulation and self-renewal, and muscle regeneration after injury. In 
addition, correlations between myostatin levels and human conditions and 
diseases such as aging and HIV have been determined. Although myostatin-null 
animals enabled significant insights into the biological effects of myostatin, the 
effects of myostatin during prenatal and postnatal myogenesis were unable to be 
discriminated. To clarify this, a number of studies have attempted to block the 
action of myostatin postnatally. Conversely, myostatin over-expression studies 
have provided confirmation of the action of myostatin and its associated null 
phenotype. Additionally, myostatin over-expression studies have corroborated the 
putative role of myostatin during muscle wasting conditions such as cachexia and 
aging. While previous studies have provided invaluable insights into the structure, 
expression, and function of myostatin, a number of areas concerning postnatal 
myogenesis remain undetermined. Therefore, the primary aim of this thesis was to 
address a number of these areas to provide a greater understanding of myostatin. 
More specifically, myostatin downstream targets were investigated, along with the 
effect of both prolonged and short term blockade of myostatin function during in 
vitro and in vivo myogenesis.  
Previous in vitro studies have indicated that myostatin regulates cell cycle 
progression during prenatal myogenesis via Rb-dependent (Thomas et al., 2000) 
and independent (Langley et al., 2004) pathways. A proposed mechanism for this 
regulation is through the down-regulation of cell cycle-related genes. However, to 
date, a systematic analysis of the global gene expression changes initiated by 
either the presence or lack of myostatin has not been described. Thus, in order to 
identify further myostatin downstream target genes, a SSH experiment was 
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performed and described here. The study revealed ARA70, a coregulator of AR, as 
a negatively regulated downstream target gene of myostatin. The administration 
of testosterone is known to elicit various effects, which are mediated through the 
AR (Chang et al., 1988b; Chang et al., 1988a), including increased muscle fibre 
volume, myonuclear number, protein synthesis and satellite cell number, 
decreased protein degradation, and increased myogenesis and decreased 
adipogenesis of pluripotent stem cells (reviewed by Herbst and Bhasin (2004)). 
Therefore, the down-regulation of ARA70 was of particular interest, and required 
further analysis. Thus, Northern and Southern blot analyses using wild-type and 
myostatin-null muscle were performed, verifying that a down-regulation of 
ARA70 by myostatin had occurred in the murine muscle. Furthermore, addition of 
exogenous myostatin to C2C12 cells resulted in the down-regulation of ARA70 
expression, confirming that the ARA70 gene is either directly or indirectly 
repressed by Myostatin. Thus a novel finding of this study was the identification 
of ARA70 as a downstream target gene of the potent negative regulator of muscle 
growth, myostatin. From these findings, it was proposed that since lack of 
myostatin and increased expression of AR leads to muscle hypertrophy, an 
absence of myostatin, in part, may induce the myostatin-null hypertrophy 
phenotype, by enhancing AR activity, through the up-regulation of ARA70. In 
order to prove this hypothesis, future work is necessary to delineate the normal 
function of ARA70 in myogenesis, as well as the role of ARA70 in signalling 
hypertrophy. This would necessitate the generation of an ARA70 over-expressing 
transgenic mouse line, to assess the possibility of a resulting muscle hypertrophy 
phenotype.  
In addition to ARA70, numerous other genes of unknown function were 
also shown to be down-regulated by myostatin. Therefore to fully investigate 
potential downstream targets of myostatin, a comprehensive analysis of these 
genes could be undertaken. This would require similar molecular techniques 
employed in this thesis.  
A well known condition associated with aging is sarcopenia, defined as a 
progressive reduction in muscle mass and strength. In humans, this condition can 
have a profound effect on a person’s quality of life, as it is frequently associated 
with reduced mobility and independence, as well as increased risk of falls 
(Grimby and Saltin 1983; Harris 1997; Roubenoff and Hughes 2000; Roubenoff 
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2001). However, to date there is no viable therapeutic intervention available for 
either the prevention or alleviation of sarcopenia. The muscle atrophy observed 
with sarcopenia has previously been attributed to alterations in the muscle fibres 
(Alnaqeeb and Goldspink 1987), which have been frequently correlated with 
insufficient or inadequate levels of muscle regeneration (Grounds 1998). It is 
believed that this results from impaired satellite cell involvement and myogenesis 
due to the aged environment (Conboy et al., 2003). Parabiotic experiments have 
indicated that circulating factors positively influence the proliferation and 
regenerative capacity of satellite cells (Conboy et al., 2005). In addition, negative 
regulators of muscle mass, such as myostatin, are most likely involved in the 
balancing of the signals that influence satellite cell activation and muscle 
regeneration. Currently it is unclear whether the impaired satellite cell behaviour 
results from a decline in positive factors and/or from an increase in negative 
regulators.  
To investigate the role of myostatin during sarcopenia, in order to design 
myostatin-based therapies, the muscle phenotype and regenerative capacity were 
examined in young and old wild-type and myostatin-null mice. In agreement with 
other studies (McPherron et al., 1997; Lee and McPherron 2001; Girgenrath et al., 
2005), the findings reported here show that young myostatin-null muscle 
displayed fibre hypertrophy and hyperplasia and an increased number of type IIB 
fibres, resulting in a more glycolytic and powerful muscle type. Additionally, this 
study shows that with aging, wild-type muscle became increasingly oxidative and 
displayed prominent fibre atrophy, whereas no fibre type switching and minimal 
atrophy was observed in the aged myostatin-null muscle. These findings are 
highly noteworthy as they indicate that myostatin has a substantial role during 
sarcopenia. As the myostatin-null muscle did not undergo significant fibre type 
shifts or atrophy associated with sarcopenia, the inhibition of myostatin, could in 
theory, ameliorate sarcopenia in humans, thus improving the quality of life in the 
elderly. Indeed, the aged animal trial using the myostatin antagonist did highlight 
the therapeutic potential of myostatin antagonism in sarcopenia.  
It is generally accepted that mammalian muscle becomes increasingly 
oxidative with age, due to oxidative fibre type shifts (Kugelberg 1976; Alnaqeeb 
and Goldspink 1987; Larsson et al., 1993; Musaro et al., 1995), though the exact 
cause for these transitions has been difficult to determine. However, earlier 
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research has indicated that denervation via a selective loss of fast α-motor neurons 
(Hashizume et al., 1988; Ansved and Larsson 1990), and alterations in hormone 
levels (Sieck et al., 1996) may significantly contribute to this condition. It remains 
unclear why, and how, myostatin-null muscle is resistant to the oxidative changes. 
In a study involving the administration of a neutralising myostatin antibody to 
adult mice, no change in the distribution of fibre types or in the expression of 
MHC isoforms was observed (Girgenrath et al., 2005). Thus, the authors 
speculated that the alteration in fibre type composition observed in myostatin-null 
mice was a consequence of the absence of myostatin during prenatal development 
and postnatal terminal differentiation. In order to confirm this, further work is 
necessary to understand prenatal and neonatal fibre development in the absence of 
myostatin. This would require an analysis of the primary and secondary myogenic 
waves using histological and molecular techniques, including in situ hybridisation 
and ICC for MHC isoforms, Pax7 and relevant MRFs. In addition, innervation 
and hormone levels would need to be assessed to determine if alterations are 
present in the myostatin-null muscle. Furthermore, attempting to forcibly alter the 
fibre types in the myostatin-null muscle through the application of CLFS, which 
has been shown to cause oxidative fibre type changes, may lead to a greater 
understanding of fibre type fate.  
Further findings reported here demonstrated that myostatin-null muscle 
had increased satellite cell numbers and activation compared to wild-type muscle, 
suggesting a greater propensity to undergo myogenesis. However, satellite cell 
activation declined significantly with age in both wild-type and myostatin-null 
muscles. Although the myostatin-null fibres retained a higher percentage of 
activated satellite cells, it was surprising that the percentage declined to such an 
extent, given that the fibre hypertrophy was maintained in the aged myostatin-null 
mice. Whether this result alludes to a greater myogenic potential that myostatin-
null satellite cells possess is unknown. However, other findings reported in this 
thesis suggest that the greater myogenic potential observed in myostatin-null 
satellite cells would significantly factor into the overall myogenic capacity of the 
aged muscle. Alternatively, it may indicate that aged myostatin-null muscle 
experiences decreased catabolic signalling via the ubiquitin-proteasome pathway. 
As this remains unknown, further work is required to clarify whether the two 
genotypes differ in the level of catabolic signalling. For this, a molecular analysis 
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of MuRF-1 and Atrogin-1, two muscle-specific ubiquitin E3 ligases associated 
with a number of atrophic conditions (Bodine et al., 2001; Gomes et al., 2001), 
could be performed. This would help to elucidate why and how reduced atrophy, 
or maintained hypertrophy, is observed in the myostatin-null muscle.   
This study also describes accelerated regeneration (following notexin 
injury) in myostatin-null muscle compared to wild-type muscle. This finding is in 
agreement with an earlier study conducted in our laboratory, which reports an 
accelerated regeneration in young myostatin-null mice (McCroskery et al., 2005). 
Although these regeneration experiments conducted in young and aged mice 
eloquently demonstrated the mechanism of myostatin regulation on regeneration, 
it did not allow myostatin signalling to be separated from other effects of 
prolonged absence of myostatin. This is relevant as the increased satellite cell 
number and activation associated with the myostatin-null phenotype would factor 
significantly during muscle regeneration. The latter use of a myostatin antagonist 
enabled the separation of the long term effects from a short term blockade of 
myostatin signalling during muscle regeneration.   
Additionally, the current study reported here shows that fibre hypertrophy 
and type were restored after regeneration in the myostatin-null muscle, unlike the 
wild-type muscle, which displayed smaller and more oxidative fibres. These novel 
findings clearly indicate the significant impact of myostatin during muscle 
regeneration. It is unclear whether the smaller fibres observed in the wild-type 
muscle were due to incomplete fibre regeneration. Alternatively, and perhaps 
more likely, the smaller fibres were representative of the fibre atrophy associated 
with sarcopenia. In contrast, the observed oxidative fibre type shift is highly 
reflective of the aging process. Notexin injury is known to be highly damaging to 
the muscle fibres, and undoubtedly complete regeneration would require the re-
establishment of muscle innervation. Therefore, the observed fibre type shifts may 
indicate an alteration in the re-innervation process. If this is the case, it is 
unknown why the myostatin-null muscle is unaffected in the way that the wild-
type muscle appears to be. Further work is therefore required to understand this 
process, and to determine how myostatin has a significant influence on fibre type 
determination. This would entail a histological analysis of the regenerated muscle 
and associated motor neurons to determine the types of neurons innervating the 
muscle and the size of the motor unit. An analysis of this type would provide an 
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indication of whether myostatin is influencing the type of neuron a fibre is 
innervated by, or simply regulating the expression of the various MHC isoforms.  
As previously discussed, muscle atrophy is commonly associated with 
aging. Furthermore, reduced satellite cell potential has been correlated with this 
age-related atrophy, as satellite cell activation potential and amount of 
proliferation are both thought to decrease with age (Schultz and Lipton 1982; 
Dodson and Allen 1987; Johnson and Allen 1993; Barani et al., 2003; Conboy et 
al., 2003; Machida and Booth 2004). Additionally, satellite cells from aged 
muscle display an extended latent period between an activation stimulus and 
proliferation (Tatsumi et al., 1998; Yablonka-Reuveni et al., 1999). Consequently, 
myoblast proliferation is retarded after injury (McGeachie and Grounds 1995). In 
humans, the proliferative ability of satellite cells starts to decline from early 
childhood years, and with increasing age, satellite cells form thinner, more fragile 
myotubes (Renault et al., 2000). A mechanism for the impaired regenerative 
capacity associated with aging has been suggested to result from the aged 
environment (Carlson and Faulkner 1989; Coggan et al., 1992; Carlson and 
Faulkner 1996; Chakravarthy et al., 2000), however, this does not entirely explain 
these previous in vitro findings.  
Myostatin has been shown to regulate satellite cell activation and myoblast 
proliferation and differentiation (Thomas et al., 2000; Langley et al., 2002; 
McCroskery et al., 2003). Thus, it was investigated, and subsequently reported 
here, how a prolonged absence of myostatin affected the normal aging process, 
with regards to muscle atrophy and the myogenic nature of the satellite cells.  
Irrespective of age, myostatin-null muscles were found to be consistently 
larger than the wild-type muscles. Young myostatin-null mice displayed increased 
MyoD protein levels compared to wild-type mice, however, at 6-months of age, 
MyoD levels were higher in the wild-type muscle compared to the age matched 
myostatin-null muscle. Thus it was proposed that the wild-type muscle had either: 
a lengthier period of myogenesis due to a lethargic rate of myogenesis; or 
conversely, experienced an earlier onset of age-related muscle wasting and 
associated myogenesis. Therefore, future work could be performed to investigate 
whether the wild-type muscle receives earlier atrophic signalling, or is simply 
more sensitive to it. As previously suggested, a molecular analysis of the 
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ubiquitin-proteasome pathway could be undertaken to establish any variation 
between the two genotypes.  
Also reported in this thesis is an in vitro analysis of aged wild-type and 
myostatin-null satellite cells, which indicated that the myostatin-null myoblasts 
had a greater proliferation rate and differentiation fusion index. This suggests that 
an increased myogenic potential may account for the muscle hypertrophy and 
reduced sarcopenia observed in the aged myostatin-null mice. A molecular 
mechanism proposed to be directly linked with the impaired proliferative capacity 
of aged satellite cells is the Notch signalling pathway. Induced expression of 
activated Notch has been shown to restore the regenerative capacity of aged 
muscle (Conboy et al., 2003; Luo et al., 2005). Furthermore, parabiotic studies 
have demonstrated a restoration of the Notch signalling as well as the muscle 
regeneration capacity of aged mice (Conboy et al., 2005). Interactions between 
myostatin and Notch signalling are yet to be understood. Since a lack of myostatin 
and an activation of Notch signalling both result in increased satellite cell 
activation and subsequent myoblast proliferation, it is tempting to speculate on a 
potential interaction between these two regulators of myogenesis. Thus an 
analysis of Notch signalling in wild-type and myostatin-null muscle could provide 
further answers as to how myostatin regulates satellite cell activation and 
proliferation. This would require a molecular study into the expression profile of 
the Notch signalling components during myogenesis, and investigations into any 
direct interactions using in vitro cell culture systems.   
Recent studies have demonstrated heterogeneity in the myoblasts derived 
from satellite cells. Myoblasts expressing Pax7-only appear to be fusion 
incompetent and thus contribute to the self-renewed population, whereas 
myoblasts expressing MyoD-only, which are fusion competent, are destined to 
become new fibre myonuclei (Seale et al., 2000; Zammit et al., 2004; Nagata et 
al., 2006). The findings presented here indicate that in the absence of myostatin 
there are increased Pax7-only myoblasts during aging. This suggests an enhanced 
self-renewal process in the myostatin-null mice, which is consistent with an earlier 
observation indicating that lack of myostatin increases the satellite cell number 
due to enhanced self-renewal (McCroskery et al., 2003). 
Increased fat accumulation is a well known characteristic of aging, 
however, myostatin-null mice reportedly demonstrate significantly decreased fat 
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accumulation compared to wild-type mice (Lin et al., 2002; McPherron and Lee 
2002). In agreement, analysis of the fat pads in this current study indicated that 
the size of both fat cell and pad were significantly decreased in the myostatin-null 
mice compared to the wild-type mice. Presently it is unknown whether the 
decreased fat accumulation in myostatin-null mice is a primary effect elicited by 
myostatin, or a secondary consequence due to the increased muscle mass, as a 
similar effect is seen in other muscle hypertrophy genetic models (Sutrave et al., 
1990; Musaro et al., 2001). Interestingly, McPherron and Lee (2002) found that 
the myostatin-null mice gonadal fat pad contained approximately 25% fewer fat 
cells than the wild-type fat pad, while Whittemore et al. (2003) reported no 
change in the fat pad mass when myostatin was inhibited with a blocking 
antibody. Due to the low (and inconsistent) number of in vitro reports regarding 
the role of myostatin during adipogenesis, it is difficult to understand how a 
prolonged lack of myostatin results in a consistently low level of fat accumulation 
even in the aged mice. Therefore, future work could be performed to elucidate the 
mechanism by which myostatin regulates fat accumulation. One way of 
addressing this issue would be to study the adipogenic nature of preadipocytes 
isolated from myostatin-null and wild-type animals. An analysis of their 
proliferative capacity as well as the expression profile of relevant adipogenic early 
and late differentiation genes would allow a comparison between the two 
genotypes. Alternatively, myostatin or myostatin antagonist treatment of 
preadipocytes would possibly provide evidence for any regulation by myostatin. 
Furthermore, investigations into possible correlations between myostatin and 
known inducers of adipogenesis may help to clarify any regulation by myostatin.  
A number of recent studies investigating the role of myostatin have 
adopted the use of antibodies which inhibit myostatin function (Bogdanovich et 
al., 2002; Whittemore et al., 2003; Bogdanovich et al., 2005; Girgenrath et al., 
2005). The inhibition of myostatin appeared successful, however, most of the 
findings concentrated on the augmentation of muscle mass and strength, and fibre 
type analysis only. Therefore, to further elucidate the molecular mechanism of 
myostatin, especially during sarcopenia, a small molecule, designed to antagonise 
myostatin and its biological function, was employed in a series of in vitro and in 
vivo experiments. Overall, the short term blockade of myostatin reported here was 
found to significantly enhance muscle regeneration in aged mice after injury and 
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during age-related muscle wasting. This was achieved through enhanced 
macrophage migration, satellite cell activation, and myogenic-related gene 
expression. Thus the findings supported the hypothesis that myostatin signalling 
plays a major role in both muscle regeneration and age-related muscle wasting. 
From these results, it was proposed that antagonism of myostatin could lead to a 
restoration of the myogenic and inflammatory responses in the aged environment. 
The consequences of restoration are highly noteworthy both scientifically and 
medically, as this is the first demonstration of how the antagonism of myostatin 
has significant therapeutic potential in the alleviation of sarcopenia as well as 
other muscle wasting conditions observed in humans. Although a short term 
blockade of myostatin has revealed significant insights into the effects of 
myostatin signalling, a number of questions still remain unanswered. For 
example, how is the antagonist molecule blocking myostatin signalling? Is it due 
to competitive binding of the Act RIIB receptor, or through dimerisation of the 
active mature myostatin protein with the antagonist, thus rendering it inactivated? 
A series of receptor binding or competitive binding assays using Act RIIB 
receptor, the myostatin antagonist, and the active mature myostatin protein could 
be performed to address these questions. Furthermore, could the antagonist be 
utilised as a prophylactic molecule, to prevent sarcopenia? This would require an 
additional in vivo trial using young mice, which would regularly receive the 
antagonist until the age when sarcopenia is observed in the control mice. 
Extensive clinical trials would also be required to assess the safety of the 
antagonist as a treatment for muscle wasting in humans. 
In conclusion, a prolonged absence of myostatin appeared to reduce age-
related sarcopenia. Antagonism of myostatin was also found to effectively 
enhance myogenesis and the muscle regenerative capacity through a number of 
mechanisms. Therefore, the use of a myostatin antagonist appears to be a viable 
treatment option for deficient muscle regeneration and sarcopenia in humans. 
Additionally, it may also alleviative other debilitating human conditions such as 
cancer and HIV. Thus, myostatin antagonist treatment for human health is 
potentially extensive.  
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